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Therapy Concordance and Drug Adherence in Parkinson's 
Disease 
Summary and Overview 
Oral drug therapy forms the mainstay of modern management of 
Parkinson's disease. Consideration of how patients take prescribed medication is 
essential in understanding therapeutic response. Much is known about therapy 
adherence in many disease areas and about half of prescribed medicines are not 
taken as prescribed, but only limited information is available about compliance in 
Parkinson's disease (PO). 
Suboptimal therapy adherence has many consequences including poor 
symptomatic control resulting in worsening quality of life. This thesis forms a 
comprehensive study of drug adherence in Parkinson's disease. Methods of 
assessing drug adherence are studied and compared, factors influencing drug-
taking behaviour including patients' beliefs are examined, and the effect of an 
educational intervention is tested. 
Concordance describes the process of a patienUdoctor interaction. The 
degree of patient involvement in therapy management decisions and satisfaction 
with the movement disorder service are examined in this thesis as an indication of 
concordance. 
A cohort of 135 patients underwent several assessments for one year, of 
which subsets were evaluable in different aspects of the study, as described in 
individual chapters. A further 99 patients taking dopamine agonists formed an 
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additional cohort (Chapter 7). Finally, another 20 patients took part in the study 
developing a patient belief questionnaire. 
Chapter 1 gives an overview of the relevance of studying therapy adherence in 
Parkinson's disease. Variable medicine-taking behaviour can affect the clinician's 
understanding of the diagnosis and rate of progression. Understanding medicine-
taking behaviour is a first step in optimising therapy. 
Chapter 2 examines drug induced neurological syndromes and considers the 
validity of patients' concerns about taking prescribed medications. Patients 
prescribed treatment for one movement disorder (e.g. the tremor and bradykinesia 
of Parkinson's disease) often find they develop another movement disorder (e.g. 
dyskinesia). Patients' concerns about long-term adverse effects are therefore valid, 
but this has to weighed against deteriorating quality of life associated with delaying 
treatment. 
Chapter 3 compares different methods of assessing therapy adherence. One 
hundred and twelve cases of idiopathic Parkinson's were randomised to active 
monitoring (n = 69, simple tablet count and electronic monitoring conducted), or to 
no monitoring (n = 43, control group). All patients completed a self-report and 
visual analogue scale indicating therapy intake. Median adherence for self-report 
was 100%) (interquartile range (10) 100-100) and for visual analogue was 100% (10 
95-100), in both active and control groups. Patients taking ~ 80% of prescribed 
medication had median total adherence of 98% (10 93-101) by electronic 
monitoring, which was similar to that from other methods: self-report (1000/0, 10 
100-100); visual analogue scale (100 % , 10 95-100); simple tablet count (98%, 10 
89-100). Median total adherence in patients taking <80% of medication was 
significantly lower by electronic monitoring (69%), 10 44-74) than by other methods: 
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self-report 100% (10 100-100); visual analogue scale 100% (10 95-100); and 
simple tablet count 90% (10 78-100) (all p<0.0001). Self-report, visual analogue 
scale and simple tablet counts are insensitive predictors of sub-optimal medicine 
usage in PD. 
Chapter 4 studies factors associated with sub-optimal medicine usage in 54 
patients. Poorer compliance was associated with younger age (p = 0.007), with 
taking more antiparkinson tablets per day (p = 0.007), and with higher depression 
scores (p = 0.02) and poorer quality of life (p=0.002). 
Chapter 5 reports a study of patient perceived involvement with management 
decisions and an assessment of satisfaction with the movement disorder service in 
107 patients. Higher involvement was associated with increased satisfaction (r = 
0.28, P = 0.003), particularly distress relief (r = 0.38, P < 0.0001). Communication 
scores correlated significantly with compliance intent (r = 0.6, P < 0.0001). 
Improved quality of life was significantly associated with higher compliance intent, 
and satisfaction. 
Chapter 6 explores patients' beliefs about antiparkinson medication in 129 
patients. Parkinson's patients held strong beliefs that their medicines were 
necessary but also had concerns about their medicines. Beliefs about medicines 
did not correlate with adherence. Although patients have concerns regarding 
medicine taking, this does not seem to affect medicine-taking behaviour. 
Chapter 7 examines the effect on Parkinson's patients of emerging data about 
drug side effects, specifically fibrosis due to ergot-based dopamine agonists. 
Ninety-nine patients taking ergot-derived dopamine agonists were informed about 
potential longer-term side effects and given therapy options. Out of 99 patients, 88 
14 
(89%») chose to switch to a non-ergot agonist (conducted overnight), 10 maintained 
therapy, and 1 stopped agonist therapy and increased levodopa. 
Chapter 8 reports on an educational intervention designed to improve Parkinson 
drug timing compliance. Eighty-three patients were randomised, 43 to the active 
group (receiving the intervention) and 40 to the control group (no extra 
information). Prior to the intervention timing compliance was median 17%) 
(interquartile range (10) 9-51) for the active group versus 21 % (10 10-59) for the 
control group (difference not significant). Post-intervention timing compliance was 
significantly better in the active group at 39% (10 22-58) than in controls at 20% (IQ 
10-47), (p=0.007). The UPORS 3 motor score improved in the active group (mean 
change -0.5, SO 11) but deteriorated in controls (mean +5, SO 8) (p=0.03). In 
conclusion, timing compliance improves after providing patients with extra 
information, which is associated with better motor scores. 
In summary, this thesis provides important new information about medicine taking 
in Parkinson's disease. A fifth of PO patients take less than 80% of prescribed 
antiparkinson medication. Electronic monitoring is the only reliable method of 
accurately detecting sub-optimal medication usage. Patients who take less than 
80%) of prescribed medicines are more likely to be younger, have concomitant 
depression, be prescribed more tablets per day and have poorer quality of life. 
Patients are more satisfied if they are involved in management decisions and have 
increased intention to comply with prescribed medication if there is better 
communication. Poorer quality of life is associated with less intention to comply 
with prescribed medication. Timing of medication intake is generally irregular but 
can be improved by informing patients of the continuous dopaminergic theory and 
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providing specific drug timings. Once daily drugs are taken more consistently than 
drugs with more frequent doses. Future research needs to evaluate further the true 
impact of sub-optimal compliance and explore methods to ease the process of 
medicine taking in Parkinson's disease. 
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Chapter 1 
The Importance of Concordance and Drug Adherence 
in Parkinson's Disease 
17 
Background 
Parkinson's disease (PO) is a common neurodegenerative disorder affecting 
approximately 1 % of the population over 65 years. Prescribing medicines is the 
mainstay of modern management of PD. In recent years there have been many 
new therapeutic developments including the development of new dopamine 
agonists (Adler et al. 1997;Clarke & Guttman 2002;Geminiani et al. 1996;Hobson, 
Pourcher, & Martin 1999;Hubble 2002;Montastruc, Rascol, & Senard 1999;Olanow 
2002;Shulman et al. 2000), slow release dopamine preparations (Koller et al. 
1999), COMT (catechol-O-methyl transferase) inhibitors (Brooks & Sagar 
2003;Fenelon et al. 2003) and combination preparations (Hauser 2004). There is 
increasing responsibility of the doctor to reach an accurate diagnosis and give up-
to-date evidence-based advice. The management of PO is a complex area. There 
are multiple considerations in deciding the best course for individual patients 
(Bhatia et al. 2001). Understanding and agreement between the patient and doctor 
(concordance) should maximise benefit and requires patients then to comply with 
the prescribed therapy (Coons 2001 ;Mulleners, Whitmarsh, & Steiner 1998). The 
patient's decision to take treatment (or not) is based on a complex interplay of 
beliefs, knowledge, experience, symptoms, disease type, co-morbidity, culture, 
personality, social support and psychological state in addition to the interaction 
between patient and doctor. Adherence rates for prescribed medication across a 
wide spectrum of conditions, both symptomatic and asymptomatic, are typically 
around 50% with a range from 0% to over 100% (Sackett & Snow 1979). In chronic 
conditions about a third of medicines are not taken as prescribed (Horne R 1997). 
In a systematic review of 76 studies using electronic monitoring the mean total 
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compliance was 71 %) (standard deviation 17, range 34-97%) (Claxton, Cramer, & 
Pierce 2001). Non-compliance has significant loss of health gain and 
socioeconomic consequences. In the geographical setting of the current research, 
the annual drug budget was £199 million for a population of around 1 million 
(2002/3 figures). Fifty percent adherence rates equate to £100 of unused 
medication per head of population, and a much higher figure if considering only 
medicated patients. 
Adherence, Compliance or Concordance? 
Compliance measurements indicate whether patients take medication in 
accordance with prescriber's intentions; they reflect patient behaviour, and 
compliance may range from excellent to poor. The term adherence can be used 
synonymously with compliance. These terms are judgmental; non-compliance or 
poor adherence identify error (patients fail to follow instructions). Compliance 
measures include self-report, tablet counts, pharmacy refills, electronic monitoring, 
blood/urine samples or biological markers of drug effect. Compliance/adherence 
represent the theoretical intention of prescription, whereas concordance signifies 
the practical goal of treatment (Royal Pharmaceutical Society of Great Britain 
1997). 
Concordance is a descriptive term and patients cannot be non-concordant as the 
term refers to the process and outcome of the consultation rather than patient 
behaviour. The Medicines Partnership was created by the UK Department of 
Health to endorse concordance in several disorders including PO (Medicines 
Partnership 2003). The Royal Pharmaceutical Society of Great Britain multi-
disciplinary working party defines concordance as follows (Royal Pharmaceutical 
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Society of Great Britain 1997}: Concordance is based on the notion that the work of 
the prescriber and the patient in the consultation is a negotiation between equals 
and the aim is therefore a therapeutic alliance between them. This alliance, may, in 
the end, include an agreement to differ. Its strength lies in a new assumption of 
respect for the patient's agenda and the creation of openness in the relationship, 
so that both doctor and patient together can proceed on the basis of reality and not 
of misunderstanding, distrust and concealment. Involving patients in their health 
care decisions is not a new concept; Szasz and Hollender described a model of 
mutual co-operation between physician and patient in 1956 (Szasz & Hollender 
1956) and the World Health Organisation stated that patients as well as health care 
professionals have a right and a duty to participate in health care decisions in 1977 
(World Health Organisation 1977). Increased patient involvement brings greater 
responsibility which not all patients desire, but it should be offered (Litva et al. 
2002). Measuring concordance involves assessment of whether the consultation is 
patient centred, and whether the patient is satisfied with the process of care 
particularly relating to drug treatment decisions. Departure from the prescription 
represents at least in part failure to address the patient's agenda. Increased 
concordance gives the clinician a better understanding of the patient, and enables 
optimisation of medicine taking, maximising health gain. 
Research Aims 
Therapy compliance and concordance are largely unpublished areas in PD. This 
research project aims to: 
• Analyse the potential importance of compliance in PO and consider 
consequences of poor compliance (Chapter 1). 
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• Explore the risks of prescription medication from a general neurological 
perspective and the patient's understanding, thereby reviewing the 
'necessity:concerns' ratio which is crucial to understanding therapy decision 
making by patients (Chapter 2). 
• Define the level of compliance in PD using four methods of assessment of 
compliance (Chapter 3). 
• Explore factors associated with sub-optimal medicine-usage (Chapter 4). 
• Assess the level of patient involvement (concordance) in therapy decisions 
and satisfaction with the consultation in a movement disorder clinic setting 
(Chapter 5). 
• Examine PD patients' beliefs about medicines and assess the impact of 
beliefs on therapy adherence (Chapter 6). 
• Involve patients in change of therapy decisions (Chapter 7). 
• Explore methods of supporting PD patients in medicine taking, by testing the 
effects of patient education on compliance (Chapter 8). 
A cohort of 135 patients underwent several assessments for one year. Figures 1.1 
and 1.2 give an overview of the study timeline and Table 1.1 indicates the 
timetable of study assessments. A CONSORT flowchart showing the flow of 
participants is shown in Figure 1.3. 
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Figure 1.1: Timeline oj study visits. Patients were all seen at 3 monthly intervals over a 
period oj 1 year. 
Baseline 3m 6m 9m 12m 
STC 
EM 
SM 
STC = simple tablet count, EM = electronic monitoring, SM = standard management 
Figure 1.2: Timeline oj educational intervention. At the 6 month visit half the patients 
(according to randomisation) received verbal and written information on the continuous 
dopaminergic theory and advice on optimal medicine dosage timings (the education pack). 
Baseline 6m 
EP 
CM 
NEP 
EP 
SM 
NEP 
CM = compliance monitoring (simple tablet count, electronic monitoring), SM = sta~dard 
management with no compliance monitoring, EP = education pack, NEP = no educatIOn 
pack 
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Table 1.1: Overview and schedule of Study-Related Assessments 
Month 
Assessment Measurement Baseline 
Diagnosis Brain Bank Criteria x 
Cognition MMSE x 
Consent x 
PD stage H&Y x 
PD status UPDRS 1-4 x 
Depression Geriatric Depression Scale x 
Functional Status Schwab&England x 
Functional Status PDQ39 x 
Side effects Side effect sheet + global impression x 
Dyskinesia UPDRS 4/PD/Goetz dyskinesia scale x 
Sleepiness Epworth sleep score x 
or ifnone Patient Drug record x 
Compliance VAS/Self-report 
Satisfaction Medical interview satisfaction scale 
Patient-centred ness Patient centred ness score 
Beliefs about medicines - General Beliefs about medicines Questionnaire 
Beliefs about medicines - PD specific Beliefs about medicines Questionnaire - PD 
Adherence self-report Medicine Adherence Rating Scale 
Satisfaction with information given on medicines Satisfaction with information given about 
medicines questionnaire 
according to randomisation 
for education cases education pack 
for STC and EM cases pill count record x 
.. , MMSE = mini mental state examination, H&Y = Hoehn and Yahr, UPDRS = Unified Parkinson s Disease rating scale, 
PDQ39 = Parkinson's Disease Quality of life questionnaire, STC=simple tablet count, EM = electronic monitoring 
VAS=Visual analogue scale 
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3 6 9 12 
x x x x 
x x x x 
x x x x 
x 
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x x x x 
x x x x 
x 
x 
x 
x 
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x 
J 
, 
x 
x x x x 
Figure 1.3: Study Overview CONSORT Flowchart 
Assessment of eligibility (n=135) 
Excluded (n=6, all declined) 
Randomised (n=129) 
Allocated to active therapy 
monitoring (n=83) 
Received allocated intervention 
(n=81) 
Did not receive allocated 
intervention (n=2) 
Reasons - withdrew consent 
Lost to follow up 
(n=2) 
Discontinued intervention 
(n=lO) 
Reasons 9 had problems 
with monitoring bottles 
1 died 
Analysed (n=69) 
Allocated to educational intervention (n=33) 
Discontinued intervention (n= 10) 
Reasons 
3 declined re-run of monitoring bottles 
6 used monitoring bottles inconsistently 
1 system recording failure 
Analysed (n= 23) 24 
Allocated to no active therapy 
monitoring (n=46) 
Received allocated intervention 
(n=45) 
Did not receive allocated 
intervention (n= 1 ) 
Reason withdrew consent 
." 
-----------, 
Lost to follow up 
(n=2) 
~, 
---------, 
Analysed (n=43) 
Allocated to no educational intervention (n=36) 
Discontinued (n=7) 
1 declined re-run of monitoring bottles 
6 used the monitoring bottles inconsistently 
I Analysed <n_=_2_9_) __ -----l 
Pharmacological Considerations in PO Compliance 
To understand the effects and consequences of non-compliance in PO, a review of 
pharmacokinetic and pharmacodynamic properties of the antiparkinsonian 
medication is necessary. 
Levodopa Preparations 
Levodopa is a naturally occurring amino acid found in seedlings, pods and 
broadbeans. It is decarboxylated to dopamine and replenishes depleted striatal 
dopamine in PD. It is combined with an extracerebral decarboxylase inhibitor to 
reduce peripheral conversion of levodopa to dopamine. This limits side effects of 
nausea, vomiting and cardiovascular effects. Even combined with a decarboxylase 
inhibitor only 10% of the administered drug reaches the brain due to extensive 
peripheral metabolism by catechol-O-methyltransferase (COMT) (Deleu, Northway, 
& Hanssens 2002). Despite the introduction of new drug classes to treat PO, 
levodopa (meaning levodopa plus decarboxylase inhibitor) remains the most 
effective therapy in terms of symptom control (as measured by the Unified 
Parkinson's Disease Rating Scale, the UPDRS). There are 12 different levodopa 
plus DCI preparations currently available in the UK. Dispersible, immediate release 
and controlled released formulations are used individually or in combination. Table 
1.2 summarises the pharmacokinetic properties of levodopa preparations. 
Dopamine metabolites are rapidly excreted in the urine. 
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Table 1.2 - Summary of Pharmacokinetic Properties of Levodopa 
Preparation Absorption Time to Bioavailability Elimination 
maximum half-life 
plasma 
concentration 
Madopar rapid 1 hour 98% 1.5 hours 
Dispersible 
Madopar rapid 
Immediate Release 
1 hour 98% 1.5 hours 
Madopar slow 3 hours 60% 1.5 hours 
Controlled Release 
Sinemet rapid 0.75 hours 99% 1 hour 
Immediate Release 
Sinemet slow 2 hours 60% 1 hour 
Controlled Release 
Motor Fluctuations 
Motor fluctuations (end of dose wearing-off, 'on-off' effects, dyskinesia and 
dystonia) occur in 50% of PO patients treated with levodopa after 5 years (Lees 
1986;Marsden & Parkes 1976). Such complications are commoner in young onset 
patients (100% after 6 years in cases developing PO before age 40) (Clarke 2002). 
The mechanism of motor complications is complex but may relate partly to erratic 
absorption and short half-life of levodopa causing fluctuating serum and brain drug 
levels (Figure 1.4) and abnormal pulsatile stimulation (Figure 1.5) of striatal 
dopamine receptors (Bezard, Brotchie, & Gross 2001 ;Jenner 2000) contrasting 
with the more continuous neurone firing (Figure 1.6) under normal circumstances 
(Grace 1991 ;Onn, West, & Grace 2000). In early disease the dopamine neurones 
have the capacity to buffer variations in striatal dopamine levels, but as the disease 
progresses fluctuating plasma dopamine levels correlate with alternating high and 
low striatal dopamine levels causing pulsatile stimulation clinically manifesting as 
emerging motor fluctuations (Spencer & Wooten 1984). 
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Figure-i. : Grep;(illustrating peaks and troughs of serum and brain levodopa levels 
in relation to dosing schedule 
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Figure 1.5: Diagram of abnormal fluctuating serum and brain levodopa levels 
causing pulsatile post synaptic stimulation resulting in motor fluctuations 
'On-off' 
Figure 1.6: Diagram of normal physiological tonic dopaminergic activity resulting 
in more continuous post synaptic stimulation 
Pre-synaptic 
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27 
Controlled release preparations 
In an attempt to prolong the clinical effect of levodopa, controlled release 
preparations were developed. Sinemet CR is designed to release active 
ingredients over a 4-6 hour period via a slowly dissolving polymeric matrix. 
Sinemet CR has approximately 70% bioavailability compared against IR; up to 
30% more levodopa per day may be necessary. Dosing interval might theoretically 
increase by 30% (Hutton et al. 1989). Madopar CR is transformed in the stomach 
to a mucoid body which delivers its content through a hydrated layer by diffusion. 
Therapy should continue with the same dose frequency although in one study the 
average number of daily doses were 5.2 for patients on Madopar CR versus 6.2 for 
patients on IR (MacMahon et al. 1990). The CR preparations provide a more 
prolonged but lower peak plasma concentration of levodopa (they increase the 
area under the curve without increasing the maximum concentration of levodopa). 
In clinical trials there was no difference in the development of motor fluctuations 
between IR and CR preparations (Hutton, Morris, Bush, Smith, Liss, & Reines 
1989;Koller, Hutton, Tolosa, & Capilldeo 1999). However patients taking CR had 
better activities of daily living and both patients and physicians preferred CR 
preparations scores (Grandas, Martinez-Martin, & Linazasoro 1998;Martinez-
Martin et al. 1999). 
Adverse effects 
Levodopa is initiated at low dose to allow tolerance to peripheral dopaminergic 
effects of nausea, vomiting and postural hypotension; gradual increases then 
depend on clinical response. Domperidone (a peripheral dopamine antagonist 
which does not cross the blood-brain barrier) may be co-prescribed to counteract 
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these peripheral effects. In late disease symptoms of dopaminergic excess 
(dyskinesia, hallucinations and confusion) are often dose limiting. Unpredictable 
'on-off' effects in advanced PD are inevitable after long-term therapy and are 
extremely difficult to control. Strategies of 'buying time' by delaying the initiation of 
levodopa have been developed. 
Dopamine Agonists 
Dopamine agonists (DAs) have a direct action on post-synaptic dopamine 
receptors. Although less potent than levodopa, DAs are proven in many 
independent trials (Hubble 2002; Rascol et al. 2000;The Parkinson Study Group 
2000) to reduce and delay motor fluctuations and can delay the need to start 
levodopa (Hubble 2002). DAs are therefore commonly used early as monotherapy 
particularly in younger patients (Olanow & Koller 1998). There are seven agents in 
this class currently available in the UK. Bromocriptine, cabergoline, lisuride and 
pergolide are ergot-derived while pramipexole and ropinirole are non-ergot. 
Apomorphine is also non-ergot but requires parenteral administration 
(subcutaneous injection or infusion) because of extensive first pass metabolism 
(LeWitt 2004). Continuous waking day subcutaneous infusion benefits advanced 
PD patients with severe dyskinesia or 'on-off' fluctuations and allows a reduction or 
even discontinuation of oral therapy (Manson, Turner, & Lees 2002). DAs vary 
considerably in their pharmacological properties (Table 1.3). 
Several new DA products are under test, including the transdermal agent 
rotigotine, and ropinirole CR, both of which may reduce fluctuations by long 
duration of action. 
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Table 1.3: Pharmacokinetic properties of dopamine agonists 
Preparation Absorption 
Apomorphine very rapid 
(sub-cutaneous) 
Bromocriptine rapid 
Time to 
maximum 
plasma 
concentration 
4-12 mins 
1-3 hours 
Bio 
-availability 
100% 
6% 
Cabergoline rapid 0.5-4 hours 50-80% 
Lisuride rapid 0.2-1.2 hours 10-20% 
Pergolide 55% absorbed 1-3 hours 20-60% 
Pramipexole rapid 1-3 hours 90% 
Ropinirole rapid 1.5 hours 50% 
Elimination Clearance 
half-life 
33 mins extra-hepatic 
15 hours* hepatic 
63-68 hours# hepatic 
1.3-2.5 hours hepatic 
27 hours hepatiC 
8-12 hours + renal 
6 hours hepatic 
* Bromocriptine plasma elimination half life is 3-4 hours for the parent drug and 50 hours for the 
inactive metabolites. The elimination of parent drug from plasma occurs biphasically, with a terminal 
half-life of about 15 hours. 
# In healthy volunteers 
+ 8 hours in the young to 12 hours in the elderly. 
Selegiline 
Selegiline is a monoamine-oxidase B inhibitor preventing dopamine breakdown in 
the brain. It also inhibits the re-uptake of dopamine at the pre-synaptic receptor. It 
can be used as an early monotherapy and prolongs the time before levodopa is 
needed by 9 months (The Parkinson Study Group 1993). In later disease when 
added to levodopa, it alleviates dose related fluctuations and end of dose 
deterioration. It is readily absorbed and maximum plasma concentrations are 
reached in 30 minutes. Bioavailability is low at 10% • It is lipophilic and quickly 
penetrates into tissues including the brain. Plasma selegiline is 94% reversibly 
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bound to protein. Enzyme inhibition is irreversible and therefore resumes only after 
new enzyme has been formed. The mean elimination half-life is 1.6 hours. 
Selegiline also comes in an oral Iyophilisate formulation which dissolves completely 
within 10 seconds of being placed on the tongue. This is particularly indicated for 
patients with swallowing difficulties. 
Rasagiline, another monoamine-oxidase B inhibitor with a longer half life (and 
therefore given once daily) has recently become available and is effacious as early 
monotherapy (The Parkinson Study Group 2004) and later as an adjunct (Rascol et 
al. 2005). 
Entacapone 
Entacapone is a reversible, specific and mainly peripherally acting catechol-O-
methyl transferase (COMT) inhibitor. There are large variations in the absorption of 
entacapone. The peak concentration is reached 1 hour after administration and the 
bioavailability is 35%. Entacapone is extensively bound to plasma proteins. It 
decreases the metabolic loss of dopamine to 3 O-methyl dopa. This increases the 
half-life of levodopa by 30-50% so that the levodopa total daily dose may be 
reduced (Fenelon, Gimenez-Roldan, Montastruc, Bermejo, Durif, Bourdeix, Pere, 
Galiano, & Schad rack 2003) with no significant effect on the Cmax (peak 
concentration) or T max (time to Cmax) . It is particularly useful for patients 
experiencing end-of-dose 'wearing off'. 
Tolcapone is a more potent COMT inhibitor which acts centrally and peripherally, 
but was temporarily withdrawn in Europe because of hepatotoxicity. It requires 
extensive liver function monitoring. 
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Stalevo is a recently launched combination of entacapone, levodopa and 
carbidopa. It comes in three strengths containing 50, 100 and 150 mg of levodopa 
(Hauser 2004). 
Anticholinergics 
The use of anticholinergics in PO has declined in recent years due to adverse 
effects on cognition and the introduction of better alternative dopamine sparing 
agents. Structurally related to atropine, these drugs block muscarinic receptors in 
the striatum, inhibit the presynaptic carrier-mediated dopamine transport 
mechanism and are N-methyl-O-aspartate (NMOA) antagonists (reversing akinesia 
and potentiating levodopa in animal models). Table 1.4 summarises the 
pharmacokinetic properties. 
Table 1.4: Pharmacokinetic properties of anticholinergics 
Preparation Time to Bioavailability Elimination Clearance 
maximum half-life 
plasma 
concentration 
Trihexyphenidyl1.3 hours 100% 33 hours renal 
(Benzhexol) 
Benztropine 7 hours low 18-24 hours renal 
Orphenadrine 2-4 hours 95% 13-20 hours renal 
Procyclidine 1 hour 75% 8-16 hours renal 
32 
Amantadine 
Amantadine is a glutamate antagonist originally developed as an antiviral agent. It 
enhances dopaminergic transmission and has mild antimuscarinic activity. 
Absorption is slow and variable, and steady-state plasma concentrations are 
reached within 4-7 days (Aoki & Sitar 1988). The drug is extensively bound to 
tissues and 90% is eliminated by renal clearance. Its main use is in more advanced 
disease, as an antidyskinesia agent (Metman et al. 1999). 
Categories of non-compliance, in relation to Parkinson's Disease 
Compliance is the extent to which a patient's actual dosage administration 
corresponds to the prescribed regimen (Urquhart & de Klerk 1998). The patient 
needs to accept the treatment decided during the consultation, redeem the 
prescription, adhere to the dose (amount and frequency), and persist with the drug 
regimen. 
33 
Primary Non-compliance 
In primary non-compliance, the patient fails to have the medication dispensed. In 
primary care, 5%) of prescriptions are not filled (Beardon et al. 1993) and 80% of 
unredeemed prescriptions are for symptomatic conditions. Unclaimed prescriptions 
detected by automated transmittals to Swedish pharmacies found primary non-
compliance in 2,171 out of 90,458 prescriptions (2.4%) in 3 months; the patient 
regarding the prescription as unnecessary was the commonest cause (Ekedahl & 
Mansson 2004). This may reflect mainly the patient's rejection of the doctor's 
diagnosis or advice and can be regarded as intentional non-compliance. 
Alternatively prescription charges may be a barrier. In PO, drug therapy is usually 
started when it is needed to help function as therapy is symptomatic and does not 
slow disease progression. Additionally, therapy initiation is often delayed due to 
inevitable future drug-related motor fluctuations. Balancing these judgements is 
often difficult for the patient and the prescriber. Primary non-compliance may occur 
if the doctor recommends drug treatment, but the patient feels it is not yet 
necessary. Patients weigh up the necessity of the treatment (in relation to their 
symptoms and disability) against concerns of adverse effects both short and long-
term. Unintentional primary non-compliance may also be due to cognitive 
impairment (which exists in 10-20% of PO patients) or depression (present in about 
40% of PO patients). 
Secondary Non-compliance 
This is when patients do not take medication as intended by the prescriber. There 
are a number of categories of secondary non-compliance, as follows. 
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Early Discontinuation 
Adverse effects are the commonest reason for premature discontinuation in other 
disease areas such as depression (Bull et al. 2002b). Informing patients of 
potential adverse effects improves therapy continuation (Bull et al. 2002a). 
Antiparkinsonian medications are frequently associated with adverse effects. Initial 
application of levodopa in the 1960s after patients with PD were found to have 
deleted neostriatal dopamine was limited by severe peripheral effects of nausea, 
vomiting and postural hypotension. Discovery of decarboxylase inhibitors (DCI) in 
the late 1960s (Bartholini, Burkard, & Pletscher 1967) led to widening use and 
acceptability of the combined levodopa and DCI products. Further reduction in 
peripheral adverse effects can be achieved by co-prescribing domperidone. These 
measures anticipate and minimize early adverse effects, minimising unnecessary 
premature discontinuation. 
Clinical trial discontinuation rates due to adverse events are high (Table 1. 5). 
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Table 1.5: Early discontinuation rates due to adverse effects in PO clinical trials 
Author 
Brooks et al (Brooks & Sagar 2003) 
Larsen et al 
(Larsen et al. 2003) 
Parkinson Study Group 
(The Parkinson Study Group 2000) 
Koller et al 
Hutton, Tolosa, & Capilldeo 1999) 
Linazasoro 
(Linazasoro et al. 1999) 
Rinne et al 
(Rinne et al. 1997) 
Shannon et al 
(Shannon, Bennett, Jr., & Friedman 1997) 
Discontinuation rate (0/0) 
Test Drug Comparator 
Entacapone 19% Placebo 14% 
Entacapone 14% none 
Pramipexole 11 % Levodopa 8% 
Levodopa IR 9% Levodopa CR 9% (Koller, 
Levodopa CR 10% none 
Cabergoline 7.7% Levodopa 5.4% 
Pramipexole 13% Placebo 14% 
Adler et al Ropinirole 23% Placebo 10% (Adler, 
Sethi, Hauser, Davis, Hammerstad, Bertoni, Taylor, Sanchez-Ramos, & O'Brien 1997) 
IR - immediate release, CR = controlled release 
Lack of efficacy also leads to early discontinuation. In depression, the time lag 
between therapy initiation and symptomatic improvement may lead to premature 
discontinuation especially in uninformed patients. In PD there are a number of 
issues relating to lack of efficacy. Patients frequently report no beneficial therapy 
effect because they expect an improvement in tremor, which occurs in only about 
half of cases (Brooks 2002) and is the most difficult feature to control from the 
classic triad of Parkinson's symptoms. Patients who are informed about realistic 
expectations of therapy goals (improvement in movements, muscle tone i.e. feeling 
less slow and stiff) may gain better realisation of therapy benefit. Initial low doses 
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to aid tolerability may compromise early efficacy. Scheduled titration such as with 
starter packs (ropinirole and pergolide) or follow-on packs (ropinirole) may assist. 
Lack of efficacy may drive a switch to an alternative preparation. Pharmacokinetic 
knowledge of the different types of levodopa preparations aids therapy conversion 
and appropriate use. The lower (70%) bioavailability of CR compared to IR needs 
to be taken into account in dose adjustments between the formulations. Modest 
increases in dosing interval can be achieved, but the main use is to lower peak 
plasma concentrations to limit peak-dose dyskinesia. However, patients who enjoy 
the relatively faster response to IR (and the increased mobility which accompanies 
dyskinesia) may dislike the slow time to peak from CR (Hutton, Morris, Bush, 
Smith, Liss, & Reines 1989). Dispersible preparations are useful with the initial 
morning dose to help patients 'get going' and can be taken to relieve wearing-off 
symptoms or for a more rapid onset response when there are unpredictable 'off 
periods. Although CR prolongs the half-life of levodopa, and improves end-of-dose 
wearing-off and especially overnight control (benefiting the hypokinesia which 
prevents turning in bed), it does not delay the motor fluctuations inherent to PO, of 
which dyskinesia is the most troublesome (Hammerstad et al. 1994; Koller, Hutton, 
Tolosa, & Capilldeo 1999). 
Effective switching from one DA to another requires careful calculation of dose 
equivalency (Bhatia, Brooks, Burn, Clarke, Grosset, MacMahon, Playfer, Schapira, 
Stewart, & Williams 2001) and where cabergoline is involved, its very long half-life 
must be taken into consideration. 
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Varying degrees of missed doses 
These have been divided into 6 categories (Urquhart 1997): patients who 
• remedicate punctually 
• have timing variations but miss very few doses 
• miss a few doses, rarely more than one at a time 
• have occasional (3-4 per year) drug holidays (no medication for 3 or more 
consecutive days) 
• take monthly drug holidays (medication missed for 3 or more consecutive days 
each month) 
• take few or no doses 
These patterns of non-compliance have not previously been published in PD. 
Results of our study are presented in Chapter 3. A small study (Leopold, Polansky, 
& Hurka 2004) concluded that about 10% (4 of 39) of PO patients stick to their 
prescribed medication regimen. Compliance was measured for one month using a 
questionnaire and a computerised electronic monitoring system (Leopold, 
Polansky, & Hurka 2004). Venous levodopa levels have been used to assess 
compliance in PD patients (Copeland et al. 1994). In this study 103 samples from 
53 patients were analysed and 3 were at or below the lower limit of the assay 
indicating poor compliance. Five values were above the therapeutic range and 
dyskinesia was more common in this group. 
Complexity of drug regimen is inversely related to compliance (Claxton, Cramer, & 
Pierce 2001). Often in PD, patients are on several different antiparkinsonian drugs 
and on various formulations of the same drug in addition to other therapy for 
coexisting conditions. Adherence to such regimens requires significant effort. 
Regimen simplification, perhaps using longer acting preparations such as 
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cabergoline or ropinirole CR (currently under trial) or combination products e.g. 
Stalevo (Hauser 2004) may ease the process of medicine taking. 
Overuse of Medication 
Overuse of medication is well recognized in many conditions, particularly with 
drugs possessing addictive properties. In PD, a small subgroup of patients use 
dopamine replacement therapy excessively and compulsively, and take increasing 
quantities of dopamine replacement therapy despite severe drug-induced 
dyskinesia and a cyclical mood disorder (Giovannoni et al. 2000; Lawrence, Evans, 
& Lees 2003). Overuse was also found in PD patients with punding (stereotyped 
repetitive manipulations of equipment or objects); 10 of 17 (59%) patients with 
punding compulsively overused medication, as assessed from drug history (Evans 
et al. 2004). A lesser degree of dopamine replacement therapy overuse to gain 
mobility despite worsening dyskinesia is common in clinical experience and merits 
quantification. 
Consequences of non-compliance in PO 
Loss of health gain Immediate consequences of non-compliance are lack of 
efficacy impairing function and quality of life. In the PD life study (Chaudhuri et al. 
2004), patients who delay therapy initiation have worse motor scores and quality of 
life. Some drugs are more forgiving to non-adherence because of different 
pharmacokinetics and pharmacodynamics. Drug potency is a factor; there may be 
no noticeable effect from a missed dose of selegiline, but missing a levodopa dose 
is more likely to induce 'wearing-off'. A long elimination half-life such as 
cabergoline leaves residual activity when a single dose is omitted. The duration of 
effect is longer for agents with irreversible or non-competitive binding (e.g. 
selegiline) than for drugs that bind reversibly or competitively to enzymes or 
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receptors (e.g. COMT inhibitors). Additional complications may result from missed 
doses. In PO, withdrawal of anti parkinsonian medication (particularly if rapid) and 
especially for levodopa can very rarely trigger neuroleptic malignant syndrome 
(Takubo et al. 2003). 
In the longer term, poor compliance may contribute to the development of motor 
fluctuations. Abnormal pulsatile stimulation of striatal dopamine receptors 
contributes to the development of motor fluctuations. Animal studies (Gagnon, 
Bedard, & Oi Paolo 1990;Juncos et al. 1989;Pearce et al. 1998) indicate that 
continuous dopaminergic stimulation prevents motor complications. In PO patients 
similar conclusions come from clinical trials: initial therapy with a relatively long-
acting OA have significantly fewer motor complications than short-acting IR 
levodopa preparations (Rascol, Brooks, Korczyn, De Oeyn, Clarke, & Lang 
2000;The Parkinson Study Group 2000). In advanced PO, continuous therapy 
reverses motor complications with apomorphine (Manson, Turner, & Lees 2002), 
duodenal levodopa (Kurth et al. 1993; Nilsson, Nyholm, & Aquilonius 2001) or 
lisuride (Stocchi et al. 2002), again mirroring similar work in animal models 
(Gagnon, Bedard, & Oi Paolo 1990;Juncos, Engber, Raisman, Susel, Thibaut, 
Ploska, Agid, & Chase 1989; Pearce, Banerji, Jenner, & Marsden 1998) . 
Intermittent dopaminergic stimulation from erratic intake of medication through poor 
compliance will contribute to fluctuating plasma and brain levels of antiparkinsonian 
therapy. It seems likely from the above experimental and clinical evidence that 
such variations in the delivery of medication would contribute to the development of 
motor fluctuations. Electronic monitoring data (Figure 1.7) converted to estimated 
drug levels (Figure 1.8) shows how erratic drug timing exaggerates peaks and 
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troughs. The prospect of reducing fluctuations by regularising oral medication is 
appealing, but may be oversimplistic. 
Adequate thresholds for clinical effect in relation to compliance vary according to 
drug type and mode of action, but for PO are largely unknown. 
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Figure 1.7: Two-week chronology plot of co-careldopa 125 prescribed one tablet 5 
times daily. Time windows for each dose (2 hours around the target) are marked. Data 
is taken from a 3-month monitoring period during which total compliance was 82%, 
daily compliance was 26%, and interval compliance was 25%. 
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Figure 1.8: Estimated plasma L-dopa levels in a 5 times daily schedule. Upper 
graph is derived from chronology plot shown in Fig 1.4. Reduced levels overnight 
reflect scheduling of medication during waking hours; daytime drug level fluctuations 
occur from erratic therapy intake including missed and extra doses. Lower graph is a 
theoretical perfect dose schedule, modelled from regular daytime intake, and shows 
more steady drug delivery. 
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Using therapy response as a diagnostic aid 
In PO where there is a degree of diagnostic uncertainty, therapy response is used 
as a diagnostic tool. An excellent and sustained response to levodopa is one of the 
supporting features in step 3 of the UK Brain Bank Criteria (Gibb 1988); assuming 
that the poorly responding patient is fully compliant with medication may mislead 
the diagnostic process. 
Clinical significance of therapy adherence in PD. 
Subsequent management decisions in PO depend on response to therapy. 
Impaired therapy response points the clinician to an alternative tremor disorder or a 
Parkinson-plus condition, but may result from low drug intake. Decisions to titrate 
medication or combine treatments also depend on estimating the therapeutic 
response from prevailing doses; patients omitting doses may be incorrectly judged 
to have more rapid disease progression. 
Clinical trials 
Adherence measures help the interpretation of both biological and pharmacological 
aspects of drug trials (Rudd et al. 1990; Rudd et al. 1992) . Nonadherence can 
therefore bias assessment of drug treatment efficacy (Gordis L 1979;Haynes & 
Dantes R. 1987). Cholesterol and coronary risk were reduced four times more 
effectively when patients took 5-6 of 6 prescribed doses of cholestyramine than in 
those taking only 1-2 doses (Lipid Research Clinics Coronary Primary Prevention 
Trial 1984). The investigators projected that adverse coronary events might be 
halved if all patients took the prescribed dose. In PO trials, adherence is usually 
measured by simple tablet count (Rascol et al. 1998;Shults et al. 2002) which may 
overestimate compliance. The lower limit usually applied is 80% of tablet intake but 
is arbitrary and does not have a strong pharmacological basis (Hughes et al. 
2001). Compliance in clinical trials is generally higher than in 'real-life' due to 
patient selection (less concomitant disease and fewer co-administered drugs) and 
closer monitoring (Andrade et al. 1995;Fayers & Hand 1997). 
Economic considerations 
Potential economic costs of non-compliance include loss of work time due to poor 
symptom control, drug stockpiles, increased consultations, hospital admissions and 
higher levels of care. Increased motor complications may lead to earlier use of 
expensive therapies including apomorphine and surgery including stimulators. 
Concordance in managing PO 
In the management of PO there are several options of drug management at each 
disease stage. Timing and choice of first and subsequent drugs and their titration 
schedules represent some of the many considerations. Such variations in practice 
are being analysed in ongoing clinical research such as the PO MED study. 
Physicians are guided by knowledge gained from clinical trials, but ideally the 
therapy choice should result from a shared process, seeking the patient's 
knowledge, views, understanding and attitudes. This requires the provision of 
accurate and concise information and ultimately giving the patient the management 
decision. The Medicines Partnership describe three pillars of concordance: (i) 
patient knowledge, (ii) involving patients as partners and (iii) supporting patients in 
taking medicines. 
Conclusion 
Knowledge of medicine-taking behaviour and clarifying the patient's intentions 
through improved concordance is essential for a complete understanding of the 
patient's clinical presentation and response. These factors impact on diagnostic 
accuracy and subsequent management decisions. Sub-optimal therapy intake has 
several potential consequences. Patients who under-dose may have increased 
disability and reduced quality of life. Mental state and behavioural problems occur 
from medication overuse. Those who take medication erratically may increase 
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clinical fluctuations. Research is needed to examine medicine-taking behaviour in 
PO to guide interpretation of therapy response in practice and in clinical trials. 
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Chapter 2 
The risks of prescription medication from a general 
neurological perspective; What are patients concerns 
about prescribed medication? 
~7 
Introduction 
A therapy history is a fundamental part of the healthcare consultation. Current 
drugs (prescribed, over the counter, herbal remedies, drugs of misuse) and how 
they are being taken (frequency, timing, missed and extra doses), drugs tried in the 
past, reason for discontinuation, therapy response, adverse effects, allergies and 
intolerances should be taken into account. Recent immunisations may also be of 
importance. Knowledge of medicine-taking behaviour may clarify clinical 
presentations such as analgesic overuse causing chronic daily headache, or 
severe dyskinesia resulting from obsessive use of dopamine replacement therapy. 
Patients' beliefs about medicines have a close relationship to therapy adherence 
(Horne & Weinman 1999). Patients weigh up the balance between their personal 
necessity for medication (based on symptoms, disease perception, and 
expectations of therapy) against potential concerns over side effects (both short 
and long-term) and worries over becoming drug dependent. A questionnaire 
scoring levels of drug necessity against concerns has been validated for both 
general and disease specific versions (e.g. asthma, HIV, cardiac and renal 
disease). Patients with high necessity and low concern scores have higher therapy 
adherence; low necessity and high concerns correlate with low adherence; while 
high necessity together with high concerns provide patients with a dilemma 
resulting in partial adherence. How valid are patients' concerns about potential 
adverse effects? This chapter reviews drug-induced neurological problems in 
relation not only to Parkinson's disease but also to frequently associated problems 
(e.g. confusion and depression). 
Movement Disorders 
Drug induced movement disorders are common. In epidemiological studies 
between a third and a half of parkinsonism is caused by medication (Jimenez-
Jimenez, Garcia-Ruiz, & Molina 1997). On the other hand dopaminergic excess 
results in hallucinations, chorea and dystonia (Figure 2.1) . 
Figure 2.1: Diagram of Dopaminergic System and Disease and Drug Effects 
Therapy to replace deficient dopamine or otherwise stimulate the dopaminergic system in 
Parkinson's disease may cause hallucinations and paranoia, a form of drug-induced 
psychosis. Schizophrenia patients treated with neuroleptics may develop a movement 
disorder, such as tremor, parkinsonism, or tardive dyskinesia. 
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Neuroleptics are particularly likely to induce movement disorders. In one 
prevalence study, 62%) of patients on neuroleptics developed movement disorders, 
encompassing a mix of akathisia (31 %), parkinsonism (23% ) and tardive 
dyskinesia (32%) (Janno et al. 2004). Extrapyramidal symptoms are associated to 
a lesser extent with all groups of antidepressants (tricyclics, monoamine OXIdase 
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inhibitors and selective serotonin re-uptake inhibitors (SSRls)) (Gill, DeVane, & 
Risch 1997), though this is based on case reports rather than controlled studies. 
The risk appears greater with the SSRls than tricyclics. Complex interactions of 
dopamine, serotonin and noradrenaline between cortical structures and basal 
ganglia are the likely mechanism. Considering antidepressant treatment for 
patients with PO is complex. Depression affects at least a third of PO patients. 
Clinical experience suggests significant benefit from antidepressant therapy in 
selected patients, although some patients report worsened parkinsonism. A 
Cochrane systematic review concluded that there is insufficient data on the 
effectiveness and safety of antidepressant therapies in Parkinson's disease 
(Chung et al. 2003). 
Akathisia (restlessness) may be induced by the antidepressants (Gill, DeVane, & 
Risch 1997), antipsychotics, antihistamines, calcium channel blockers, 
carbamazepine or metoclopramide. Akathisia is described as a sense of inner 
restlessness, a subjective need to move, such as shuffling of the legs, marching on 
the spot, pacing, rocking or crossing/uncrossing the legs. It is a frequent and early 
side effect of antipsychotic therapy (Miller et al. 1997) usually occurring within 2 
weeks of initiation. If the offending drug cannot be stopped, propranolol or 
benzodiazepines may alleviate the symptoms. 
Chorea is an adverse effect of dopaminergic excess. Thus in patients with PO, 
levodopa (Rascol, Brooks, Korczyn, De Deyn, Clarke, & Lang 2000), dopamine 
agonists (Hubble 2002) and COMT inhibitors (Fenelon, Gimenez-Roldan, 
Montastruc, Bermejo, Durif, Bourdeix, Pere, Galiano, & Schadrack 2003; Larsen, 
Worm-Petersen, Siden, Gordin, Reinikainen, & Leinonen 2003) may all contribute. 
About half of PO patients treated with levodopa will develop motor complications of 
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end-of-dose 'wearing off', dyskinesia (chorea/dystonia) and 'on-off fluctuations 
within 5 years (Lees 1986;Marsden & Parkes 1976). Such motor complications are 
commoner in young onset patients (100 010 after 6 years in cases developing PO 
before age 40) (Clarke 2002). Dopamine agonists are now a frequent choice of 
initial antiparkinsonian medication (Montastruc, Rascol, & Senard 1999), based on 
strong evidence from many independent controlled studies that DAs delay the 
onset of motor complications and the need to initiate levodopa therapy for many 
months and even years (Hubble 2002). Selegiline is an alternative dopamine 
sparing agent which delays the need for levodopa by 9 months (Shoulson 1989). 
Reducing antiparkinsonian medication lessens dyskinesia but increases 'off' time, 
and most patients prefer to maintain 'on' time despite the dyskinesia. Amantadine 
has some antidyskinetic activity in levodopa induced motor complications (Metman, 
Del Dotto, LePoole, Konitsiotis, Fang, & Chase 1999). A small subgroup of 
Parkinson's disease patients use dopamine replacement excessively and 
compulsively (Giovannoni, O'Sullivan, Turner, Manson, & Lees 2000; Lawrence, 
Evans, & Lees 2003), and take increasing quantities of dopamine replacement 
therapy despite severe drug-induced dyskinesia and a cyclical mood disorder. 
Anticonvulsant induced chorea is rare but the risk increases with polytherapy 
perhaps due to an additive or synergistic effect on central dopaminergic pathways; 
the combination of phenytoin and lamotrigine in particular predisposes to drug 
induced chorea (Zaatreh et al. 2001). Other drugs such as amiodarone, 
amphetamines, antihistamines, anti-psychotics, oral contraceptives and 
metoclopramide may cause chorea. 
Tardive syndromes are a group of delayed-onset abnormal involuntary movement 
disorders induced by dopamine receptor blocking agents (Fernandez & Friedman 
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2003). Tardive dyskinesia (rhythmic involuntary movements of tongue, face and 
jaw) is the best known and may occur even up to years after withdrawal of the 
drug. Tardive dystonia (usually of the face and neck), akathisia (which begins 
during neuroleptic therapy or within 3 months of discontinuation and persists for 1 
month or more after drug discontinuation), tics (tardive Tourettism), myoclonus (of 
the neck or upper arms and particularly associated with high doses of neuroleptics) 
and tremor can also result from chronic antipsychotic use (Rodnitzky 2002). These 
syndromes also occur with the newer atypical anti psychotics but the risk is lower. 
Informing and monitoring the patient may help to reduce malpractice claims which 
are common in the US in this therapeutic area (Kaye & Reed 1999). Kaye et al 
(Kaye & Reed 1999) describe the 4 commonest reasons for malpractice claims 
brought by patients with tardive dyskinesia (TO). 
1. The risk of developing TO was not explained and consent was not obtained. 
2. Diagnostic error, treatment with dopamine blocking drugs was not warranted. 
3. The physician failed to monitor the patient. 
4. The drug manufacturer and the doctor (as the manufacturer's agent) produced a 
drug with defective design, testing or warning information (product liability). 
Onset of TO within 3 months of drug exposure is possible but uncommon. Some 
improvement after withdrawal of the offending drug occurs in a third of cases 
(Jeste & Wyatt 1979), but complete recovery is rare (Glazer et al. 1990). If 
antipsychotic therapy cannot be discontinued, an atypical agent or tetrabenazine 
may help (tetrabenazine is dopamine depleting and blocks postsynaptic dopamine 
receptors ). 
Acute Dystonic reactions can be induced by dopamine depleting drugs such as 
antihistamines, antipsychotics, antiemetics (domperidone, metoclopramide, 
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prochloperazine), tetrabenazine and antimalarials. Domperidone and 
metoclopramide use is restricted in children and young adults (under 20 years) in 
whom acute dystonic reactions are commoner. The dystonia usually occurs on the 
first day of drug exposure and affects the head, neck and trunk muscles with neck 
retraction, tongue protrusion, trismus and oculogyric crisis. Acute dystonic 
reactions are treated with anticholinergics (benztropine) or benzodiazepines. 
Chronic dystonia is associated with antiparkinsonian medication (Ievodopa and 
the dopamine agonists), phenytoin, phenobarbitone and tetrabenazine. The 
dystonia of Parkinson's disease, typically early morning calf or foot cramps, is a 
'wearing-off' symptom which responds to DA or levodopa. 
Tremor is caused by many drugs through several mechanisms (Smaga 2003) 
(Table 2.1). Drugs may enhance physiological tremor, typically a high frequency 
postural tremor. Dopamine depleting drugs cause a parkinsonian tremor typically 
the 4-6 Hz 'pill-rolling' rest tremor. Drugs causing a cerebellar syndrome cause an 
intention tremor; withdrawal tremors follow discontinuation of drugs of dependence 
or alcohol. 
Table 2.1: Mechanisms of Drug-induced Tremor 
Enhanced Physiological 
Sympathomimetics 
Bronchodilators 
Theophylline 
Pseudoephedrine 
Antidepressants 
Amiodarone 
Sodium valproate 
Parkinsonian 
Neuroleptics 
Metoclopramide 
Prochloperazine 
Antidepressants 
Calcium antagonists 
Sodium valproate 
Cerebellar 
Lithium 
PhenytOin 
Chemotherapy-SFU 
Chronic alcoholism 
Amiodarone 
SSRI = Selective Serotonin Reuptake Inhibitor; SFU = 5 Fluorouracil 
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Withdrawal 
Benzodiazepines 
SSRI-Paroxetine 
Alcohol 
Opiates 
Parkinsonism can be drug induced and may be clinically indistinguishable from 
idiopathic Parkinson's disease (PO) (Arblaster et al. 1993). Although symptoms 
may be asymmetrical (Caligiuri, Bracha, & Lohr 1989), a symmetrical presentation 
is commoner than in idiopathic PD. Functional imaging using [1231]-FP-CIT 
(OaTSCAN, GE Healthcare, pic) single photon emission computerized tomography 
(SPECT), a measure of presynaptic dopamine transporters, differentiates drug 
induced parkinsonism (normal scan) from idiopathic PO (abnormal scan). Drug-
induced parkinsonism is most commonly attributed to anti psychotics or 
prochloperazine. Other implicated drugs are antidepressants, cinnarizine, 
metoclopramide and tetrabenazine. Atypical anti psychotics are less likely to induce 
extrapyramidal adverse effects (Baldessarini & Tazazi 2001), ranked in the 
following order: clozapine < quetiapine < olanzapine = zisprasidone (though this 
excludes akathisia and neuroleptic malignant syndrome) (Tarsy, Baldessarini, & 
Tarazi 2002). Antipsychotic induced parkinsonism is treated with an antimuscarinic 
(less correctly anticholinergic) usually procyclidine, if the antipsychotic medication 
cannot de discontinued. Sodium valproate can induce reversible parkinsonism 
(Armon et al. 1996). There are reports of calcium channel blockers such as 
diltiazem and verapamil causing drug-induced parkinsonism on rare occasions 
(Rodnitzky 2002). 
Neuroleptic Malignant Syndrome (NMS) is caused by acute dopamine 02 
receptor blockade (Pelonero, Levenson, & Pandurangi 1998) in the corpus 
striatum, hypothalamus and spinal cord. It is an acute and severe form of drug-
induced parkinsonism with a mortality of around 10% (Addonizio, Susman, & Roth 
1987; Pearlman 1986; Rosenberg & Green 1989) due to rhabdomyolysis, 
disseminated intravascular coagulation and acute renal failure. Estimations of 
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incidence vary between 0.02%) and 3.2% of patients on neuroleptics. Dehydration 
is an important predisposing factor. NMS is characterised by hyperthermia, 
fluctuating level of consciousness, muscular rigidity (often axial), dystonia, 
autonomic dysfunction and elevated levels of muscle proteins (creatine kinase and 
myoglobin) (Table 2.2). Several diagnostic criteria have been proposed; 
hyperthermia and muscle rigidity are cardinal features. Drugs causing 
parkinsonism may all produce NMS (particularly antipsychotic drugs, with a delay 
in onset for depot preparations) but withdrawal, particularly if rapid, of 
antiparkinsonian medication especially levodopa is also a trigger mechanism, as is 
rapid switch of dopamine agonists (Levenson 1985; Reimer, Kuhlmann, & Muller 
2002;Takubo, Harada, Hashimoto, Inaba, Kanazawa, Kuno, Mizuno, Mizuta, 
Murata, Nagatsu, Nakamura, Yanagisawa, & Narabayashi 2003). Treatment 
involves stopping the causative agent (and lithium if the patient is taking this) and 
supporting with IV fluids, antipyretics and a cooling blanket. Several case reports 
demonstrate effective use of specific therapy such as dopamine agonists, 
levodopa, amantadine or dantrolene. Recovery usually occurs within 2 to 14 days. 
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Table 2.2: Characteristics of Neuroleptic Malignant Syndrome and Serotonin 
Syndrome 
Serotonin Syndrome 
Causative Drugs SSRls, TCAs, MAOls 
Mechanism 5-HT receptors overstimulation 
Onset of symptoms Within 24 hours 
Symptoms Autonomic, Mental, Neurological 
Neuroleptic Malignant Syndrome 
Neuroleptics, metoclopramide, 
amoxapine (a TCA), sudden 
dopaminergic therapy withdrawal 
D2 receptor blockade 
Within 7 days (longer with depot drugs) 
Autonomic, Mental, Neurological 
Differentiating Symptoms Myoclonus, diarrhoea, 
nausea, shivering 
Dysphagia, hypersalivation,incontinence 
Signs 
Laboratory results 
Disease severity 
Dilated pupils, myoclonus, 
Hype r-reflexi a 
tWCC, tCK 
Wide spectrum mild - severe 
Temp >380 C, akinesia, extrapyramidal 
rigidity 
t WCC, nCK 
More severe - most cases require 
intensive care 
Serious complications DIC, leukopenia, thromboytopenia, DIC, acute renal failure, rhabdomyolysis 
Main treatment 
Specific Treatments 
Recovery 
Mortality 
seizures, multi-organ failure, myocardial infarction, sepsis 
rhabdomyolysis cerebellar neuronal degeneration 
Discontinue causative drug(s); 
supportive 
Discontinue causative drug(s); 
supportive 
Benzodiazepines, cyproheptadine, Dopamine agonists, amantadine, 
chlorpromazine carbidopa-Ievodopa, dantrolene 
70% within 24 hours 2-14days 
Total of 23 deaths to 1999 15 - 20 % of cases 
SSRls = Selective Serotonin Reuptake Inhibitors, TCAs = Tricyclic Antidepressants, MAOls = 
Monoamine Oxidase Inhibitors, 5-HT = 5-Hydroxytryptamine (serotonin), WCC = White Cell Count, 
CK = Creatine Kinase, DIC = Disseminated Intravascular Coagulation 
Cognitive Impairment 
Confusion, cognitive impairment and hallucinations are manifestations of relatively 
reduced cholinergic activity as illustrated in Figure 2.2. 
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Figure 2.2: Diagram of Acetylcholine System and Disease and Drug Effects 
Relative cholinergic excess in Parkinson's disease may be corrected by using 
anticholinergic drugs, but the risks of causing confusion and aggravating Parkinson 's-
related cognitive impairment or dementia means that these drugs are less commonly 
prescribed today. Acetylcholinesterase inhibitor drugs, used to treat Alzheimer's disease, 
have an opposite effect, and have tremor amongst the list of side-effects. 
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Anti-parkinsonian medications particularly anticholinergics (Sarter & Bruno 1998) 
and dopamine agonists (Bhatia, Brooks, Burn, Clarke, Grosset, MacMahon, 
Playfer, Schapira, Stewart, & Williams 2001; Hubble 2002) may induce such 
adverse effects which necessitate dose reduction although discontinuation is often 
required. Frank psychosis occurs more rarely. Cognitive impairment is also 
reported with valproate (Armon, Shin, Miller, Carwile, Brown, Edinger, & Paul 
1996). Many drugs can cause confusional states including amphetamines, 
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anticonvulsants, antidepressants, antituberculous drugs, antimalarials, anti-
inflammatories, cardiac glycosides, diuretics, hypotensive agents, H2 antagonists, 
neuroleptics, opiates, sympathomimetics, and sedatives. Agitation and confusion 
may be part of a withdrawal syndrome from drugs of addiction and alcohol. Central 
neurotoxicity can result from chemotherapy (particularly methotrexate, cytarabine 
and ifosfamide used in the treatment of acute leukaemias) ranging from minor 
cognitive impairment to encephalopathy (Verstappen et al. 2003). 
Serotonin Syndrome is an acute iatrogenic drug-induced condition, characterised 
by a triad of cognitive behavioural changes, autonomic instability and 
neuromuscular excitability (Ener et al. 2003). It is caused by overstimulation of 5-
HT receptors (Birmes et al. 2003). However, the clinical similarity between 
serotonin syndrome and neuroleptic malignant syndrome (an acute dopaminergic 
blockade) indicates a more complex reciprocal interplay in the balance between 
serotonergic and dopaminergic systems rather than a simple serotonergic excess 
or dopamine deficiency. Since serotonin excess inhibits dopamine secretion, there 
is clinical overlap in the two syndromes (see Table 2.2). Different mechanisms of 
serotonin (5-HT) excess are summarised in Table 2.3 and Figure 2.3. 
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Table 2.3: Mechanisms of serotonin overstimulation 
Mechanism 
Drugs metabolised to serotonin 
or promoting serotonin release 
Inhibition of serotonin reuptake 
Inhibition of serotonin metabolism 
Postsynaptic receptor stimulation 
Drugs 
Levodopa, Lithium, MAOls, Tryptophan, Trazodone, 
Tetrabenazine 
SSRls, TCAs, Trazodone, Tramadol, St John's wort, 
Venlafaxine 
MAOI (phenelzine, isocarboxid, selegiline), St John's 
wort 
Buspirone, Triptans, Lithium, Carbamazepine 
MAOls = Monoamine Oxidase Inhibitors; SSRls = Selective Serotonin Reuptake Inhibitors; TeAs = 
Tricyclic Antidepressants 
Figure 2.3: Mechanisms of Serotonin Syndrome 
Metabolism of tryptophan to serotonin and release and recycling in the synaptic 
system is shown. Sites of potential disruption from exogenous drugs, which may be 
involved in generating a serotonin syndrome, are numbered (see key). 
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Stimulation via 5-HT receptors 
4 
1 Increased substrate 
2 Inhibition of serotonin metabolism 
3 Increased release serotonin into synaptic cleft 
4 Postsynaptic receptor stimulation 
5 Inhibition of serotonin reuptake 
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Postsynaptic Neurone 
The main causative drugs are selective serotonin reuptake inhibitors (SSRls), 
tricyclic antidepressants (TeAs) (Trindade et al. 1998) and monoamine oxidase 
inhibitors (MAOls e.g. selegiline). The syndrome usually occurs after a dose 
increase or after adding a second serotonergic agent. Fortunately the risk of 
inducing this syndrome is low. For example, SSRI treatment of depression in 
patients with Parkinson's disease already on selegiline, found possible serotonin 
drug interaction in only 11 of 4568 patients (0.24%) (Richard et al. 1997). Serotonin 
syndrome has been reported as an interaction between St.John's wort (Hypericum 
perforatuma, a herbal remedy used in depression) and SSRls in several case 
reports (Ernst 2003). Theoretically the 5-HT agonists (the triptans) could cause a 
serotonergic overstimulation but there are no reports of serotonin syndrome when 
these drugs are prescribed as monotherapy although cases are described where a 
triptan has been combined with another serotonergic drug. Revised diagnostic 
criteria of serotonin syndrome are outlined in Table 2.4 (Radomski et al. 2000). 
Serotonin syndrome should be considered in patients who present with an acute 
confusional state with mild pyrexia, sweating, agitation, nausea, tremor and 
diarrhoea. Symptoms typically occur rapidly after the medication change, within 2 
hours in 50% and 24 hours in 75% of cases. Neuromuscular excitability 
(myoclonus, rigidity, tremor) occurs in 50% (Mills 1995) and changes in mental 
state (usually excitation) occur in 40% of cases. Elevated serum creatine kinase, 
white cell count, hepatic transaminases and lowered serum bicarbonate levels 
support the diagnosis. The serotonergic agent or agents must be discontinued. 
Supportive therapy should be given; 40% require intensive care admission and 
25% need intubation. Benzodiazepines have been used to reduce anxiety. 
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Cyproheptadine (an antihistamine with antiserotonergic characteristics) and 
chlorpromazine (a 5-HT receptor antagonist neuroleptic) may be tried although 
their benefit is not proven. Deaths have been reported but the mortality rate is 
unknown. 
Table 2.4: Diagnostic Criteria for Serotonin Syndrome 
• Increase in dosage or addition of a second serotonergic agent 
• Plus 4 major symptoms or 3 major and 2 minor symptoms 
Autonomic Symtoms 
Major 
Fever 
Hyperhidrosis 
Mental Symptoms 
Major 
Confusion 
Hypomania 
Coma or altered consciousness 
Neurological Symptoms 
Major 
Rigidity 
Myoclonus 
Tremor 
Hyperreflexia 
Exclusions 
Minor 
Tachycardia 
Tachypnoea, dyspnoea 
Diarrhoea 
Hypo or hypertension 
Minor 
Agitation, nervousness 
Insomnia 
Minor 
Akathisia 
Impaired co-ordination 
Mydriasis 
No recent introduction or dose increase of neuroleptic 
Other causes (e.g. infective, metabolic, endocrine, toxic) excluded 
No similar symptoms attributed to psychiatric condition prior 
to introduction of serotonergic agent 
from Radomski et al 
Cholinesterase Inhibitors indicated for mild to moderate Alzheimer's disease 
have the potential to cause hypercholinergic effects either central (excitation, 
agitation) or peripheral (bradycardia, gastrointestinal symptoms) via drug 
interactions with psychotropics or antiarrythmics (Bentue-Ferrer et al. 2003). 
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Conclusion 
A wide spectrum of neurological presentations may be caused or precipitated by 
drugs, both prescribed and non-prescribed. This can be at first presentation, or in 
cases with already established neurological disease. Doctors have responsibility in 
preventing iatrogenic symptoms by careful prescribing, and in identifying drug-
induced syndromes. Failure to consider a drug-induced cause or incorrect 
attribution of the presentation to drug therapy may lead to inappropriate 
investigations and management. 
Quantifying and summarising risk to guide patients in starting treatment and 
becoming aware of emerging side-effects is a key component of the concordance 
process. A European Union directive recommends qualitative descriptions for 5 
bands of risk ranging from very rare (defined as <0.01 %» to very common (>10 % ) 
(European Commission Pharmaceutical Committee 1998). However, when people 
are given qualitative descriptions of risk, the degree of risk is overestimated 
compared against risk information given in numerical terms. The patient is less 
likely to adhere to a drug regimen if they perceive side effects to be very common 
(Berry, Knapp, & Raynor 2002). Thus misplaced or exaggerated concerns about 
adverse effects may need addressed. In PO, treating one movement disorder 
(tremor, rigidity, bradykinesia) may result in another (chorea, dystonia). Benefits in 
terms of symptom control and improved in quality of life are weighed against 
potential adverse effects by both patients and clinicians. The patient's perspective 
on risks of therapy will be reflected in their medicine taking behaviour. 
62 
Chapter 3 
Measuring therapy adherence in Parkinson's disease: a 
comparison of methods 
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Introduction 
In this chapter four methods of assessing therapy adherence are compared with a 
view to practical use in day to day clinical practice and relevance for clinical trials. 
Consideration of how patients take their medication is vital in understanding the 
therapeutic response in any patient group. In Parkinson's disease, an excellent 
response to levodopa supports the accuracy of the clinical diagnosis (Hughes et al. 
1992), while in other disorders poor adherence to drug therapy is often identified 
and accepted as a principal reason for impaired response (Urquhart 1994). 
Evidence for excess medication intake by some Parkinson's patients is based 
largely on self-reporting (Lawrence, Evans, & Lees 2003) while electronic 
monitoring identified that only one in ten patients had complete schedule 
adherence (Leopold, Polansky, & Hurka 2004). Simple tablet counts, which are 
often used in clinical trials to indicate satisfactory adherence in Parkinson's 
(Rascol, Brooks, Brunt, Korczyn, Poewe, & Stocchi 1998;The Parkinson Study 
Group 1997) and elsewhere (Hughes, Bagust, Haycox, & Walley 2001) can be 
inaccurate when patients maintain multiple supplies (e.g. home, work) (Cramer et 
al. 1989;Stephenson et al. 1993) or discard drugs deliberately (Rand et al. 1992). 
Measurement of compliance 
There are 2 main categories, direct and indirect. 
Direct Measurement of drug or metabolite levels in blood, urine or saliva is one 
approach. Measures of disease severity reflecting the drug mechanism are also 
considered direct e.g. lymphocyte subpopulation counts in assessing antiretroviral 
therapy, or glycosylated haemoglobin in diabetes. Serum and urine levels can be 
misleading because sampling is limited and compliance may improve at the time of 
measurement (e.g. in anticipation of a clinic visit) (Rudd, Ahmed, Zachary, Barton, 
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& Bonduelle 1990;Urquhart 1994). Compared against electronic drug monitoring 
devices, serum drug concentrations had no significant relationship to compliance in 
epilepsy (Cramer, Mattson, Prevey, Scheyer, & Ouellette 1989). Also, non-drug 
effects may influence disease markers, such as diet in diabetes. Venous levodopa 
levels (Copeland, Dutton, Roberts, & Playfer 1994) in 103 samples from 53 PO 
patients suggested poor compliance in 3 (2.9°k) whose levels were at or below the 
lower limit of the assay. 
Indirect Methods include pharmacy refill data and appointment keeping (both of 
which are broad indicators) and self-reports, healthcare professional's assessment, 
simple tablet count and electronic monitoring devices. Electronic monitoring 
assumes that medication is ingested, while it may simply be collected and stored or 
destroyed. Pharmacy refill data is useful in large population-based studies (Steiner 
& Prochazka 1997) but is of limited value in short-term studies. Self-reports vary 
from simply asking patients about compliance (avoiding a judgmental approach or 
prompting) to structured validated questionnaires. Careful questioning identifies 
over half of non-compliant patients (Stephenson, Rowe, Haynes, Macharia, & Leon 
1993). There are structured validated self reports such as the brief medical 
questionnaire (Svarstad et al. 1999) and the Morisky self-report (Morisky, Green, & 
Levine 1986). Using blood pressure control as a measure of adherence, the 
Morisky scale has a sensitivity of 81 % and specificity of 44°k. Compared against 
pill counts, self-reports are 55% sensitive and on average 87°k specific 
(Stephenson, Rowe, Haynes, Macharia, & Leon 1993). Self-reports of sub-optimal 
adherence are accurate (Hugen et al. 2002), but reports of full adherence may be 
misleading and self-reporting often overestimates true adherence behaviour 
(Melbourne et al. 1999). In PO studies of excess dopamine replacement therapy 
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intake, medication history was used to assess dosages taken (Evans, 
Katzenschlager, Paviour, O'Sullivan, Appel, Lawrence, & Lees 2004;Giovannoni, 
O'Sullivan, Turner, Manson, & Lees 2000; Lawrence, Evans, & Lees 2003). Clinical 
judgement of compliance is inaccurate and no better than chance (Gilbert et al. 
1980;Roth & Caron 1978); in Primary Care sensitivity was 10% (Gilbert, Evans, 
Haynes, & Tugwell 1980) for patients well-known to the reporting physician. Simple 
tablet counts are easy and inexpensive for routine practice and indicate total dose 
compliance (ratio of total taken dose: recommended dose) but consistently 
overestimate compliance (Cramer, Mattson, Prevey, Scheyer, & Ouellette 
1989; Paes, Bakker, & Soe-Agnie 1998; Pullar et al. 1989; Rudd, Ahmed, Zachary, 
Barton, & Bonduelle 1990). Accuracy improves with unannounced "spot checks" in 
the patient's home (Haynes et al. 1980) which requires ethical consideration. 
Electronic monitoring devices are the gold standard for monitoring compliance 
(Cramer, Mattson, Prevey, Scheyer, & Ouellette 1989), but are expensive and 
impractical for routine care. Medication Event Monitoring Systems (MEMS®, 
Aardex, Switzerland) are pill bottles with microprocessors which record dose date 
and time (Figure 3.1 ). 
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Figure 3.1 Medication Event Monitoring Systems (MEMS®, Aardex, Switzerland) . 
These are pill bottles with microprocessors which record the date and time of boffle 
opening. 
In addition to total dose compliance, daily compliance (percentage of days when 
dose taken correctly) and time interval compliance (ratio of correct: incorrect doses 
by time interval) are calculated. Electronic devices are more accurate and detailed 
than other methods (Cramer, Mattson, Prevey, Scheyer, & Ouellette 1989;George 
et al. 2000; Hugen, Langebeek, Burger, Zomer, van Leusen, Schuurman, 
Koopmans, & Hekster 2002; Kruse et al. 1992; Lee et al. 1996; Olivieri et al. 
1991; Rivers, Ardagh-Walter, & Wright 1998;Waterhouse et al. 1993). Electronic 
monitoring in 39 PO patients showed frequent under-compliance (Leopold, 
Polansky, & Hurka 2004). 
The most appropriate compliance measurement method depends on the clinical 
situation; combining methods may improve accuracy. In depression electronic 
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monitoring was the most accurate and serum levels had the least patient 
acceptability of 4 methods tested (George, Peveler, Heiliger, & Thompson 2000). 
The current study applied multiple techniques of assessing therapy adherence in 
PO, to define sensitivity of these methods against the gold standard of electronic 
monitoring (Cramer, Mattson, Prevey, Scheyer, & Ouellette 1989). 
Methods 
Study Population 
Consecutive patients in a movement disorder clinic and with idiopathic PO fulfilling 
UK Brain Bank Criteria were enrolled. Patients provided signed informed consent 
and the local ethics committee approved the protocol. Patients were taking at least 
one antiparkinson drug but were excluded if use of electronic bottles might 
adversely affect care (e.g. patients relying on a dosette box or similar device). 
Study Design 
A prospective single blind randomised crossover design was undertaken (Figure 
3.2). A computerised randomisation list was generated and group allocation was 
inserted into opaque envelopes. The sealed envelopes were then given to the 
investigator. A Parkinson's disease nurse specialist who remained blinded to group 
allocation (active therapy monitoring or no active therapy monitoring) carried out 
the clinical assessments. 
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Figure 3.2: Outline of study design in 129 patients with Parkinson's Disease. 
Patients were randomised to active therapy monitoring, with crossover between 
methods, but al/ patients completed self-reports of medicine intake. 
Baseline 3 months 6 months 
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(n = 44) 
STC = simple tablet count, EM = electronic monitoring 
Two thirds of patients underwent active monitoring, consisting of 2 x 3 month 
periods of simple tablet count alone, or simple tablet count concurrent with 
electronic monitoring, in random order. The remaining one third received no 
additional therapy monitoring (control group). Data was tested for any order effect 
on electronic monitoring results (performed first or second in the crossover design). 
Baseline assessments were of Unified Parkinson's Disease Rating Scale (UPDRS) 
1 to 4, Hoehn and Yahr, Schwab and England, Geriatric Depression Scale (GDS), 
Epworth sleep scale (ESS), Parkinson disease quality of life (PDQ 39), and mini 
mental state examination (MMSE). Current therapy and adverse events were noted 
and clinical scoring was blind to therapy monitoring method. Patients undergoing 
electronic monitoring had their PO medication dispensed into separate bottles for 
each drug type and strength. 
At 3 months patients completed a validated self-report (Svarstad, Chewning, 
Sleath, & Claesson 1999) from which medication intake was calculated. They also 
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marked a visual analogue scale for each PO drug (range 0-120) annotated as 
follows: 
• 50 representing about half of prescribed medication 
• 100 meaning all medication taken exacted as prescribed 
• 120 representing excess medication intake 
Patients also answered two questions: 
Please estimate how accurately you take your medication, 
• 1. I miss a dose of medication 
• 2. I take an extra dose of medication 
- with choices of response for each of these two questions of: 
• frequently I sometimes I rarely I never. 
• Patients recorded their opinion about being undertreated, overtreated or if 
antiparkinson therapy level was 'about right' and the clinician independently 
recorded a similar impression. 
• UPORS 1 to 4, Hoehn and Yahr, Schwab and England and adverse events 
were repeated at 3 and 6 months. 
Patients unable to use the electronic monitoring bottles or who misused them were 
withdrawn. 
Outcome Measures 
The following definitions were applied, which follows standard methodology: 
Total adherence refers to the amount of medication taken compared to the 
amount prescribed. In this study, total adherence was estimated by 4 different 
methods: 
• self-report 
• visual analogue scale 
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• simple tablet count 
• electronic monitoring 
Days adherence refers to the percentage of days the correct number of doses is 
taken. 
Timing adherence is the percentage of doses taken at the correct time interval. 
Timing adherence is calculated from time intervals which give an optimum 
pharmacokinetic profile, allowing for a 25%) deviation in timing (e.g. for a drug 
taken three times a day time intervals of between 6 and 10 hours are satisfactory). 
• Both days adherence and timing adherence were calculated from electronic 
monitoring. 
One-way analysis of variance (ANOVA) was undertaken to compare methods of 
measuring compliance, using Bonferroni correction for multiple comparisons if 
overall significance was less than 0.05. 
Average medicine intake was used to categorise actively monitored patients as 
follows: 
• 'satisfactory adherence' meaning ~80% intake, or 
• 'underuse' meaning <80% intake 
Electronic and tablet count methods were compared by McNemar's test. 
• The 80% cut off is commonly applied in compliance studies (George, Peveler, 
Heiliger, & Thompson 2000;Gilbert, Evans, Haynes, & Tugwell 1980;Haynes, 
Taylor, Sackett, Gibson, Bernholz, & Mukherjee 1980;Lee, Kusek, Greene, 
Bernhard, Norris, Smith, Wilkening, & Wright, Jr. 1996; Rosen et al. 2004; Rudd, 
Ahmed, Zachary, Barton, & Bonduelle 1990) and clinical trials including PO 
(Hughes, Bagust, Haycox, & Walley 2001 ;Rascol, Brooks, Brunt, Korczyn, 
Poewe, & Stocchi 1998). Although this grouping would include patients with 
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medication overuse (another form of non-adherence) these numbers were 
expected to be small. 
• The sensitivity and specificity of simple tablet count, self-report and visual 
analogue scale in detecting medicine underuse defined by electronic monitoring 
data were calculated. Statistical analysis used GraphPad Prism® (GraphPad® 
Software, San Diego, USA) and Statistica® (StatSoft, Bedford, UK). 
Results 
Of 135 patients approached, 6 (4%) declined mainly due to perceived disruption 
from using electronic monitoring bottles, leaving 129 cases randomised (Figure 
3.3). There was no significant difference in age, gender, disease duration, type or 
dose of antiparkinson medication (Ievodopa, dopamine agonist) for patients who 
declined (data not shown). Seventeen patients (13% of randomised cases) were 
excluded from analysis, as follows: 
• 3 withdrew consent 
• 9 had problems with the electronic monitoring bottles (difficulty using, 
mainly due to dyskinesia n = 3; misuse ego removing a full day's 
medication in the morning n = 4; lost bottles n = 2) 
• 4 patients were lost to follow up 
• 1 died 
This left 112 evaluable cases. 
• There were no significant differences in baseline characteristics between 
patients completing versus drop-outs (data not shown) or between patients with 
active therapy monitoring versus controls (Table 3.1). 
Median adherence rates for self-report and visual analogue were 100% for both 
actively monitored and control patients (Figure 3.4). More actively monitored 
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patients reported missed doses (39 of 69, 57%») than controls (17 of 43, 40% ) but 
the difference was not significant, and extra doses were reported in 23%) of cases 
for both actively monitored and control patients. 
Figure 3.3: CONSORT flowchart of 135 eligible patients. 
Assessment of eligibility 
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monitoring (n=83) 
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Did not receive allocated 
intervention (n=2) 
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Reasons 9 reported problems with 
monitoring bottles 
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7~ 
(n=6, all declined) 
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monitoring (n= 46) 
Received allocated intervention 
(n=45) 
Did not receive allocated 
intervention (n= 1) 
Reason withdrew consent 
Lost to follow up 
(n=2) 
Analysed (n=43) 
Table 3.1: Patient characteristics by group 
Active Therapy No Additional 
Monitoring Therapy Monitoring 
(n = 69) (n = 43) 
Percentage male 57% 70% 
Age 64 (12) 63 (8) 
Number prescribed levodopa 46 (67%) 30 (70%) 
Mean levodopa dose 526 mg (333) 427 mg (262) 
Number on dopamine agonist 50 (72%) 30 (70%) 
Number of PO drugs 2 (1) 2 (1) 
Number of PO administrations 4 (2) 4 (1) 
Number of PO tablets per day 9 (5) 8 (5) 
Number of non-PO drugs per day 2 (2) 3 (3) 
Number of tablets per day 12 (5) 11 (5) 
Number on >4 levodopa daily doses 15(20%) 9 (21 %) 
Number usually use compliance aid 18 (26%) 19 (44%) 
Number carer helps with medication 13 (19%) 8 (19%) 
Duration of PO (years) 7 (5) 7 (5) 
UPORS 2 14 (6) 15 (7) 
UPORS 3 27 (12) 28 (10) 
Number with dyskinesia 21 (30%) 10(23%) 
Number with "wearing off' 33 (48%) 23 (53%) 
Hoehn & Yahr 2.4 (0.6) 2.5 (0.6) 
Schwab & England 78 (13) 74 (16) 
MMSE 28 (4) 28 (3) 
Geriatric depression score 11 (7) 10 (8) 
PDQ 39 SI 28 (16) 31 (16) 
Data are mean (standard deviation) or number (percentage). PO = Parkinson's disease, UPDRS = 
Unified Parkinson's disease rating scale, MMSE = mini mental state examination, PDQ 39 SI = 
Parkinson's disease quality of life summary index. There were no significant differences between 
groups. 
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For the 69 active monitoring patients data was available as follows: 
• 142 drugs had electronic monitoring data 
• 205 drugs had simple tablet count data (simple tablet counts were 
performed both alone and simultaneous with electronic monitoring). 
• Paired data for simple tablet count and electronic monitoring was available for 
111 drugs. 
• Overall, the median total adherence measured by simple tablet counts was 
97% (interquartile range (10) 84-100) versus 96%, (10 82-100) using electronic 
monitoring. 
• Median daily adherence was 77% (10 41-89) 
• Median timing adherence was 18% (10 9-54) (Figure 3.4, daily and timing 
results only available from the electronic monitoring technique). There was no 
evidence of any order effect on electronic monitoring results. 
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Figure 3.4: Therapy adherence in 112 patients according to monitoring method. 
Self-report, visual analogue score, simple tablet count, and total adherence by 
electronic monitoring all showed high adherence rates. Days and timing adherence 
rates were lower, indicating irregular and erratic medicine intake. 
Data are median and interquartile range. 
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Of the 69 actively monitored patients medication intake was as follows: 
• 56 (81 %) taking 110 PO drugs took ~80%) 
• 13 (19%) prescribed 32 PO drugs took <80%) of prescribed medication 
(Figure 3.4). 
• Considering the <80% group, self-report (median 100%, 10 100-100), visual 
analogue (median 100%, 10 95-100) and simple tablet counts (median 90%, 10 
78-100) all significantly overestimated median total adherence when compared 
to the result of electronic monitoring (69%, 10 44-74, p<0.0001, ANOVA) 
(Figure 3.5). 
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Figure 3.5: Therapy adherence in 56 patients with good adherence and 13 
patients with poor adherence, based?n 80% threshold by electronic monitoring. 
Each.of.t~e 3 other met~ods re~/ects Intake well in patients with good adherence, 
but ~/gnlflcantly ?veres~/m~tes Intake in the poor adherence group (p<O.0001 
agaInst electronIc monltonng). Data are median and interquartile range. 
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• Considering those with ~80% adherence, self-report (median 1 00%, 10 100-
100), visual analogue (median 100%, 10 95-100) and simple tablet counts 
(median 98%, 10 89-100) were not significantly different from electronic 
monitoring adherence (98%, 10 93-101). 
• Categorisation of medicine intake as ~80% or <80% showed a significant 
difference between electronic monitoring and simple tablet count (p<0.0001, 
McNemar test). 
In patients reporting sub-optimal adherence, electronic monitoring confirmed 
underuse indicating high specificity (self-report 100% ; visual analogue score 97%), 
but sensitivity was low (self-report 1 0%; visual analogue score 17%). The broader 
adherence question of reporting any missed doses increased sensitivity to 77%, 
but at the expense of low specificity (46%), compared against electronic 
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monitoring. The sensitivity of simple tablet count was 50% and specificity was 76%, 
compared to electronic monitoring. The sensitivity of self-report against simple 
tablet count was 23% with 100% specificity. There was no significant difference in 
the proportion of patients with electronic monitoring showing <80% adherence who 
scored positive on the sub-optimal adherence questions (10 of 13 cases, 77% ) 
versus those with good (?::80%) adherence (36 of 56 cases, 64%). Of the 112 
patients, 45 (40 % ) reported never missing or taking an extra dose (from the two 
adherence questions), which would represent 1 00% daily adherence in these 
cases, while in fact no patients achieved 100% daily adherence, and only 3 cases 
(3%) had daily adherence >95%. Median daily adherence of those who reported 
missed doses was 70% (10 36-88) which just reached significance compared to 
those reporting perfect adherence (81 %, 10 70-89) (p = 0.05). 
One quarter of patients reported a global impression of 'under-treatment', less than 
5% 'over-treatment', and the remainder regarded their medication level as 'about 
right' (see Appendix 2, page 203). Patients taking less than 80% of their 
medication (by electronic monitoring) were more likely to report undertreatment (5 
of 13, 38%) than those adhering to the prescribed regimen (13 of 56, 23% )(not 
significant). None of the underusers reported that they were being overtreated. 
Doctors were more likely than patients to judge that therapy levels were on the side 
of overtreatment (doctors 10% , patients 6%, not significant). 
There were no significant differences between the number and types of adverse 
effects between those with active therapy monitoring and controls. 
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Discussion 
Our finding that self-reports, visual analogue scale and simple tablet counts 
overestimate adherence compared against electronic monitoring in Parkinson's 
Disease is consistent with observations in depression (George, Peveler, Heiliger, & 
Thompson 2000), diabetes (Cramer 2004), hypertension (Hamilton 2003;Rudd, 
Ahmed, Zachary, Barton, & Bonduelle 1990) and angina (Straka et al. 1997). 
Electronic monitoring is established as the reference technique in several diseases 
(Cramer, Mattson, Prevey, Scheyer, & Ouellette 1989;Cramer 2004;Lee, Kusek, 
Greene, Bernhard, Norris, Smith, Wilkening, & Wright, Jr. 1996), and has provided 
evidence of sub-optimal medication intake in PD (Leopold, Polansky, & Hurka 
2004), but ours is the first Parkinson's Disease study comparing compliance 
assessment methods. The results challenge the assumption that symptoms 
motivate the Parkinson patient to adhere tightly to the drug regimen. This is 
consistent with poor compliance rates in other symptomatic diseases (de Klerk et 
al. 2003;Milgrom et al. 1996). Although Parkinson patients are often interested in 
their medication, and some chart drug intake and symptom fluctuation (at times 
obsessively), we found that many patients deviate from the prescribed regimen, 
and moreover are not accurate in reporting such behaviour. Simple questioning of 
the PD patient, or more detailed methods such as tablet counting, fails to identify 
around half of those Parkinson patients whose therapy compliance is poor. Blood 
levels or urinalysis were not conducted but are of limited validity in compliance 
studies (Urquhart 1994), nor did we apply other supporting methods (such as 
pharmacy refill data) which might be helpful in some clinical settings. 
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In our study patients were fully informed about the monitoring of their medication, 
which might artificially improve compliance. When study design was concealed 
from patients (Leopold, Polansky, & Hurka 2004) (who were told that a new pill 
bottle was under test), 15% had sub-optimal compliance below the 80% threshold, 
which compares to our rate of 19%. This suggests that blinding patients to 
electronic monitoring is not necessary to detect sub-optimal adherence. There may 
however be some effect of monitoring on self-reporting: missed doses tended to be 
declared more often by actively monitored patients than by controls. 
Although the self-report had very low sensitivity (10 % ) for detecting patients taking 
their PD medication sub-optimally, it was highly specific and also quantifies 
underuse. Our adherence question of missed doses (sometimes or frequently) had 
a similar sensitivity (77%) to the Morisky self-report (72%) in depression (George, 
Peveler, Heiliger, & Thompson 2000) but neither approach quantifies non-
adherence and the improved sensitivity comes at the expense of specificity. Some 
caution over such figures is needed; in a review of several studies self-reports 
were 55% sensitive and 87% specific (Stephenson, Rowe, Haynes, Macharia, & 
Leon 1993) but this was against pi" counts, which themselves overestimate 
adherence compared to the electronic monitoring standard used in our study and 
elsewhere (Cramer, Mattson, Prevey, Scheyer, & Ouellette 1989;George, Peveler, 
Heiliger, & Thompson 2000; Paes, Bakker, & Soe-Agnie 1998; Pu"ar, Kumar, 
Tindall, & Feely 1989;Rudd, Ahmed, Zachary, Barton, & Bondue"e 1990). In 
clinical practice in PD, when the self-report and/or visual analogue score are less 
than 80%, therapy intake is extremely likely to be sub-optimal. Occasional missed 
doses, or other minor deviations, which we commonly observed even in good 
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compliers, are of uncertain clinical relevance and are probably inevitable given the 
inherent complexity of today's antiparkinson drug regimens. 
Around 40% of our patients declared never missing or taking an extra dose, which 
compares to 43% in hypertension (Morisky, Green, & Levine 1986) and 30% in HIV 
positive patients (Walsh et al. 2001), but 3 cases amongst our 40% declaring 
perfect adherence used less than 80% by electronic monitoring, and as in other 
studies (Macintyre, Goebel, & Brown 2005) none of our patients had perfect 
compliance. In diabetes, the sulphonylurea intake was 92% by self-report and 75% 
by electronic monitoring (Mason, Matsuyama, & Jue 1995), lower rates than ours 
of 100% for self report and 96% for electronic monitoring. The perception that 
Parkinson patients take their medication well is correct based on self-reporting, and 
is correct for overall medication intake, but disguises invariable deviation from the 
regimen, quite often at levels with potential therapeutic significance. 
Simple tablet counts missed half of under-medicating patients, which has 
implications for this method in clinical trials (Hughes, Bagust, Haycox, & Walley 
2001). In hypertension, 'near perfect' pill counts misclassified 22% as having 
satisfactory adherence (Rudd, Ahmed, Zachary, Barton, & Bonduelle 1990) and pill 
counts were dismissed as offering little more than misleading reassurance. Another 
hypertension study found 68% of patients with acceptable adherence (80 to 100% 
of prescribed tablets taken) by pill count, but electronic monitoring indicated that 
almost half of these patients were non-adherent (Lee, Kusek, Greene, Bernhard, 
Norris, Smith, Wilkening, & Wright, Jr. 1996). In epilepsy, only 13% of patients with 
sub-optimal compliance were detected by pill count (Cramer, Mattson, Prevey, 
Scheyer, & Ouellette 1989), and in depression tablet counts were unreliable in 
220/0 of patients (George, Peveler, Heiliger, & Thompson 2000). Since adherence 
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levels influence therapeutic efficacy (Gordis L 1979;Haynes & Oantes R. 1987), 
some adjustment may be appropriate in clinical trials. Additionally, while simple 
tablet counts are achievable in most patients (96%, in one study in depression) they 
are often unreliable (22% of cases) (George, Peveler, Heiliger, & Thompson 2000). 
We were able to calculate accurate simple tablet counts in 78% of cases during the 
period when simple tablet count was carried out simultaneously with electronic 
monitoring, and 66% of cases when simple tablet count was done alone. Again, 
the complexity of PO therapy influenced this: patients requiring ready access to 
frequent doses often maintained supplies in more than one location, and in 
addition containers were often emptied before the return clinic visit, as experienced 
elsewhere (Myers & Calvert 1984; Rudd et al. 1988; Rudd et al. 1989). Although 
unannounced home visits improve the accuracy of simple tablet counts (Haynes, 
Taylor, Sackett, Gibson, Bernholz, & Mukherjee 1980) this approach in impractical. 
Considering total adherence, 81 % of our cases had very high rates of adherence. 
However, daily adherence is the more usual benchmark (Claxton, Cramer, & 
Pierce 2001) and was lower at 77% while time interval adherence was only 18%. 
Similar adherence rates occurred in hypertension (total 85%, daily 63% and time 
interval 340/0) for a twice daily drug (Rudd, Ahmed, Zachary, Barton, & Bonduelle 
1990). There is no consensus on which one of the 3 electronic compliance 
measures provides the most useful information. In Parkinson's Disease the 
proposed role of pulsatile rather than continuous dopaminergic stimulation in 
developing motor fluctuations would place greater significance on daily and 
particularly timing rather than total adherence, since wide variations between days 
could be missed by the total adherence measure. Accordingly we adopted timing 
83 
compliance as the main end point in our subsequent study designed to improve 
compliance in PO therapy (Chapter 8). 
It was interesting that patients who take less medication than prescribed more 
frequently reported feeling undertreated. This clinical scenario can lead to a 
recommendation to increase therapy further, with the potential for further 
divergence between prescribed and actual medication intake. Unfortunately, 
identifying undermedicating patients amongst poor therapy responders is difficult 
through simple compliance approaches. In some instances where there are 
inadequate pointers to an alternative reason for poor therapy response (such as 
development of a Parkinson plus disorder) the application of more sophisticated 
compliance techniques such as electronic monitoring may be worthwhile. 
In conclusion, self-report, visual analogue scale and simple tablet counts are 
insensitive in prediction of sub-optimal medicine usage in PD, but when these 
methods score positively this is likely to be accurate. Electronic monitoring devices 
show a subset of Parkinson patients who take less medication than prescribed, 
and indicate that most patients use their medication erratically, even when total 
tablet intake is correct. How patients take their medicines influences the 
interpretation of therapy response and consequent management decisions, with 
implications for clinical practice and clinical trial analysis. 
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Chapter 4 
Sub-optimal medication adherence in Parkinson's 
Disease: which factors are associated with medication 
'underuse'? 
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Introduction 
The purpose of this chapter is to explore factors associated with sub-optimal 
adherence. Associated factors do not imply cause, but guide the clinician in 
recognising circumstances where therapy adherence may be an issue. 
Oral drugs are the mainstay in Parkinson's disease (PO) treatment. Although 
efficacy in controlling symptoms (Adler, Sethi, Hauser, Davis, Hammerstad, 
Bertoni, Taylor, Sanchez-Ramos, & O'Brien 1997;Brooks & Sagar 
2003; Hammerstad, Woodward, Nutt, Gancher, Block, & Cyhan 1994;Shannon, 
Bennett, Jr., & Friedman 1997), and exploration of potential neuroprotective drugs 
(Shults, Oakes, Kieburtz, Beal, Haas, Plumb, Juncos, Nutt, Shoulson, Carter, 
Kompoliti, Perlmutter, Reich, Stern, Watts, Kurian, Molho, Harrison, & Lew 
2002;The Parkinson Study Group 1993) along with short and long term adverse 
effects are widely published, the way in which patients take their drugs has 
received little attention. In a study of 39 PO patients, adherence was monitored for 
one month using a questionnaire and electronic monitoring, and significant non-
adherence occurred in 54%) of patients while only 4 patients (10% ) took medicines 
exactly as prescribed (Leopold, Polansky, & Hurka 2004). The present study was 
designed as a comprehensive examination of anti parkinson medication intake, and 
compared the characteristics of patients according to medicine intake using 
established parameters in the therapy compliance literature (George, Peveler, 
Heiliger, & Thompson 2000;Gilbert, Evans, Haynes, & Tugwell 1980;Haynes, 
Taylor, Sackett, Gibson, Bernholz, & Mukherjee 1980;Lee, Kusek, Greene, 
Bernhard, Norris, Smith, Wilkening, & Wright, Jr. 1996;Rosen, Rigsby, Salahi, 
Ryan, & Cramer 2004). Effects of medicine taking on clinical outcome (motor 
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scores and quality of life) were tested as well as influences of demographic factors 
and co-morbidities (impaired cognition and depression). 
Methods 
A single centre observational study was conducted in patients fulfilling UK Brain 
Bank criteria (Hughes, Daniel, Kilford, & Lees 1992) and prescribed at least one 
antiparkinson drug, but excluding patients on monotherapy with selegiline or 
amantadine. The study received ethics approval and signed consent was obtained. 
Patients unable to manipulate the electronic monitoring devices or using 
compliance aids (e.g. dosette box) where study participation would compromise 
their compliance were excluded. Out-patients were selected by randomisation (as 
previously described in Cahpter 3) of two thirds of the caseload from two doctors' 
lists in the movement disorder team. Baseline assessment included unified 
Parkinson's disease rating scale (UPDRS) (Fahn, Elton, & members of the UPDRS 
Development Committee 1987), Hoehn and Yahr (H&Y), Schwab and England, 
mini mental state examination (MMSE) (Folstein, Folstein, & McHugh 1975), 
Geriatric depression score (GDS) (Yesavage et al. 1982), Epworth sleep score 
(ESS) (Johns 1991), quality of life assessment (PDQ39) (Peto, Jenkinson, & 
Fitzpatrick 1998), patient-perceived involvement in therapy management decisions 
(Makoul, Arntson, & Schofield 1995) and satisfaction (Meakin & Weinman 2002) 
with the movement disorder health care service. Prevailing anti parkinson 
medication was dispensed into electronic monitoring bottles (MEMS®, Aardex, 
Switzerland) (one bottle for each tablet type and strength) and patients were given 
verbal and written instruction. At 3 months, the electronic monitoring devices were 
collected and UPDRS, H&Y and Schwab and England were repeated. 
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Correlation between total dose compliance (total dose taken, expressed as a 
percentage of the total dose prescribed), daily compliance (percentage of days 
when correct number of doses taken) and time interval compliance (percentage of 
doses taken at the correct time interval) and other variables was examined using 
Pearson correlations (Prism 3, GraphPad®, CA, USA, and Statistica®, StatSoft, 
Bedford, UK). Patients were categorised according to medication use calculated 
from MEMS data: 
• (1) Patients with medication underuse, defined as total compliance of 
less than 80%), or 
• (2) Patients with satisfactory adherence, defined as total compliance of 
equal to or over 80% 
The 80% threshold has been applied in several compliance studies as described in 
the methods section of Chapter 3. Since this threshold is not validated in PO we 
also applied a 70% threshold. Average compliance was calculated for patients on 
more than one antiparkinson drug. 
Results 
Of 68 patients asked to participate, 6 (9% ) declined mostly due to perceived 
disruption of the electronic monitoring bottles, including one who used a 
compliance aid. There was no significant difference in age, gender, disease 
duration, type or dose of antiparkinson medication (Ievodopa, dopamine agonist) 
for patients who declined (data not shown). Of 62 patients issued with electronic 
monitoring bottles (EM), 8 dropped out, one with severe dyskinesia which 
precluded EM bottle usage, two lost the EM bottles, one died, one had prolonged 
hospital admission and three patient misused the EM. There was evaluable data 
for 54 patients. Baseline characteristics are shown in Table 4.1. 
88 
Table 4.1: Characteristics of 54 Parkinson patients 
undergoing compliance monitoring 
Percentage male 
Age 
Number taking levodopa 
Mean levodopa dose 
Number on DA 
Dopamine agonists 
Number taking ropinirole 
Mean daily dose 
Number taking pramipexole 
Mean daily dose (base) 
Number taking pergolide 
Daily dose 
Number taking levodopa + DA 
Number of PO drugs 
Number of PO administrations 
Number of PO tablets per day 
Number of non-PO drugs per day 
Number of tablets per day 
Duration of PO (years) 
UPDRS 2 
UPDRS 3 
Number with dyskinesia 
Hoehn and Yahr 
Schwab & England 
MMSE 
Geriatric depression score 
Epworth sleep score 
PDQ 39 SI* 
MISS-21 
Patient-centredness 
56%) 
61.9 (11) 
33 (61 % ) 
533 mg 
38 (70%) 
20 
10.6mg 
16 
2.2mg 
2 
1.4mg 
18 (33%) 
2.0 (1) 
4.1 (2) 
8.6 (4.7) 
2 (2) 
11 (5) 
5.4 (3.9) 
13.5 (6) 
27 (13) 
14 (26 % ) 
2.3 (0.6) 
79 (12) 
28 (2) 
1 0.4 (7) 
8 (5) 
29 (17) 
5.3 (0.8) 
14.4 (3.6) 
Data are mean (standard deviation) or number (%). 
DA = dopamine agonist, PO = Parkinson's disease, 
UPDRS = Unified Parkinson's disease rating scale, 
MMSE = mini mental state examination, 
PDQ 39 SI = Parkinson's disease quality of life summary index, 
MISS-21 = medical interview satisfaction scale. 
*PDQ 39 SI data is based on 53 patients (see text). 
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Increased age was associated with better total compliance (p = 0.007, Pearson r = 
0.4, 9S%) confidence interval [CI] 0.1 to 0.6), daily compliance (p = O.OS, Pearson r 
= 0.3, 9S% CI 0.004 to O.S) and timing compliance (p = 0.04, Pearson r 0.3, 9S01o 
CI 0.006 to O.S). Patients taking more medication had poorer daily compliance, 
considering PO medication alone (p = 0.007, Pearson r = -0.4, 9S% CI -0.6 to -0.1) 
and all medication (for PO plus other disorders)(p = 0.01, Pearson r -0.3, 9So/0 CI 
-0.6 to -0.07). Total compliance was associated with worse depression (p = 0.02, 
Pearson r = -0.3, 9S% CI -O.S to -O.OS) and with poorer quality of life (p = 0.002, 
Pearson r -0.4, 9S% CI -0.6 to -0.2). UPORS (including sub-scores of bradykinesia, 
rigidity and tremor), MMSE and Epworth scores did not differ according to medicine 
usage. Similarly, there was no correlation between medicine usage with either 
patient-perceived involvement in therapy decisions or with satisfaction with the 
movement disorder service. Multivariate analysis was not performed as the study 
was exploratory and the sample size was insufficient in proportion to the number of 
variables tested. 
Of the S4 evaluable patients, 11 (20%) receiving a total of 26 PO preparations (e.g. 
ropinirole 7mg taken as a Smg plus a 2mg tablet represents 2 preparations) were 
underusers « 80% total compliance) while 43 (80%) taking a total of 91 PO 
preparations showed satisfactory adherence. Patients were monitored for a mean 
of 88 days (SO 17 days). Antidepressant therapy was in place in 1 of the 11 
patients (9%) in the underuse group (amitriptyline SOmg daily) and in 7 of the 43 
patients (16%) with satisfactory adherence (6 selective serotonin reuptake 
inhibitors and 1 trazodone). All eight sub-domains of quality of life quality of life 
data (based on S3 patients, as one questionnaire was inadequately completed) 
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were worse (higher scores) in the underuse group, most markedly for social 
support (Mann-Whitney test, p < 0.0001, r2 = 0.3). 
Compliance results consisting of total dose compliance, daily compliance and time 
interval compliance are shown in Figure 4.1. 
Figure 4.1: Dotplot of adherence for individual drugs according to 
satisfactory adherence (91 drugs taken by 43 patients) and 
underusers (26 drugs taken by 11 patients). Daily and timing 
compliance was lower than total compliance, especially in underusers. 
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• Median total dose compliance was 98% (interquartile range 10 93-102) 
in the satisfactory adherence group versus 65% (10 37 - 74) in 
underusers. 
• Median daily compliance was 84%) (10 67 - 90) for satisfactory 
adherence versus 27% (10 4 - 37) for underusers. 
• Median time interval compliance was 25% (10 11 -73) for satisfactory 
adherence group compared to 11 % (10 2 - 20) in underusers. 
Timing compliance was better for drugs prescribed as once daily (14 of 25 drugs 
(56%) had time interval compliance over 80%) than for drugs taken more 
frequently (3 of 92 drugs (3%) had time interval compliance over 80%))(p < 
0.00001). A" drugs with time interval compliance over 90% were prescribed as 
once daily. None of the underuse patients overused (>100 % total dose 
compliance) any individual drug (total dose compliance for individual drugs ranged 
from 19% to 95%). In patients with satisfactory adherence, underuse and overuse 
of individual drugs occurred (range 71 % to 133%). Medication usage between 110 
and 133% occurred for 8 preparations (3 selegiline, 2 levodopa, 2 amantadine and 
1 dopamine agonist) in 5 patients, but none met criteria for the dopamine 
dysregulation syndrome (Lawrence, Evans, & Lees 2003). Removal of these 
patients from the analysis did not affect the results. A 70% compliance threshold 
classified 47 of 54 (87%) patients as having overall satisfactory adherence and 7 of 
54 (13%) as underusers. Compliance results by drug class are shown in Figure 
4.2a (satisfactory adherence) and Figure 4.2b (undersusers). 
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Figure 4.2a: Compliance measures according to drug type in 43 
patients with satisfactory adherence. Compliance was good except in 
relation to the timing of intake of medications prescribed more than 
once daily. 
Figure 4.2b: Compliance measures according to drug type in 11 
patients with underuse of antiparkinson therapy. Daily and timing 
compliance rates were very low, indicating erratic medication intake 
with frequent missed doses. 
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Adverse events per patient did not differ between satisfactory adherence (mean 
1.2, SD 1.3) and underusers (mean 1.4, SD 0.7), nor was there any difference in 
individual adverse events (in declining frequency: insomnia, sleepiness, 
dyskinesia, and nausea). Changes in UPDRS 2, 3, Hoehn and Yahr and Schwab 
and England between baseline and 3 months were not different between groups. 
Discussion 
Our study shows medication underuse in about one fifth of PD patients, which is a 
little higher than the 15% of 39 patients with compliance less than 80% using 
similar methodology (Leopold, Polansky, & Hurka 2004). We found an association 
between worse depression and poor total dose compliance although only one 
patient categorised as underusing PD medication was co-prescribed an 
antidepressant (which was at a subtherapeutic level). Depression has a high 
prevalence in PD (Rojo et al. 2003). In other diseases depressed patients are three 
times more likely to have poor adherence based on systematic review 
(Ciechanowski, Katon, & Russo 2000);(DiMatteo, Lepper, & Croghan 2000). The 
exclusion of depressed patients from the previous PD study (Leopold, Polansky, & 
Hurka 2004) is therefore a likely factor in our study having lower compliance rates. 
Given the major influence of depression on quality of life in PD (Schrag, 
Jahanshahi, & Quinn 2000;The Global Parkinson's Disease Survey Steering 
Committee 2002) and the deterioration in motor score and quality of life in patients 
who defer initiation of antiparkinson treatment (Chaudhuri, Taurah, MacMahon, 
Turner, Kelly, Burn, Forbes, Bowron, Foster, & PD LIFE Committee 2004), our 
results suggest that more detailed evaluation of the link between depression and 
medicine-taking behaviour in PD is needed. 
The poorer quality of life in patients taking less medication than prescribed could 
not be explained by disease duration, since these two measures are not strongly 
associated (Schrag, Jahanshahi, & Quinn 2000). We found that lack of social 
support correlated significantly with poorer medicine intake, which is consistent 
with the known role of the carer in assisting PD patients with medication 
administration. The lower proportion of patients taking less than 80% of medication 
who had a carer (9%») compared to the satisfactory adherence group (21 %) is 
consistent with the lack of social support identified through the PDQ39 
questionnaire. The triad of depression, medication underuse and poor quality of life 
in socially isolated patients may be self-perpetuating, and runs counter to the often-
assumed importance of education in optimising therapy intake (Heath 2003). 
In other disease areas, factors potentially influencing compliance show inconsistent 
results (Buck et al. 1997;Cramer 2004;Stephenson, Rowe, Haynes, Macharia, & 
Leon 1993). In PD, women estimate the frequency of missed dose more accurately 
than men, but men report more mistimed doses (Leopold, Polansky, & Hurka 
2004). 
We found that older PD patients had better therapy compliance. Varying effects of 
age are reported in other disease areas (Horne R 2001), with lower rates attributed 
to co-existing cognitive impairment and depression (Salas et al. 2001) while 
uncomplicated cases, particularly those termed the 'young-old' (i.e. those whose 
biological age is less than their chronological age) (Morrell et al. 1997) have higher 
adherence which may indicate greater caution about their health (Leventhal & 
Crouch 1997). Age, education level and disease severity did not individually 
correlate with compliance (assessed using a four point rating scale) in Parkinson's 
patients participating in clinical trials (Dobson, Rodnitzky, & Uc 2004). 
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The finding of worse daily compliance with increasing numbers of PO and other 
medications is consistent with other studies (Claxton, Cramer, & Pierce 
2001 ;Cramer 2004). Given that complexity of drug regimens detrimentally affects 
adherence (Claxton, Cramer, & Pierce 2001) and that drug regimen simplification 
improves adherence and outcome measures in other diseases (Richter et al. 
2003), the use and development of longer-acting PO drugs appears warranted. 
Further evidence supporting this comes from our observation that once-daily drugs 
had better adherence rates than more frequently taken drugs. 
Adverse effects are a widely recognised reason for non-adherence (Adler, Sethi, 
Hauser, Davis, Hammerstad, Bertoni, Taylor, Sanchez-Ramos, & O'Brien 
1997; Brooks & Sagar 2003; Hughes, Bagust, Haycox, & Walley 2001), but neither 
the number or type of adverse events differed according to medication intake in our 
study. The fact that our patients were largely on established therapy may explain 
this, since adverse events are associated most strongly with early discontinuation 
(Hughes, Bagust, Haycox, & Walley 2001 ). 
Daily adherence and time interval adherence levels were much lower compared to 
total adherence. Similar findings are reported in hypertension where total 
compliance was 90%, but the correct number of daily doses were taken on only 
630/0 of days (daily compliance) and only 38% of doses were taken at the correct 
time interval (timing compliance) (Rudd, Ahmed, Zachary, Barton, & Bonduelle 
1990). Analysis of 76 studies across several disease areas reported total 
compliance of 71 % (SO 17%, range 34 - 97%) and in studies where time interval 
adherence was measured, the rate averaged 59% (SO 24%) (Claxton, Cramer, & 
Pierce 2001). Rates declined as the number of doses increased for both 
compliance measures (Claxton, Cramer, & Pierce 2001). Poor timing compliance 
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was universal in our study, whether or not there was underuse, suggesting that 
erratic drug taking is the norm rather than the exception in PD. This is consistent 
with observations in hypertension (Rudd, Ahmed, Zachary, Barton, & Bonduelle 
1990), epilepsy (Cramer et al. 1995) and the one other available PO study 
(Leopold, Polansky, & Hurka 2004). Given the significance attached to erratic and 
pulsatile stimulation of striatal dopamine receptors (Bezard, Brotchie, & Gross 
2001 ; Grace 1991 ;Jenner 2000;Onn, West, & Grace 2000; Spencer & Wooten 
1984) resulting in fluctuations and dyskinesia, our results suggest that irregular 
medication may be at least as significant as variable absorption in day-to-day and 
longer term fluctuations. Regularising oral medication using an educational 
intervention is reported in Chapter 8. 
The present study is the largest of its kind in PO, and is unique in monitoring all 
doses and strengths of anti parkinson medication, rather than choosing one 
preparation (Leopold, Polansky, & Hurka 2004). We consider inclusion of all 
antiparkinson drugs important, especially in more advanced disease when different 
formulations are used concurrently by individual patients. None of our evaluable 
patients showed evidence of the dopamine dysregulation syndrome, even although 
there was intake exceeding 110% • The syndrome occurred in about 4% of cases in 
another UK clinic (Lawrence, Evans, & Lees 2003), which has a higher proportion 
of tertiary referrals. Further, we suspect that cases with dopamine dysregulation 
may decline or fail participation in therapy monitoring projects, which may explain 
why the syndrome has been defined without detailed compliance monitoring. One 
of our patients could not manipulate the EM bottles which is another practical 
difficulty in encompassing patient types in compliance studies in PD. Our longer 
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study duration of 3 months compared to 1 month (Leopold, Polansky, & Hurka 
2004) should reduce any effect of monitoring on study results. 
While the present study is large amongst compliance studies, it is appropriate to 
expand the project to multiple centres to allow more robust examination of 
associations found here. A limitation of the current study is that the data had 
inadequate power for multivariant analysis which would of interest in a larger study. 
Such a collaborative project is now underway in 5 European countries. 
In conclusion, taking less medication than prescribed occurs in one fifth PO 
patients. Poorer compliance is more likely in younger patients and when drug 
regimens are complex, and is associated with worse depression and lower quality 
of life. Even patients who adhere well to their medication take drugs at erratic time 
intervals. Maximising gain from antiparkinson therapy requires consideration of 
these issues. 
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Chapter 5 
Concordance: Patient-perceived involvement and 
satisfaction in Parkinson's disease: effect on therapy 
decisions and quality of life 
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Introduction 
Concordance is descriptive of the process and outcome of the consultation rather 
than patient behaviour. Accordingly, patients cannot be non-concordant. Treating 
patients as partners in therapy decisions is crucial to the therapeutic process 
(Royal Pharmaceutical Society of Great Britain 1997). To maximise therapeutic 
benefit, healthcare consultations should share knowledge, beliefs and expectations 
and negotiate agreement on the best course of action. In concordant consultations, 
relevant understandable information should be given to enable active patient 
participation in management decisions. More involvement brings more 
responsibility, which is not welcomed by everyone. The only way to determine the 
degree of involvement desired by an individual is to ask them. Concordance is less 
easy than compliance to quantify, but is based on patient satisfaction with the 
process of care and the degree of patient-centredness of the consultation. 
Departure from the prescription represents at least in part failure to address the 
patient's agenda. 
In diabetes (Kinmonth et al. 1998), primary care (Kinnersley et al. 1999) and 
headache clinics (Headache Study Group of The University of Western Ontario 
1986) patient-centred consultation styles increase patient satisfaction. Active 
patient involvement is associated with improved health outcome in hypertension 
(Stewart 1995) and chronic disease (Michie, Miles, & Weinman 2003). 
Dissatisfaction with communication is associated with non-compliance in headache 
(Fitzpatrick & Hopkins 1981), diabetes (Hulka et al. 1975), hypertension (Hovel! et 
al. 1986), asthma (Wissow et al. 1998) and chronic disease (Bartlett et al. 1984), 
but has not been studied in PD. 
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In this chapter, patient-perceived involvement in PO therapy decisions in relation to 
consultation satisfaction (including communication and compliance intent), disease 
stage, co-morbidity (depression and cognitive impairment) and quality of life, using 
established methodology from other disease areas (Makoul, Arntson, & Schofield 
1995; Meakin & Weinman 2002) is reported. 
Methods 
One hundred and seventeen patients attending the movement disorder clinic were 
enrolled. All fulfilled PO Brain Bank criteria (Hughes, Daniel, Kilford, & Lees 1992), 
except one with progressive parkinsonism despite stopping neuroleptics in whom 
the clinical diagnosis of PO was supported by abnormal presynaptic dopamine 
transporter imaging (DaTSCAN, GE Healthcare, UK). Unified Parkinson's Disease 
Rating (UPDRS 1 to 6) (Fahn, Elton, & members of the UPDRS Development 
Committee 1987) and mini mental state examination (MMSE) (Folstein, Folstein, & 
McHugh 1975) were scored. The protocol received local Ethics Committee 
approval and signed consent was obtained. After the consultation, patients 
completed 4 questionnaires and were asked to base their responses based on 
their overall clinic experience: 
• (1) An assessment of perception of involvement in therapy decisions, 
adapted by the Medicines Partnership (Medicines Partnership 2003) 
from Makoul et al (Makoul, Arntson, & Schofield 1995) with 4 questions 
graded for agreement on a Likert scale, then converted to a numerical 
score (4 to 25 representing low to high perceived involvement). 
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• (2) MISS-21 (medical interview satisfaction scale), a validated 21-
question assessment of consultation satisfaction (Meakin & Weinman 
2002) with 4 components: 
• a) distress relief (6 items e.g. the doctor seemed to know just 
what to do for my problem) 
• b) communication comfort (4 items e.g. the doctor did not allow 
me to say everything I had wanted about my problems) 
• c) rapport (8 items e.g. the doctor seemed warm and friendly) 
• d) compliance intent (3 items e.g. I'm not sure the doctor's 
treatment will be worth the trouble it will take). 
Each component is converted to a numerical score between 1 and 7 (low through 
to high satisfaction). 
• (3) Geriatric Depression Scale (GDS) (Yesavage, Brink, Rose, Lum, 
Huang, Adey, & Leirer 1982) to screen for co-morbid depression. 
• (4) PDQ39, a validated quality of life tool in PO (Peto, Jenkinson, & 
Fitzpatrick 1998). 
Statistical analysis Prism® (GraphPad®, San Diego, USA) and Statistica® 
(StatSoft, Bedford, UK) were used for unpaired t tests to compare patient 
characteristics, Fisher's exact test for categorical variables, and Pearson 
correlation to test association between variables. Due to the number of 
comparisons, statistical significance was accepted at p < 0.005 (applying the 
Bonferroni adjustment). 
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Results 
Of 117 patients recruited, 2 withdrew before commencing questionnaires and 8 
had incomplete data, leaving 107 (91 O;(») evaluable cases (Table 5.1). 
Table 5.1: Characteristics of 1 07 evaluated cases 
Number male 
Age (y) 
Duration of Parkinson's disease (y) 
Number on levodopa 
Duration of levodopa therapy (y) 
Number on dopamine agonist 
Duration of dopamine agonist therapy (y) 
Hoehn & Yahr 
UPDRS 2 
UPDRS 3 
UPDRS total 
Geriatric Depression Scale 
Schwab & England 
Mini-mental State Examination 
PDQ 39 Summary Index 
Data are means (standard deviation or percentage). 
64 (60%) 
62 (10) 
6.7 (5) 
67 (63%) 
3.1 (4.8) 
76 (69%) 
3.8 (3.8) 
2.5 (0.6) 
14 (6) 
26.5 (11) 
47.6 (18) 
10(7) 
77 (12) 
27.8 (2) 
31 (17) 
y = years; UPDRS = Unified Parkinson's disease rating scale; 
PDQ = Parkinson's disease quality of life 
The 10 (9%) cases not completing were more likely to have dyskinesia and there 
was a trend to longer disease duration (Table 5.2), but there was no significant 
difference for age, sex, UPDRS, Hoehn and Yahr or Schwab and England (S&E). 
Patient-perceived involvement is shown in Figure 5.1, which converts to a 
numerical score of 14.4 (SO 2.8) (scale range 4 to 25). The mean satisfaction 
score (MISS-21) was 5.3 (SO 0.7) (scale range 1 to 7). 
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Table 5.2: Characteristics of excluded versus included patients 
Characteristic 
Age (years) 
Duration of PD 
Number with dyskinesia 
UPDRS 2 
UPDRS 3 
Excluded 
(n = 10) 
62.7 (8) 
10.5 (7) 
6 (60 % ) 
14 (7) 
27.8 (7) 
Included 
(n = 107) 
62.2 (10) 
6.7 (5) 
29 (27%) 
14 (6) 
26.5(11) 
P 
ns 
P = 0.02 
p<0.0001 
ns 
ns 
Data are mean (standard deviation or percentage). PD = Parkinson's Disease; ns = not significant; 
UPDRS = Unified Parkinson's disease rating scale 
lO-t 
Figure 5.1: Patient-perceived involvement in 107 cases of Parkinson 's Disease. 
Although patients scored favourably regarding responsibility, information, and 
opinion, almost half of patients reported that they were not asked to choose their 
treatment. This has implications for therapy compliance, disease control and 
quality of life (see text). 
The doctor gave me responsibility for 
deciding how to deal with my health 
problem 
. 74% Agree 
0 19% Neutral 
. 7% Disagree 
I was given enough information to 
make my own decision about 
treatment 
. 74% Agree 
017% Neutral 
. 9% Disagree 
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I was asked to choose a treatment for my 
health problem 
. 31% Agree 
024% Neutral 
. 45% Disagree 
The doctor did not ask my opinion abou~ 
medicines 
. 12% Agree 
0 9% Neutral 
. 79% Disagree 
Higher involvement correlated overall with increased satisfaction (r = 0.28, P = 
0.003) shown in Figure 5.2, particularly the distress relief sUb-component of the 
satisfaction scale (r = 0.38, P < 0.0001) (Figure 5.3). 
Figure 5.2: Patient satisfaction against involvement in 107 patients. Patient 
satisfaction was higher in those who felt more involved in therapy management 
decisions (r=0.28, p=0.003). 
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Figure 5.3: Distress relief scores in relation to perceived patien~ involv~ment in 
therapy management decisions. Higher involvement was associated with greater 
distress relief (r=0.38, p<0.0001). 
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The communication sUb-component correlated with compliance intent (r = 0.6, P < 
0.0001) shown in Figure 5.4. 
Figure 5.4: Communication in relation to intention to comply with therapy in 107 
patients. Better communication was associated with higher intention to comply with 
therapy (r=0.6, p<0.0001). 
.., 
c 
Cl) 
.., 
c 
-Cl) 
7.5 
(.) 
c cu 5.0 
.-
C. 
E 
o (J 
... 
• 
... 
...... 
• • • 
• 
••• • • 
'" 
. . -,'" 
... '" 
'" "," 
• ........ .JI.... _--
'" --. ..... ~-- ...... -... 
... 
• 
• 
J ... ~- ",~"'. • • • 
- '" 
_ .. -,- ~...... . 
............ 
... . • • 
...... ~ ...... 
• 
• 
2.5+--~----~----------' 
2 3 4 5 6 7 8 
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Neither patient involvement nor satisfaction correlated with motor scores (UPDRS 
3), depression (GDS), activities of daily living (UPDRS 2 and Schwab and England) 
or cognition (MMSE). Quality of life was inversely associated with depression (r = 
0.7, P < 0.0001) (Figure 5.5) and disease severity (UPDRS) (r = 0.5, P < 0.0001) 
(Figure 5.6). Duration of PO, compliance intent and satisfaction correlated 
significantly with quality of life (Table 5.3). There was no statistically significant 
correlation of satisfaction and depression. 
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Figure 5.5: Depression in relation to quality of life. Higher levels of depression 
correlated with poorer quality of life (higher scores)(r=O. 7, p<0.0001). 
c: 
o 
'c;; 
30 
m 20 
... 
e.CI) 
CI) ... 08 
~ en 10 
10 
.~ 
CI) 
(!) o 
o 25 50 
Parkinson's Disease Quality of Life 
Summary Index 
75 
Figure 5.6: Quality of life in relation to disease severity. Quality of life deteriorated 
with worsening disease severity, measured by higher scores in the total Unified 
Parkinson's Disease Rating Score (r=0.5, p<O. 000 1). 
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Table 5.3: Quality of life (PDQ39-SI) compared to other variables 
Variable 
GDS 
UPDRS total 
Duration of PO 
Compliance Intent 
Satisfaction 
Pearson r 
0.7 (0.6 to 0.8) 
0.5 (0.4 to 0.7) 
0.28 (0.1 to 0.5) 
-0.28 (-0.4 to - 0.1) 
-0.28 (-0.4 to - 0.1) 
P 
<0.0001 
<0.0001 
0.003 
0.003 
0.004 
Data in brackets are 95% confidence intervals for correlation coefficients. 
PDQ39-SI = Parkinson's disease quality of life summary index; 
GDS = Geriatric depression scale; UPDRS = unified Parkinson's disease 
rating scale; PD = Parkinson's disease 
Discussion 
This cohort of PO patients reported involvement in therapy decisions and levels of 
satisfaction above the midpoint of the relevant scales, which is considered 
positively in such assessments (Horne R 2003). Involvement correlated with 
satisfaction, as seen in other disease areas (Kinnersley, Stott, Peters, & Harvey 
1999; Simpson et al. 1991 ;Woolley et al. 1978), and our results were strikingly 
similar to those in a primary care study (Kinnersley, Stott, Peters, & Harvey 1999). 
Satisfaction was positively associated with quality of life, but neither involvement 
nor overall satisfaction correlated with motor score or co-morbidity (depression or 
cognition). Patient satisfaction is often linked to improved health status (Stewart 
1995), (Patrick, Scrivens, & Charlton 1983) but this is not a universal finding, such 
as in a large study of recently hospitalised patients (otolaryngology, orthopaedics, 
cardiothoracic, transplant) where the relationship between satisfaction and physical 
and mental health was too weak to interpret (Welton & Parker 1999). 
While patient-centred consultations improved communication and satisfaction in 
diabetic patients, paradoxically patient knowledge and glycaemic control worsened 
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in the patient-centred group (Kinmonth, Woodcock, Griffin, Spiegal, & Campbell 
1998). A review of studies which tested associations between patient-centredness 
and health outcomes highlighted inconsistent results (Michie, Miles, & Weinman 
2003) and suggested that different styles of patient-centredness have different 
effects. Active patient involvement (Kaplan, Greenfield, & Ware, Jr. 1989) 
compared against merely seeking patients' views (Kinmonth, Woodcock, Griffin, 
Spiegal, & Campbell 1998) is more likely to positively associate with health 
outcome. 
The Makoul questionnaire which we applied takes account of both perspectives, 
with items' I was asked to choose ..... ' reflecting active involvement, and 'the 
doctor did not ask my opinion ...... ' reflecting patients' views. The overall level of 
patient involvement which we found is similar to that in primary care (Makoul, 
Arntson, & Schofield 1995), and in both environments patients report being 
informed, having their opinion sought, and being given responsibility to decide on 
treatment but that they did not have the opportunity to choose their therapy. The 
last aspect is potentially the most active role of the patient, and lower scores may 
result in poorer outcomes such as quality of life. Incorporating such approaches 
into a health management programme (PROPATH) improved patient perception of 
general health and psychological wellbeing, but notably satisfaction was not 
increased (Mercer 1996). Further aspects are the added time needed for patient-
centred consultations (Bissell, May, & Noyce 2004;Jones et al. 2004), often 
problematic in the neurology setting (Ringel et al. 2003), and the value to physician 
morale and job satisfaction which correlate with patient communication (Ringel, 
Vickrey, Schembri, & Kravitz 2003). 
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In our study, communication correlated with compliance intent. This is similar to 
observations in neurology out-patients (Fitzpatrick & Hopkins 1981), where 
dissatisfaction with communication was associated with non-compliance. Patient-
centred ness is linked to better compliance and is considered a marker of success 
in the doctor-patient interview (Stewart 1984). We found a relationship between 
compliance intent and quality of life, and report in Chapter 4 that there is an 
association between sub-optimal compliance and poorer quality of life. Further 
work is required to evaluate if improving compliance improves quality of life. 
We found significant association between satisfaction and quality of life. This 
broadens the findings of the Global Parkinson's Disease Survey (The Global 
Parkinson's Disease Survey Steering Committee 2002) in which "satisfaction with 
the explanation of the condition at diagnosis" contributed significantly to health-
related quality of life. Depression and disease severity correlated strongly with 
quality of life, again consistent with other studies (Schrag, Jahanshahi, & Quinn 
2000;The Global Parkinson's Disease Survey Steering Committee 2002). Similarly, 
high satisfaction with information provided to PO patients was associated with 
better quality of life (Shimbo et al. 2004). Our study shows that patient involvement 
in therapy decisions is associated with patient satisfaction, and that satisfaction 
and compliance intent are associated with quality of life in PD. Since maximising 
quality of life is a key target agreed by patients, their representative organisations, 
and healthcare professionals from several disciplines, the factors which influence 
this, including the patient satisfaction components highlighted in the present study, 
deserve due consideration in the design and implementation of models of care. 
III 
Chapter 6 
Parkinson's Disease patients' beliefs about 
medicines: how does this influence therapy 
adherence? 
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Introduction 
In other disease areas beliefs about medicines are known to influence how 
patients take prescribed medication. The beliefs about medicines questionnaire 
assesses patient perceived necessity of, and concerns about, medication. There is 
a generic version of the beliefs about medicines questionnaire and also disease 
specific versions. In a Swedish pharmacy study where 2,171 prescriptions were 
unclaimed in a 3 month period, the patient regarding the prescription as 
unnecessary was the commonest reason given (Ekedahl & Mansson 2004). Acute 
conditions requiring short courses of medication are generally taken more 
consistently than long term medication for chronic conditions (Haynes, McDonald, 
& Garg 2002). In idiopathic Parkinson's disease it has traditionally been assumed 
that patients with a marked symptomatic benefit from levodopa would adhere to 
prescribed therapy. On the other hand, if adverse effects are experienced, patients 
may reduce or discontinue medication, and medication intolerance (both in the 
short and long term) is common with all types of antiparkinson medication as 
outlined in Chapters 1 and 2. 
In this chapter, we describe a Parkinson's disease specific beliefs about medicines 
questionnaire which was developed in conjunction with Professor Rob Horne, 
Centre for Health Care Research, University of Brighton. 
113 
Background 
Historically it has been assumed that most Parkinson's disease (PO) patients take 
their medication fastidiously, but there is more recent evidence of sub-optimal 
therapy adherence (Leopold, Polansky, & Hurka 2004). Sub-optimal therapy 
adherence may be unintentional, due to forgetfulness or co-morbid conditions such 
as cognitive impairment or depression, or may be fully intentional as some patients 
make positive decisions not to take prescribed medication. Factors that influence 
therapy adherence have been examined in many studies (McDonald, Garg, & 
Haynes 2002;Stephenson, Rowe, Haynes, Macharia, & Leon 1993). Social, 
demographic, disease or drug related associations are weak and inconsistent 
(Stephenson, Rowe, Haynes, Macharia, & Leon 1993). Beliefs about medicines 
may have a stronger influence on adherence than these other factors (Horne & 
Weinman 1999) and are related to adherence in HIV patients (Horne et al. 2004), 
asthma (Chambers et al. 1999) and other diseases (Horne & Weinman 1999). The 
beliefs about medicines questionnaire assesses patient-perceived necessity for 
prescribed medication, versus concerns about adverse effects and dependence 
(Horne, Weinman J., & Hankins 1999). Patients with high necessity and low 
concerns scores have associated high adherence rates; while those with low 
necessity and high concerns have low therapy adherence. The necessity-concerns 
differential is more strongly associated with therapy adherence than either 
necessity or concerns alone (Horne & Weinman 1999). We developed and tested a 
Parkinson's disease specific version of the beliefs about medicines questionnaire, 
and examined PO patients' beliefs about their antiparkinson medicines. We tested 
the association between the necessity/concerns score and therapy adherence, and 
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assessed patient satisfaction with the information they receive about antiparkinson 
medication. 
Methods 
PO patients' beliefs about medicines were assessed by asking 20 consecutive 
patients from one doctor's list attending a neurology movement disorder clinic 
using a semi-structured interview. All responses were collected and examined for 
common themes. These were used to form a PO specific beliefs about medicines 
questionnaire. This follows the methodology used in other diseases, and the 
exploratory approach used in developing patient rating scales in neurological and 
other disorders. 
Consecutive patients from 2 doctors' lists attending the movement disorder clinic 
were then asked to participate. Baseline assessments of demographic factors and 
disease severity were recorded using the following scales: 
• Unified Parkinson Disease Rating Scale (Fahn, Elton, & members of the 
UPDRS Development Committee 1987) 
• Hoehn and Yahr (Hoehn & Yahr 1967) 
• Schwab and England (Schwab & England, Jr. 1961) 
• mini-mental state examination (Folstein, Folstein, & McHugh 1975) 
• Geriatric depression score (Yesavage, Brink, Rose, Lum, Huang, Adey, 
& Leirer 1982) 
• Quality of life using PDQ 39 (Peto, Jenkinson, & Fitzpatrick 1998) 
Amongst the patients completing the above assessments, electronic pill bottle 
monitoring data was available in a subset of patients. 
Additional scoring was recorded as follows: 
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• At 3 months all patients were asked to complete the general version of 
the beliefs about medicines questionnaire (Horne, Weinman J., & 
Hankins 1999). 
• At six months all patients were asked to complete the PO specific 
version of the beliefs about medicines questionnaire and a modified 
version of the medicine adherence rating scale (MARS) self-report. 
Therapy intake was monitored over 3 months using electronic pill bottles with a 
microprocessor in the cap that records the date and time of bottle opening 
(MEMS®, Aardex, Switzerland). Clinical scoring was blinded to active or no 
monitoring. 
• Patients were also asked to complete a questionnaire about their 
satisfaction about information received about medicines (Horne, 
Hankins, & Jenkins 2001 ). 
Statistical analysis used linear regression to test association between variables 
using Prism® (GraphPad®, San Diego, USA) and Statistica® (StatSoft, Bedford, 
UK). 
Results 
Three themes emerged from the 20 semi-structured interviews exploring beliefs 
about medicines: concerns over 
• (1) adverse effects 
• (2) complicated drug regimens 
• (3) lack of efficacy. 
A fourteen point PO specific beliefs about medicines questionnaire was formulated 
(Appendix 1 ). 
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Of 135 patients approached, 6 (4%) patients declined mainly due to perceived 
disruption from active therapy monitoring bottles, leaving 129 cases. There was no 
significant difference in age, gender, disease duration, type or dose of 
antiparkinson medication (Ievodopa, dopamine agonist) for patients who declined 
(data not shown). 
Data from the general beliefs about medicines questionnaire was evaluable for 119 
patients and for the PD specific version for 111 patients due to 3 withdrawing 
consent, additional cases being either lost to follow up or having incomplete 
questionnaires (7 at 3 months, a further 8 at 6 months). Baseline characteristics 
are shown in Table 6.1. 
117 
Table 6.1: Characteristics of 119 PO patients 
Percentage male 
Age (years) 
Number prescribed levodopa 81 (68%) 
Average levodopa dose 516 mg 
Number on dopamine agonist 86 (72 % ) 
Number of PO drugs 2.5 (1) 
Number of non-PO drugs per day 2.5 (3) 
Number of tablets per day 12 (6) 
Duration of PO (years) 7 (5) 
UPORS 2 14 (6) 
UPORS 3 27 (12) 
Hoehn & Yahr 
Schwab & England 
MMSE 
Geriatric depression score 
PDQ 39 SI 
2.4 (0.6) 
78 (13) 
27 (4) 
11 (7) 
28 (16) 
Data are mean (standard deviation) or number (percentage). 
PO = Parkinson's disease, UPDRS = Unified Parkinson's 
disease rating scale, MMSE = mini mental state examination, 
PDQ 39 SI = Parkinson's disease quality of life summary index. 
On the general version of the beliefs about medicines questionnaire, scores were 
as follows: 
• mean necessity score was 20 (standard deviation (SO) 3) [the score 
ranges from 5=low necessity to 25=high necessity] 
• mean concerns score was 14 (SO 4) against a range of 4=low 
concerns to 20=high concerns 
• mean necessity-concerns differential of 6.7 (SO 5). 
All of the 119 (100 % ) patients believed their prescribed medication was necessary 
(indicated by a score higher than the midpoint of the scale), while 53% (63 of 119) 
had high levels of concerns (scores above the midpoint) regarding their 
medication. 
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Full adherence measured by a modified version of the medication adherence rating 
scale (MARS) was reported by 18% of patients, and 84% of patients had high 
levels of reported adherence with scores of 25 or over (scale ranging from 6 
indicating low adherence to 30 representing perfect adherence). Adherence 
measured by the MARS self-report did not correlate significantly with beliefs 
(necessity, concerns or the necessity concerns differential), and there was no 
correlation between adherence measured by the MARS self-report and any of the 
adherence measures by electronic monitoring. For the subset of 66 patients 
undertaking electronic monitoring of medicine intake compliance results were as 
follows: 
• median total compliance (the percentage of prescribed tablets taken) 
was 95% (interquartile range (10) 81-101) 
• median daily compliance (the percentage of days the correct number 
of doses were taken) was 73% (10 38-88) 
• median timing compliance (the percentage of doses taken at the 
correct time interval) was 19% (10 9-52). 
The PD specific SMO had a high level of internal consistency with a Cronbach's 
alpha of 0.8. Cronbach's alpha, which is a standard tool for this purpose, and is 
calculated from the formula: 
a = K / K-1 ( 1 -LS? / ST 2) 
where K is the number of items, s? is variance of the ith and ST2 is the variance of the 
total score formed by summing all the items. 
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Patients' main concerns were as follows: 
• (1) potential future adverse effects (involuntary movements and 
drowsiness in particular) 
• (2) not wishing to escalate doses or add medication until really 
necessary, and 
• (3) worry about unresponsive symptoms and benefit wearing off (Figure 
6.1 ). 
Figure 6.1: Concerns about antiparkinsonian medication in 109 PO patients. The 
y-axis represents the percentage of patients who responded agree or strongly 
agree. The x-axis represents the individual questions (see Appendix 2). Patients' 
main concerns centred around developing side effects in the future, increasingly 
complex dose regimens and lack of efficacy. The 50% level is highlighted as an 
arbitrary indicator of half of the study population. 
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For the 105 patients with evaluable data on the questionnaire on satisfaction with 
information received about medicines (Figure 6.2), overall satisfaction was high 
(mean score of 13 (SD 4), against a range O=low satisfaction to 17=high 
satisfaction). Patients generally reported absent or inadequate information 
regarding medication as follows: 
• effects on their sex life 
• interaction with other drugs 
• ability to take alcohol 
• appropriate action for omitted tablets. 
Figure 6.2: Satisfaction with information given about antiparkinsonian medication in 
105 PO patients. Overall there were very high levels of satisfaction but a significant 
proportion of patients would like more information on how the medicine will affect 
their sex life and if the medicine interacts with other drugs. 
100 
"Cfe 50 
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Satisfaction with information about medicines did not correlate with beliefs about 
medicines, reported adherence or any of the adherence measures by electronic 
monitoring. 
Discussion 
Our study shows that PD patients believe their therapy is necessary but they have 
significant concerns about the effects of antiparkinson medication, which has 
similarities to other diseases such as asthma, diabetes and renal disease (Horne & 
Weinman 1999). We did not find a relationship between either reported adherence, 
or electronically monitored adherence, and beliefs. Previous studies report 
associations between reported adherence and beliefs about medicines (Horne & 
Weinman 1999) (Horne, Buick, Fisher, Leake, Cooper, & Weinman 2004), but the 
method of self report to estimate adherence is widely recognised to have 
limitations (Burney et al. 1996;Melbourne, Geletko, Brown, Willey-Lessne, Chase, 
& Fisher 1999;Straka, Fish, Benson, & Suh 1997;Waterhouse, Calzone, Mele, & 
Brenner 1993). In our study we found no correlation between adherence estimated 
by self-report and adherence assessed by electronic monitoring. Wider evidence of 
the relationship between beliefs and adherence measured using electronic 
monitoring is lacking. Reported adherence inherently has recall bias which itself 
may be influenced by beliefs about medicines. Overall, both necessity scores and 
total adherence were very high and this may reflect the typical PD personality 
(Bodis-Wollner 2003). Beliefs about medicines may influence the total amount of 
medicine taken rather than how it is taken. 
Debate remains over initial drug choice in the management of PD. Less long-term 
dyskinesia with initial dopamine agonist monotherapy (Rascol, Brooks, Korczyn, 
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De Deyn, Clarke, & Lang 2000;The Parkinson Study Group 2000) has to be 
weighed against greater early symptom control from levodopa. In our study around 
80% of patients were concerned about future adverse effects and 70% were 
worried about developing involuntary movements; such patients may prefer a 
dopamine agonist initially. Lack of efficacy is another main concern and these 
patients may opt for levodopa therapy. Taking individual patient's beliefs into 
account may therefore influence therapy choice. 
Patients were generally satisfied with information provided about their 
antiparkinson medication with over two thirds stating that the level of information 
was appropriate or that information was not needed. Unlike previous studies 
(Horne, Hankins, & Jenkins 2001) where less satisfied patients had stronger 
concerns about medicines, we found no association between satisfaction and 
beliefs about medicines. There was no correlation between higher satisfaction with 
information about medicines and better reported adherence, unlike cardiac 
rehabilitation patients (Horne, Hankins, & Jenkins 2001), and there was no 
correlation with actual medicine taking behaviour measured by electronic 
monitoring. In our study this may be influenced by the high levels of both 
satisfaction with information about medicines, and the high levels of total 
adherence. 
In conclusion, PD patients believe strongly in the necessity of their medicines, but 
also have significant concerns about them, in particular adverse effects, increasing 
quantities of medicines and lack of efficacy. However, beliefs do not affect 
medication adherence in PD. 
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Chapter 7 
Patient involvement in therapy management decisions. 
Switching from ergot to non-ergot dopamine agonists in 
Parkinson's disease 
12-l 
Introduction 
The Royal Pharmaceutical Society of Great Britain defined concordance as 
involving negotiation between equals (prescriber and patient) to form a therapeutic 
alliance and defined the three pillars of concordance as providing the patient with 
sufficient knowledge, involving patients in their management plan and supporting 
the patient in medicine taking (Royal Pharmaceutical Society of Great Britain 
1997). This chapter describes a study based on these concepts of concordance 
whereby patients were provided with knowledge of potential drug adverse effects, 
allowed to choose between different management options and supported in their 
decision. 
Dopamine agonists (DA) are now standard anti parkinson treatment both as early 
monotherapy (Adler, Sethi, Hauser, Davis, Hammerstad, Bertoni, Taylor, Sanchez-
Ramos, & O'Brien 1997;Albin & Frey 2003;Clarke & Guttman 2002;Hubble et al. 
1995;Montastruc et al. 1994;Montastruc, Rascol, & Senard 1999;Olanow 
2002; Rascol, Brooks, Korczyn, De Deyn, Clarke, & Lang 2000;Schrag, Keens, & 
Warner 2002;The Parkinson Study Group 2000) and as a later adjunct (Guttman 
1997;Hubble 2002; Lieberman et al. 1998;Lieberman, Ranhosky, & Korts 
1997;Molho et al. 1995;Pinter, Pogarell, & Oertel 1999). In April 2002 the UK 
Committee of Safety in Medications (CSM) reported on 79 cases of fibrotic 
reactions in patients taking an ergot-based DA (49 on pergolide, 24 on 
bromocriptine, and 6 on cabergoline) which had been notified through their 'Yellow 
Card' scheme, a postal reporting system of clinically observed adverse events 
(Committee on Safety of Medicines (Medicines Control Agency) 2002}. Many 
cases were advanced when discovered, 3 patients died and regular clinical 
monitoring was therefore recommended for earlier detection (Committee on Safety 
of Medicines (Medicines Control Agency) 2002}. These reactions are well known 
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but considered rare. Quantifying risk is not possible from the CSM process, or from 
clinical studies that are of relatively short duration. Ergot-related side-effects 
highlighted are pulmonary (Benard et al. 1996;Geminiani, Fetoni, Genitrini, 
Giovannini, Tamma, & Caraceni 1996;Ling et al. 1999;Saura, Aguilar, & Alio 
1991 ;Shaunak et al. 1999;Todman, Oliver, & Edwards 1990), pericardial (Ling, 
Ahlskog, Munger, Limper, & Oh 1999;Saura, Aguilar, & Alio 1991 ;Shaunak, 
Wilkins, Pilling, & Dick 1999) and retroperitoneal (Jimenez-Jimenez et al. 
1995;Kains et al. 1990;Kunkler, Osborn, & Abbott 1998;Sanchez-Chapado et al. 
1995; Shaunak, Wilkins, Pilling, & Dick 1999) fibrosis. More recently pergolide and 
cabergoline have been associated with cardiac valvulopathy (Committee on Safety 
of Medicines (Medicines Control Agency) 2003; Pritchett et al. 2002;Van Camp et 
al. 2003). Fibrotic changes in the heart valves (particularly the tricuspid) of 
asymptomatic patients were found in a third of cases on pergolide (Van Camp et 
al. 2004). The definite advantages of DA therapy including a delay in the onset of 
fluctuations especially dyskinesia (Adler, Sethi, Hauser, Davis, Hammerstad, 
Bertoni, Taylor, Sanchez-Ramos, & O'Brien 1997;Albin & Frey 2003;Clarke & 
Guttman 2002; Hubble, Koller, Cutler, Sramek, Friedman, Goetz, Ranhosky, Korts, 
& Elvin 1995;Montastruc, Rascol, Senard, & Rascol 1994;Montastruc, Rascol, & 
Senard 1999;Olanow 2002; Rascol, Brooks, Korczyn, De Deyn, Clarke, & Lang 
2000;The Parkinson Study Group 2000) need to be considered against such side-
effects. The wide availability of two non-ergot oral DA drugs pramipexole and 
ropinirole (Hobson, Pourcher, & Martin 1999), both licensed for monotherapy and 
as an adjunct, and both with confirmed advantages over levodopa in reducing 
motor fluctuations (Rascol, Brooks, Korczyn, De Deyn, Clarke, & Lang 2000;The 
Parkinson Study Group 2000), leads to consideration of a switch away from ergot 
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DA treatments. These factors need to be carefully balanced when guiding patients 
about side-effect issues, and the option to switch between DA drugs. 
Adjustment of anti parkinson drugs is most frequently driven either by side effects 
which are more likely with DA drugs (such as hallucinations) or lack of benefit 
(such as the addition of levodopa to DA). Switching between DA drugs has 
primarily been conducted at a point of waning efficacy (Canesi et al. 1999;Goetz, 
Blasucci, & Stebbins 1999). We recognised that switching antiparkinson drugs in 
patients with good symptom control and no evidence of side-effects is against 
prevailing practice. However, we considered the fibrotic reaction issue as sufficient 
justification to inform patients of the issues, and offer a treatment change, thus 
involving the patient in their therapy management (Council of the European 
Communities. European Commission Council Directive. Brussels European 
Commission. 1992). 
Methods 
Patients with idiopathic PD attending the regional movement disorder clinic and 
taking an ergot-derived DA were identified. They were given verbal and written 
information about potential side effects and options to: 
• (i) change to a non-ergot DA 
• (ii) stop DA therapy and start or increase levodopa 
• (iii) maintain treatment and be monitored per CSM recommendations 
(symptom enquiry, chest X-ray, urea and electrolyte levels, erythrocyte 
sedimentation rate, consideration of lung function tests and 
echocardiogram). 
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Patients electing to switch to a non-ergot DA underwent an ovemight switch based 
on prior evidence that this was safe, and better tolerated than overlapping titration 
(Canesi, Antonini, Mariani, Tesei, Zecchinelli, Barichella, & Pezzoli 1999;Goetz, 
Blasucci, & Stebbins 1999). 
Dose equivalents were defined from a literature review and summary of product 
characteristics for each drug. Ratios used were as follows: 
• 1: 1 for pergolide to pramipexole (salt) 
• 1:4 for pergolide to ropinirole (modified to between 1:4 and 1 :5.3 at 
the upper end of the dose range) 
• 4:3 for cabergoline to pramipexole 
• between 1:3 and 1:4 for cabergoline to ropinirole 
• 10: 1 for bromocriptine to pramipexole 
• between 2: 1 and 3: 1 for bromocriptine to ropinirole (Canesi, Antonini, 
Mariani, Tesei, Zecchinelli, Barichella, & Pezzoli 1999;Goetz et al. 
1989; Goetz, Blasucci, & Stebbins 1999; Hanna et al. 2001). 
A conversion chart based on these ratios and providing example doses was 
applied (Table 7.1). Equivalent doses were used in most cases. Clinical judgement 
allowed doses at conversion to be adjusted upwards if the patient was 
undertreated, or downwards if there were any features suggesting dopaminergic 
excess (dyskinesia, hallucination, nausea, dizziness). Domperidone was 
maintained or commenced on clinical grounds. Concomitant antiparkinson therapy 
was recorded. Written switching instructions were handed to the patient. 
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Table 7.1 Conversion chart; approximate dose equivalents for dopamine agonists 
Bromocriptine Cabergoline Pergolide Pramipexole Ropinirole 
Salt Base 
1 mg tid 0.5mg per day 0.125 mg tid 0.125 mg tid 0.088 mg tid Starter pack then 1 mg tid 
2.5 mg tid 1 mg per day 0.25 mg tid 0.25 mg tid 0.18 mg tid 1 mg tid 
5 mg tid 2 mg per day 0.5 mg tid 0.5 mg tid 0.36 mg tid 2 mg tid 
7.5 mg tid 3 mg per day 0.75 mg tid 0.75 mg tid 0.54 mg tid 3 mg tid 
10 mg tid 4 mg per day 1 mg tid 1 mg tid 0.7 mg tid 4 mg tid 
12.5 mg tid 5 mg per day 1.25mg tid 1.25mg tid 0.88 mg tid 6mg tid 
15 mg tid 6 mg per day 1.5 mg tid 1.5 mg tid 1.05 mg tid* 8mg tid 
*or 1.06mg If uSing 0.7mg tablet + (2 tablets x 0.18 mg) 
Follow-up was routinely at between 3 and 6 months but telephone advice and 
earlier clinic review were also available. Adverse events were classified as 
suggesting undertreatment (worsening PO), overtreatment (dopaminergic side-
effects such as hallucinations or dyskinesia) or other side-effects (sleepiness, 
headache). DA doses were subsequently adjusted andlor levodopa added or 
adjusted on clinical grounds, on a balance between tolerability and level of 
symptom control. Results were stratified according to whether the dose at the time 
of switching was lower, equivalent, or higher than the conversion chart. 
Pramipexole and ropinirole data for adverse events were combined due to small 
group sizes. The primary endpoint was retention of the new OA at last follow-up; 
retention of any DA at last follow-up was the main secondary endpoint. 
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Results 
Patients Of 579 Parkinson's Disease patients attending the movement disorder 
clinic since October 1999, 383 (66%)) had ongoing attendance at the time of the 
conduct of the study. Of these 383, 99 (26%)) were on ergot DA agonists and 88 of 
these 99 (89%) opted to switch to a non-ergot DA. Ten patients (10%) chose to 
retain their existing DA; all underwent blood tests and chest X-ray with normal 
results. One patient increased levodopa and stopped DA treatment. Characteristics 
of the patients who switched therapy are shown in Table 7.2. 
Table 7.2 Baseline characteristics of 88 patients undergoing Dopamine Agonist 
switch 
Pergolide Cabergoline Bromocriptine 
Number of patients 69 15 4 
Male:female ratio 1.4:1 4:1 1:1 
Age in years 60 (8.3) 65 (8.8) 60 (10.8) 
Duration of PO in years 6.2 (3.6) 8.7 (5.4) 9.5 (5.6) 
Duration of DA therapy 26.5 (15.8) 26 (17) 74 (21) 
in months 
Hoehn and Yahr 2.2 (0.5) 2.4 (0.4) 2.3 (0.5) 
at time of switch 
Duration of follow-up 11 (9) 12 (6) 9 (5) 
in months 
Data are means with standard deviation in brackets; PD=Parkinson's Disease; 
DA=Dopamine Agonist 
Reason for therapy switch. In 81 % (71 of 88 cases) the reason for switching DA 
was the potential fibrosis issue highlighted by the CSM warning. Recognised 
ergot side effects were present in 4 cases (4 % ), and other side effects in 11 
(120/0) some of which might have been ergot-related (Table 7.3). 
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Table 7.3 Reason for switching to a non-ergot Dopamine Agonist in 88 patients 
Reason Number of patients Side-effects 
CSM alert 71 
Ergot side-effects* 4 
Other side-effects 11 
Patient request 1 
Lack of efficacy 1 
CSM=Committee of Safety in Medicines 
Pleural effusion n=2 
Pulmonary fibrosis n=2 
Respiratory symptoms n=3 
Fluid retention n=3 
Nausea n=2 
Skin rash n=2 
Constipation n=1 
Dizziness n=1 
Flushing n=1 
* Diagnosed by chest X-ray n = 4, Computed Tomography of thorax n = 3, lung 
biopsy n =1; all cases diagnosed by respiratory physicians and all improved after 
discontinuation of ergot. 
Doses of Dopamine Agonists. DA doses at switch are listed in Table 7.4. The 
dose of non-ergot DA post-switch was relatively higher for pramipexole than for 
ropinirole, considering their respective dose ranges. At follow up DA doses were 
higher reflecting upward dose titration with progressing disease (Table 7.5). 
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Table 7.4 Baseline and post-switch doses of Dopamine Agonist in 88 patients 
Baseline doses Post-switch doses 
Pergolide Cabergoline Bromocriptine Pramipexole Ropinirole 
Number 69 15 4 74 14 
of patients 
Mean dose 2.1 3.2 28 2.3 6.4 
(SO) (1.1 ) (1.1 ) (20) (1.3) (3.2) 
All d.o~es are total per day and expressed in milligrams (mg); SD=Standard 
Deviation; dose of pramipexole as salt 
Table 7.5 Doses of Dopamine Agonist in 72 patients at follow-up 
Mean dose 
(SO) 
Pramipexole 
3.0 
(1.3) 
Ropinirole 
10.3 
(4.8) 
All doses are total per day and expressed in milligrams (mg); 
SD=Standard Deviation; dose of pramipexole as salt 
Adverse events. Overall 23 of 88 patients (26%») experienced adverse events 
suggestive of over or undertreatment (Table 7.6). The majority of patients were 
switched at equivalency (54 of 88,61 %); 20 of 88 (23%») had a lower than 
equivalent dose; and 14 of 88 (16%») had a higher than equivalent dose. Side 
effects were less common in patients on equivalent doses (11 of 54 cases, 20% ) 
against 30% (6 of 20 cases) in the lower than equivalent dose group, and 43% (6 
of 14 cases) in the higher than equivalent dose group. There were no adverse 
events suggestive of undertreatment in the 14 patients given a higher than 
equivalent dose. In the lower than equivalent dose group, adverse events were 
mainly symptoms of undertreatment. 
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Table 7.6 Adverse events according to baseline DA and dose equivalency used at 
conversion 
Adverse events 
Suggesting 
undertreatment 
Conversion dose: Lower Equal Higher 
Baseline DA 
Pergolide 
(n=69) 
Cabergoline 
(n=15) 
Bromocri pti ne 
(n=4) 
Total 
(n=88) 
5/14 3/45 0/10 
(36%) (6.7 % )(0%) 
0/5 2/7 0/3 
(0%) (29%) (0%) 
0/1 0/2 0/1 
5/20 5/54 0/14 
(25%) (9%) (0%) 
Suggesting 
overtreatment 
Lower Equal Higher 
0/14 5/45 3/10 
(0%) (11 0/0) (30%) 
0/5 1/7 3/3 
(0%) (14%) (100%) 
1/1 0/2 0/1 
1/20 6/54 6/14 
(5%) (11 %) (43%) 
DA=Dopamine Agonist; percentages omitted for bromocriptine due to 
small numbers; Lower, Equal, and Higher refer to doses chosen at switch 
(see text); adverse events not attributable to undertreatment or 
overtreatment are not shown 
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Additional side-effects are shown in Table 7.7. Overall side-effect rates were not 
statistically significant by dose group; small group sizes prevented more detailed 
analysis. 
Domperidone was co-prescribed (pre-existing or started at therapy switch) in 
35 of the 88 cases (40%) with no significant differences according to dose 
equivalency. 
Table 7.7: Adverse Events in 88 patients undergoing dopamine agonist switch 
Adverse Event 
Worsening parkinsonism 
Nausea 
Excessive sleepiness 
Dizziness 
Poor balance 
Hallucinations 
Feeling 'disconnected' 
Worsening dyskinesia 
Ankle oedema 
Skin rash 
Headaches 
Total 
Number of patients* 
10 (11%» 
5 (6%» 
3 (3 % ) 
3 (3 % ) 
2 (2%) 
2 (2 % ) 
1 (1 0/0) 
1 (1 0/0) 
1 (1 %) 
1 (1 %) 
1 (1 % ) 
30 
*patients may have reported more than one adverse event 
At the time of switch, levodopa was in place in 43 of the 88 cases (49% ), 
which increased to 53 of 88 cases (60%) at follow-up. Considering 
levodopa usage at baseline according to dose equivalence for DA 
treatment at the time of switching, 25 of 54 (46%) at dose equivalence 
were on concomitant levodopa, 13 of 20 (65% ) in the 'lower' group, and 5 
of 14 (36 % ) in the 'higher' group. The mean total daily levodopa dose at 
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the time of switch was 506mg (95% confidence interval 413-600mg). At 
follow-up 31 of 54 (57% ) 'equivalent' cases, 15 of 20 (75 % ) 'lower' cases, 
and 7 of 14 (50%) 'higher' cases were on levodopa. 
Patients were more likely to remain on the switch DA if their switch was 
at equivalent or lower doses (Table 7.8). Retention rates were 82% for 
the switch DA and 93% for any DA. 
Table 7.8: Retention of dopamine agonist therapy 
DA at follow-up 
Conversion Remains Reverted Switched 
Dose on switch DA to baseline to other Total 
DA non-ergot on DA 
Equivalent 44 (81%) 3 (6%) 4 (7%) 51 (94%) 
(n=54) 
Higher 11 (79%) 1 (7%) o (0%) 12 (86%) 
(n=14) 
Lower 17 (85%) o (0%) 2 (10%) 19 (95%) 
(n=20) 
Total 72 (82%) 4 (40/0) 6 (7 % ) 82 (93%) 
(n=88) 
DA=Dopamine Agonist; Equivalent, Higher, and Lower refer to doses 
chosen at switch (see text) 
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Discussion 
Prior DA switching reports are based mainly on waning efficacy (Canesi, Antonini, 
Mariani, Tesei, Zecchinelli, Barichella, & Pezzoli 1999;Goetz, Shannon, Tanner, 
Carroll, & Klawans 1989;Goetz, Blasucci, & Stebbins 1999) unlike the present study 
in which switching was primarily a result of the CSM warning over ergot DA side-
effect risks. Switching antiparkinson therapy because of a risk of ergot-related side-
effects is a previously unreported territory. When provided with available information 
and potential options, the majority of patients chose to switch to a non-ergot agent, 
although a few delayed the switch for up to 9 months after initial discussions, and 
failing efficacy began to playa part in this decision. The rate of possible ergot 
related side effects (pleural effusion or fibrosis) in our series was 4%), which is 
classified as a common side effect by the European Union directive (European 
Commission Pharmaceutical Committee 1998). In three additional cases, symptoms 
of breathlessness may have been ergot-related, or alternatively due to co-morbidity 
(chronic obstructive pulmonary disease/congestive cardiac failure). 
Pre-switch DA doses were near the midpoint of standard dose ranges for pergolide, 
comparable with other studies (Canesi, Antonini, Mariani, Tesei, Zecchinelli, 
Barichella, & Pezzoli 1999;Goetz, Blasucci, & Stebbins 1999;Hanna, Ratkos, Ondo, 
& Jankovic 2001). The four patients on bromocriptine were in the upper dose range, 
while previous studies switched nearer the midpoint of the dose range (Canesi, 
Antonini, Mariani, Tesei, Zecchinelli, Barichella, & Pezzoli 1999;Gimenez-Roldan, 
Esteban, & Mateo 2001); this reflected a longer duration of disease in our patients 
on bromocriptine. Overall, the mean duration of Parkinson's disease was shorter in 
our study at around 8 years compared to 11 years (Gimenez-Roldan, Esteban, & 
Mateo 2001), 12.5 years (Hanna, Ratkos, Ondo, & Jankovic 2001), and 15 years 
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(Goetz, Blasucci, & Stebbins 1999), reflecting our process of switching because of 
potential or actual ergot side-effects, rather than after efficacy had been exhausted. 
For the same reason, the duration of dopamine agonist therapy prior to switching in 
our cohort was shorter at 3.5 years versus 6 years (Goetz, Blasucci, & Stebbins 
1999) and 7 years (Gimenez-Roldan, Esteban, & Mateo 2001), and 51 % of our 
cases were on dopamine agonist monotherapy at the time of switch while other 
studies included a higher proportion of advanced cases (Gimenez-Roldan, Esteban, 
& Mateo 2001 ; Goetz, Shannon, Tanner, Carroll, & Klawans 1989;Goetz, Blasucci, & 
Stebbins 1999). Despite these differences, our mean post switch daily dose of 2.3 
mg pramipexole was virtually the same as Goetz et al (2.2mg /day) (Goetz, 
Blasucci, & Stebbins 1999), although Hanna et al (Hanna, Ratkos, Ondo, & 
Jankovic 2001) converted patients over a one month period and with this 
optimisation the daily dose reached 3.2 mg. Our post-switch doses of ropinirole 
were lower than previously reported (Canesi, Antonini, Mariani, Tesei, Zecchinelli, 
Barichella, & Pezzoli 1999; Gimenez-Roldan, Esteban, & Mateo 2001) for 2 main 
reasons: patients switched to ropinirole were on lower than average baseline 
agonist doses, and none was given higher than equivalent dose. 
The dose conversions we applied were based on previous definitions, but there is 
variability amongst these. The reported ropinirole to pergolide ratio varies between 
3: 1 and 6: 1 (Canesi, Antonini, Mariani, Tesei, Zecchinelli, Barichella, & Pezzoli 
1999). While arithmetically precise optimal conversion ratios were suggested at 
0.77: 1 for pergolide to pramipexole, and 10 to 1.5 for bromocriptine to pramipexole, 
the simple 1: 1 pergolide to pramipexole, and 10: 1 bromocriptine to pramipexole are 
more practical (Goetz, Blasucci, & Stebbins 1999). Since conversions need further 
adjustment because of available tablet sizes, we collated these suggestions into a 
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guide covering frequently encountered doses (Table 7.1). The individual patient 
response which is well-known in PO means that switching at 'equivalency' can still 
cause temporary worsening; 20% of our cases in this category had either under or 
over treatment, but we found the structured approach useful. Moreover, such 
observations are in keeping with known variations in affinity for dopamine receptor 
subtypes, reflected in studies combining two different OA drugs (Stocchi et al. 
2003). However, detailed comparisons between switching and non-switching 
patients, or between equivalent versus non-equivalent switching, were not 
considered appropriate for the present study design and group sizes; these 
aspects may form the basis for a larger investigation. 
We adopted an overnight switch in view of the comparative data against slow 
titration in other studies (Canesi, Antonini, Mariani, Tesei, Zecchinelli, 
Barichella, & Pezzoli 1999;Gimenez-Roldan, Esteban, & Mateo 2001 ; Goetz, 
Shannon, Tanner, Carroll, & Klawans 1989;Goetz, Blasucci, & Stebbins 1999). 
Patients generally tolerated this process and maintained reasonable efficacy. 
The long half-life of cabergoline might theoretically cause overtreatment when 
switching to a new agent, and in support of this we observed overtreatment 
side-effects in all 3 patients switched from cabergoline to higher than equivalent 
doses. However, we did not find evidence of such a problem at equivalent, or 
lower than equivalent doses. 
Overall 82% of our patients retained the post-switCh dopamine agonist and 93% 
remained on a dopamine agonist, after 11 months follow-up. Canesi et al (Canesi, 
Antonini, Mariani, Tesei, Zecchinelli, Barichella, & Pezzoli 1999) reported a 91 0/0 
retention of new OA in 68 patients, but follow-up was short at only 4 weeks. With 6 
months follow-up, 86% retention of new OA was reported in another study (Hanna, 
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Ratkos, Ondo, & Jankovic 2001 ). A longer follow-up captures patients who switch 
therapy for other clinical reasons, as also observed in comparative trials of OA 
versus levodopa, for example an 85% retention of pramipexole in the CALM-PO 
study (The Parkinson Study Group 2000). 
Our findings guide the practising clinician in several important ways. When provided 
with verbal and written information balancing risks and benefits (and given 
prolonged consideration time if they wish it) most patients choose to switch from an 
ergot OA to a non-ergot OA. When switched, an equivalent dosage is less likely to 
result in adverse events. If a lower dose is used about a quarter of patients will have 
symptoms of undertreatment; up-titration is likely to become necessary. Retention of 
dopamine agonist therapy is more likely if a lower or equivalent dose is used. 
Switching can be achieved as part of routine clinical care, aided by the conversion 
table in this chapter. 
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Chapter 8 
Can an educational intervention improve adherence to 
prescribed medicines in Parkinson's Disease? 
l-lO 
Introduction 
We have identified sub-optimal medicine usage in Parkinson's disease; can this be 
improved? In this chapter we test the effect of an educational intervention to 
regularise medication timing. We hypothesize that irregular medicine intake 
contributes to pulsatile dopamine stimulation which contributes to motor 
fluctuations. 
Although the majority (about 80%) of PO patients take almost 100% of prescribed 
medication, irregular timing of drug ingestion is almost universal (Chapters 3 and 
4). The precise clinical effect of erratic drug ingestion are not known, but pulsatile 
dopaminergic stimulation in the basal ganglia (Stocchi et al. 2005) is implicated in 
the development and manifestation of motor fluctuations. Short drug half-life and 
erratic absorption both contribute to pulsatile stimulation, but irregular drug intake 
may be equally important. In other disease areas, interventions to assist patient 
adherence to prescribed medication include simplifying drug regimens (Girvin, 
McDermott, & Johnston 1999;Melikian et al. 2002), providing additional education 
(Henry & Batey 1999; Peveler et al. 1999), counselling and behavioural approaches 
(O'Donnell et al. 2003;Rosen, Rigsby, Salahi, Ryan, & Cramer 2004;Weber et al. 
2004) and providing reminder packaging (Becker et al. 1986). We tested the effect 
on the timing of medicine ingestion of an educational intervention of informing 
patients about the continuous dopaminergic theory (Juncos, Engber, Raisman, 
Susel, Thibaut, Ploska, Agid, & Chase 1989;Stocchi, Vacca, Ruggieri, & Olanow 
2005), to provide a reason for patients to take antiparkinsonian medication at 
regular time intervals. 
l-ll 
Methods 
Two out of every three patients attending the movement disorder clinic with 
idiopathic Parkinson disease (according to UK Brain Bank criteria) were invited to 
participate. Patients were prescribed at least one antiparkinson drug (including a 
dopamine agonist and/or levodopa). Patients were excluded if study participation, 
particularly use of the electronic monitoring bottles was potentially detrimental to 
their treatment. The study received ethics approval and signed consent was 
obtained. Baseline assessments of unified Parkinson's disease rating scale 
(UPDRS) (Fahn, Elton, & members of the UPDRS Development Committee 1987), 
Hoehn and Yahr (Hoehn & Yahr 1967), Schwab and England (Schwab & England, 
Jr. 1961), mini-mental state examination (Folstein, Folstein, & McHugh 1975), 
geriatric depression scale (Yesavage, Brink, Rose, Lum, Huang, Adey, & Leirer 
1982) and quality of life score (PDQ 39) (Jenkinson et al. 1997) were performed. 
Clinical scoring was performed in an 'on' state' and was blinded to patient group. 
All antiparkinson medicines were monitored for three-months using electronic 
monitoring pill bottles (MEMS®, Aardex, Switzerland), the lid of which records the 
time and date of bottle opening. Patients were randomly assigned (method 
described in Chapter 3) to receive (the active group) or not receive (the control 
group) an educational intervention of verbal and written information about the 
continuous dopaminergic theory and written advice on optimal medicine timing 
tailored to the individual's drug regimen. This was then followed by a further 3 
months of antiparkinson electronic medicine monitoring. UPDRS and adverse 
events were recorded at each visit. The quality of life score (PDQ 39) was repeated 
at the final visit. Medication was adjusted according to clinical need. The increase 
in levodopa equivalent units during the study period was calculated according to 
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established formulas (Ievodopa + 1/3 if on entacapone + ropinirole x 20 + 
pramipexole or cabergoline x 67 + pergolide x 100 + bromocriptine x 10) (Parkin et 
al. 2002). 
Total compliance (the total amount of prescribed medication taken), daily 
compliance (the percentage of days on which the prescribed number of doses 
were taken) and timing compliance (the percentage of doses taken at the correct 
time interval) were calculated from the electronic monitoring data. Timing 
compliance is calculated from time intervals which give an optimum 
pharmacokinetic profile, allowing for a 25%) deviation in timing. For example a 
satisfactory interval between doses for a 3 times daily drug is between 6 and 10 
hours; time intervals outwith this are unsatisfactory. Selegiline 5mg twice daily was 
excluded from this analysis as the second dose is taken at lunchtime to avoid sleep 
disturbance. 
Longitudinal data of changes in compliance measures, UPDRS 3 and quality of life 
were calculated. Groups were compared using unmatched t-tests for parametric 
data and Mann-Whitney for non-parametric data. The primary end point was a 
difference in timing compliance between groups. Secondary end points were 
differences in UPDRS 2 and 3 and quality of life (PDQ 39) between groups. 
Statistical analysis used Prism 3 (GraphPad®, CA, USA). 
Results 
Of 89 patients asked to participate, 6 (7%») declined. Of the remaining 83, 43 were 
randomised to the active group and 40 to the control group. Baseline 
demographics and data are shown in Table 8.1. Fourteen patients dropped out 
during the pre-intervention stage as follows (Figure 8.1 ): 
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• 10 from the active group 
• 2 withdrew consent after baseline assessment , 
• 1 died 
• 7 had problems with the electronic monitoring bottles (e.g. being 
unable to manipulate the bottles due to dyskinesia, taking all the next 
day's medication out the night before or losing the bottles), and 
• 4 from the control group 
• 3 misused the bottles 
• 1 withdrew consent 
There were no Significant differences in baseline characteristics in patients who 
dropped out versus those continuing the study. Baseline compliance data was 
therefore available for 69 patients (33 in the active group and 36 in the controls). 
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Figure 8.1: CONSORT flowchart of 89 eligible patients. 
Assessment of eligibility 
(n= 89) 
t----------1 ... ~ Excluded 
.... 
Randomised 
(n= 83) 
Allocated to intervention (n=43) 
Received allocated intervention (n=33) 
Did not receive allocated intervention 
(n=lO) 
Reasons 
2 withdrew consent 
7 problems with monitoring bottles 
1 died 
Discontinued intervention (n=lO) 
Reasons 
3 declined rerun of monitoring 
bottles 
6 used the monitoring bottles 
inconsistently 
1 system recording failure 
Analysed (n= 23) 
1~5 
(n=6, all declined) 
Allocated to no intervention (n= 40) 
Received allocated intervention 
(n=36) 
Did not receive allocated intervention 
(n= 4) 
Reasons 
1 withdrew consent 
3 problems using monitoring 
bottles 
Discontinued (n=7) 
1 declined rerun of monitoring 
bottles 
6 used the monitoring bottles 
inconsistently 
Analysed (n=29) 
Table 8.1: Patient characteristics by group 
Males (%) 
Age (years) 
Prescribed levodopa (%) 
Levodopa dose (mg) 
Prescribed dopamine agonist (%) 
Change in levodopa equivalent units 
Number of PD drugs 
Number of PD daily doses 
Number of PD tablets per day 
Number of non-PD drugs per day 
Total number of tablets per day 
Carer helps with medication (%) 
Duration of PD (years) 
UPDRS 2 
UPDRS 3 
UPDRS 4 
Hoehn & Yahr 
Schwab & England 
MMSE 
Geriatric depression score 
PDOSI 
Total compliance, median (10) 
Days compliance, median (10) 
Timing compliance, median (10) 
Active 
(n = 43) 
56% 
61 (10) 
28 (65%) 
508 (227) 
30 (70%) 
2.6 (1.2) 
4.0 (2.3) 
9 (5) 
2.8 (3) 
12 (6) 
10 (23%) 
7.7 (6) 
14 (6) 
29 (11) 
3.2 (3) 
2.4 (0.6) 
78 (10) 
28 (2) 
12 (6) 
31 (14) 
Pre-Intervention 
92% (72-99) 
68% (30-87) 
17% (9-51) 
Control 
(n = 40) 
58% 
62 (10) 
29 (73%) 
607 (458) 
29 (73%) 
2.6 (1.3) 
4.3 (2.2) 
9.5 (5) 
1.9 (2) 
12 (5) 
10(25%) 
6.9 (4.6) 
14 (6) 
24 (13) 
3.5 (3) 
2.5 (0.7) 
76 (14) 
28 (2) 
10 (7) 
31 (14) 
97% (87-102)* 
77% (56-88) 
21% (10-59) 
Active 
(n = 23) 
Post-Intervention 
Control 
(n = 29) 
18 (78%) 
511 (306) 
18 (78%) 
51 (148) 
2.4 (1.2) 
4 (0.8) 
9.5 (5) 
2.5 (3) 
13 (7) 
7 (30%) 
14 (6) 
29 (14) 
3.2 (2.3) 
2.5 (0.7) 
71 (18) 
36 (15) 
96% (82-1 00) 
75% (48-88) 
39% (22-58) 
22 (76%) 
670 (380) 
18 (62%) 
70 (149) 
2.2 (1.5) 
4 (1.2) 
9 (5) 
3.5 (4) 
12 (7) 
9 (31%) 
15 (7) 
28 (14) 
3.6 (2.3) 
2.5 (0.7) 
73 (15) 
28 (14) 
94% (78-99) 
69% (36-86) 
20% (10-47)** 
Data are mean (standard deviation) unless otherwise stated. PD = Parkinson's disease, UPDRS = Unified Parkinson's disease rating scale, MMSE = mini 
mental state examination, PD~ 39 SI = Parkinson's disease quality of life summary index, 10 = interquartile range. 
Compliance data is based on 33 patients in the active group and 36 patients in the control group in the pre-intervention phase. 
*p=0.01. **p=0.007. There were no other significant differences between groups. 
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Baseline total compliance was significantly lower in the active group (median 
92% (interquartile range (10) 72-99) versus median 97% (10 87-102) for 
control patients, p=0.01). The upper 10's of 99 and 102 indicate that some 
medications were taken in excess of that prescribed. Although daily 
compliance was lower in the active group (median 68%, 10 30-87) than in the 
control group (median 77%, 10 56-88), as was timing compliance (active 
group median 17% (10 9-51) versus 21 % (10 10-59) for controls), these 
differences were not significant. All other parameters did not differ significantly 
between active and control groups (Table 8.1). 
In the post-intervention period 17 patients dropped out as follows 
• 1 0 from the active group 
• 3 did not wish to re-run the electronic monitoring bottles 
• 6 used them inconsistently 
• 1 failure of the recording system, and 
• 7 from the control group 
• 1 declined to re-run the electronic monitoring 
• 6 did not use the bottles consistently 
Post-intervention compliance data was evaluable for 52 patients (23 in the 
active group and 29 controls)(Table 8.1). Dosage as levodopa equivalent units 
increased by 51 (SO 148) in the active group versus 70 (149) in controls (not 
significant). After the intervention median total compliance was 96% (10 82-
100) in the active group, versus 94% (10 78-99) in controls (not significant) 
and daily compliance was 75% (10 48-88) in the active group versus 69% (10 
36-86) in controls, not significant. However, timing compliance was 
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significantly better in the active group at 39% (IQ 22-58) compared to controls 
20% (IQ 10-47) (p=0.007). The changes in total and daily compliance, from 
pre- to post-intervention, were not significantly different between active and 
control patients, but timing compliance post-intervention improved by mean 
11.4 (SO 28) in active group versus a deterioration (mean -7.4, SO 21) in 
controls, p=0.001. There was a worsening of all compliance measures in the 
control group for the second testing period compared to the first. There were 
no significant differences between UPORS 3 or quality of life scores or 
adverse events between groups before the intervention (Table 8.1). The mean 
change in POQ single index score was 8 (SO 11) in the active group versus -
2 (SO 15) in controls (not significant). However, UPORS 3 improved in the 
active group (mean -0.5, SO 11) versus a deterioration in controls (mean +5, 
SO 8)(p=0.03). 
There were no significant differences in frequency or type of adverse events 
between groups. In the active group there were 1.5 adverse events (SO 1.3) 
per patient, while in the control group there were 1.1 adverse events (SO 1.5) 
per patient. Oyskinesia, nausea, sleepiness and ankle swelling were the most 
frequent adverse events. Timing compliance was significantly better for once 
daily drugs such as selegiline 10mg (median 82% , IQ 70-93) than drugs 
prescribed twice daily (33% , IQ 4-47) or more frequently (p<0.0001 ))(Figure 
8.2). 
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Figure 8.2: ~om~liance (m~dia.n and upper quartile) against number of daily 
?oses ~f antlparklnson medication. Compliance measures were lower with 
mcrea~/ng numbe~ o~ ~aily doses, most notably for timing compliance. Timing 
compliance was significantly better for once daily drugs than drugs taken 
more frequently (p<O.0001). Data is from 69 patients in the pre-intervention 
phase of the study. 
Total Daily liming 
Compliance Compliance Compliance 
(1) 
(.) 
100 
c: 
cu 
.-Q. 
E 
o 
o 
?fl. 
Discussion 
50 
0--1~2~3~4~5~--~~~~ 
Number of Daily Doses 
We found improved timing of oral anti parkinson medicine intake after an 
educational intervention. However, there was variability in the response, which 
ranged within the active group from a worsening of 23%) to an improvement of 
96%) in timing compliance, and there was an overall worsening of compliance 
measures in the control group. The initial 3-month compliance-monitoring 
period may provide artificially high levels of compliance, boosted by the 
novelty of the technique which diminished by the second three months of 
monitoring. Deterioration in control group compliance figures post-intervention 
is reported elsewhere: in compliance with antiretroviral therapy where a 
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cognitive behaviour intervention was tested in H IV positive patients (Weber, 
Christen, Christen, Tschopp, Znoj, Schneider, Schmitt, Opravil, Gunthard, & 
Ledergerber 2004) and in elderly patients prescribed cardiac medications 
(Fulmer et al. 1999). A small group of our patients (6 of 28 in the active group 
(21 010) who entered the post-intervention phase) were highly motivated and 
improved timing dramatically, with a mean improvement in timing compliance 
of 53% (SD 27); 3 of these patients were prescribed only one drug and the 
other 3 were on two drugs, thus representing simpler drug regimens than 
average. The majority of our patients found regularisation of medicine-taking 
difficult. Although we did not explore the reasons for this, they are well 
documented in PD (Leopold, Polansky, & Hurka 2004) and other diseases 
(Chesney et al. 2000;Stephenson, Rowe, Haynes, Macharia, & Leon 1993) 
and include forgetfulness and leaving home without medication. 
A significant proportion of our PD patients had a carer who helped with their 
medicines, and this is another potential influence on medicine taking 
behaviour. 
We found no difference in adverse events between active and control groups. 
Drug side-effects influence compliance, in particular leading to premature 
therapy discontinuation (Bull, Hu, Hunkeler, Lee, Ming, Markson, & Fireman 
2002a), but this is commoner after therapy initiation (Bull, Hunkeler, Lee, 
Rowland, Williamson, Schwab, & Hurt 2002b) whereas in our study patients 
were on established medication. 
The dropout rate in this study was high as many patients found difficulty with 
the technique. Patients who dropped out of the study tended to be on higher 
doses of medication. Such patients may have lower medication compliance, 
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so that our figures may artificially elevate the 'real-life' situation of medicine 
intake. 
A multitude of studies have tested interventions to improve therapy 
compliance (Haynes et al. 2002), but this is the first such study in Parkinson's 
disease. The vast majority of studies in other disease areas used pill counts, 
self report or physician/nurse assessment (McDonald, Garg, & Haynes 2002) 
to measure compliance despite well-recognised shortcomings and inaccuracy 
of these methods (Cramer, Mattson, Prevey, Scheyer, & Ouellette 
1989;Melbourne, Geletko, Brown, Willey-Lessne, Chase, & Fisher 1999; Paes, 
Bakker, & Soe-Agnie 1998; Pullar, Kumar, Tindall, & Feely 1989; Stephenson, 
Rowe, Haynes, Macharia, & Leon 1993). Many different types of intervention 
have been tested (Haynes, McDonald, Garg, & Montague 2002) most being 
complex involving multiple components, which leaves uncertainty as to which 
aspects have a positive effect. We therefore chose a simple one-dimensional 
intervention. In diabetes, when baseline electronic monitoring data was used 
to provide individualised cue-dose training (linking medicine taking to daily 
activities, including routine change such as weekends) timing compliance 
improved by a mean of 15%) (Rosen, Rigsby, Salahi, Ryan, & Cramer 2004), 
similar to the improvement in timing compliance in our study. Other studies 
report either no benefit or only a modest improvement (McDonald, Garg, & 
Haynes 2002). 
In our study drugs taken once daily were taken more regularly than 
complicated regimens, which is consistent with a systematic review of 76 
electronic monitoring studies (Claxton, Cramer, & Pierce 2001). 
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Pharmaceutical development of more once daily antiparkinson preparations 
may help ease the process of medicine taking. 
The improvement in motor score in active patients relative to controls 
occurred despite similar dose increases during the monitoring period, 
suggesting benefit of the intervention. Quality of life did not improve between 
active and control groups, nor was there an improvement in quality of life in 
the subset of patients whose compliance improved. This may be attributable 
to the stronger influence of factors other than motor score (eg. depression) on 
quality of life (Schrag, Jahanshahi, & Quinn 2000). Another consideration is 
the well-known improvement in compliance immediately prior to the clinic visit, 
which may artificially improve the clinic UPDRS reading. More prolonged 
observation of clinical response may be more accurate, which we are now 
undertaking using ambulatory tremor readings. We speculate that longer-term 
regularisation of medicine intake might delay or reduce future motor 
fluctuations, but this is clearly beyond the scope of current work. Clinical 
indicators have sometimes improved in other diseases (e.g. epilepsy (Cramer, 
Glassman, & Rienzi 2002), hypertension (Leenen et al. 1997) and diabetes 
(Morris et al. 1997)) in association with better compliance, but such findings 
are not universal (Rosen, Rigsby, Salahi, Ryan, & Cramer 2004;Weber, 
Christen, Christen, Tschopp, Znoj, Schneider, Schmitt, Opravil, Gunthard, & 
Ledergerber 2004). Further larger, longer-term studies are necessary to 
evaluate the clinical significance of irregular medicine taking in Parkinson's 
disease. Other methods such as simplifying drug regimen, which is of proven 
of value in other disease areas (Brun 1994; Eisen et al. 1990), may be more 
universally achievable and is another topiC for further study. 
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Therapy Concordance and Drug Adherence in Parkinson's Disease 
Future developments 
Our findings are based on observations from a single centre in the West of Scotland. The 
next step is to examine if these observations reflect medicine-taking behaviour in 
Parkinson's disease in a wider population. We are currently co-ordinating a study of 
medication adherence using electronic monitoring in Parkinson's disease across Europe. 
Five countries (the United Kingdom, France, Spain, Italy and Germany) are participating 
each with one or two centres and a total of 120 patients will be studied. The hypotheses 
being tested are:-
1. Drug taking in Parkinson's disease is erratic 
2. The first dose in the day is taken more consistently than doses later in the day 
3. Adherence is inversely related to the number of daily doses 
4. Disease stage and the presence of fluctuations influence medicine taking behaviour 
5. Poorly controlled patients consume more health care resources than well controlled 
patients 
This study is scheduled to start in the autumn 2005 and is estimated to take a year to 
complete. 
How does therapy intake relate to clinical response? Fluctuations in the clinical 
response to antiparkinson medication occur in virtually all patients in the later stages of 
disease, are difficult to manage, and cause significant functional impairment and morbidity. 
Pulsatile stimulation of the post-synaptic dopamine receptor is considered a key factor, and 
is contributed by pharmacokinetic properties of anti parkinson drugs (such as short half-life 
and variable absorption). We hypothesise that irregular drug ingestion contributes to motor 
fluctuations and that improved regularity of medicine intake will smooth the clinical 
response. The first step is to quantify the clinical response to individual doses of therapy 
using objective methods. 
Tremor is the most commonly experienced 'wearing-off symptom at the end of a dose of 
antiparkinson medication. We have planned a study which will use an accelerometer (a 
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small device attached to the limb via a Velcro strap) and relate tremor response to 
medication timing (measured using electronic monitoring bottles, Aardex@, Switzerland) 
over a 7 day period. The primary outcome measure is increase in tremor severity in relation 
to delayed doses of antiparkinson medication. 
Conclusions 
The work presented in this thesis shows that electronic monitoring is the most accurate 
method of measuring therapy adherence and gives detailed information on medicine-taking 
behaviour. About a fifth of Parkinson's patients take less than 80% of prescribed 
medication, and a tenth take medication in excess of that prescribed. The majority of 
patients take medicines at irregular time intervals. Taking less than 80% of prescribed 
medication is associated with depression, more tablets, younger age and poorer quality of 
life. Patients who are more involved in therapy management decisions are more satisfied 
and have higher intentions to comply with therapy, but this does not translate into actual 
therapy-taking behaviour. Parkinson's patients believe their antiparkinson medication is 
necessary and although they have concerns regarding medicine taking, this does not 
influence overall medicine intake. Parkinson's patients' main concerns are of adverse 
effects, increasingly complicated drug regimens and lack of efficacy of drug treatment. 
Timing compliance and motor scores can be improved by an educational intervention, and 
once daily drugs are taken more consistently than drugs prescribed more frequently. 
There are significant implications of this work for clinical practice. Simplifying drug regimens 
and education on the continuous dopaminergic theory help to regularise medicine taking. 
Future work to evaluate the clinical significance is needed. 
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Appendix 1: Patient Information Leaflets 
Department of Neurology 
: Information Sheet on Dopamine Agonists for 
. Patients with Parkinson's Disease 
A recent reminder from the Committee on the Safety of Medicines concerns some of the drugs used in 
Parkinson's Disease. It reminds doctors that in a few patients taking a type of drug called a dopamine 
agonist (pergolide or Celance, bromocriptine or Parlodel , cabergoline or Cabaser) , there have been son 
side effects which may be serious unless treated appropriately. This information is not new, and has be 
known for many years, but as these drugs are being used more frequently instead of L-Dopa containing 
drugs, the reminder is timely. 
Two members of this class of drug do not cause this problem as they are of a different 
formulation. They are ropinirole and pramipexole. It has always been our practice at review 
appointments to ask about side effects or problems with the drugs, but in line with the 
recommendations of the Committee on Safety of Medicines, we have introduced a more 
formal monitoring system with regular blood tests and chest x-rays. This is because the 
unwanted side effects may include breathing and circulation problems. 
All dopamine agonists may cause nausea, drowsiness (including sudden onset of sleep) and 
hallucinations. 
You have the following choices: 
A. Change from your present tablet to either pramipexole or ropinirole. 
B. Continue on your present medication but be monitored with regular blood tests and lung tests. 
C. Come off the dopamine agonist completely and use alternative medication. This is a 
possible option if you have not had Levodopa or could manage with L-Dopa instead of 
dopamine agonist treatment. 
We shall be happy to discuss this with you at your clinic visit. 
• • • • • 
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WHY IT IS IMPORTANT TO TAKE MEDICATION FOR PARKINSON'S DISEASE ON A 
REGUlAR BASIS 
In Parkinson's disease, there is a loss of brain nerve cells containing a 
chemical called dopamine. The dopamine is needed to help control 
movements. Parkinson's medication either replaces the dopamine, boosts 
the dopamine by preventing its breakdown, or stimulates the brain in the 
same way as dopamine. Normally, the brain is stimulated by dopamine in a 
continuous fashion . In patients with Parkinson's disease, the dopamine 
levels are too low. When medication is taken , the levels of dopamine 
increase and are high after 30-60 minutes, the levels then gradually fall as 
the body breaks down the dopamine. This causes high and low levels of 
dopamine in the brain. If tablets are taken at regular intervals, there are 
smoother levels of dopamine in the brain giving smoother control of 
symptoms. Taking medicines at regular time intervals also helps prevent the 
development of long term side effects in the future. 
Unfortunately, sometimes after taking medicine for Parkinson's disease for 
several years, variations or fluctuations occur in the control of the symptoms. 
When the symptoms are well controlled and you are able to function , th is is 
termed "on", if the symptoms are poorly controlled and the movements are 
slow and stiff, this is termed "off". When the symptoms fluctuate this is called 
the "on/off" effect. If medications are taken on a regular basis, there is a 
steadier supply of dopamine to the brain and these fluctuations can be 
minimised. 
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UNIFIED PARKINSON'S DISEASE RATING SCALE (UPDRS) 
------------------------------------ -
Since its introduction in 1987, the UPDRS has been used extensively by researchers and clinicians aroun 
the world. The UPDRS is a rating tool to follow the longitudinal course of Parkinson's Disease. It 
comprises: Section 1: Mentation, Behavior, and Mood; Section 2: Activities of Daily Living; Section 3. 
Motor Examination. These are evaluated by interview. Some sections require multiple grades assigned tc 
each extremity. A total of 199 points are possible: 199 represents the worst (total) disability, 0 represents 
no disability. 
Fahn S, Elton R, Members of the UPDRS Development Committee. 
In: Fahn S, Marsden CD, CaIne DB, Goldstein M, eds. 
Recent Developments in Parkinson's Disease, Vol 2. 
Florham Park, NJ. 
Macmillan Health Care Information 1987, pp 15 3-163, 293-304 
I - MENTATION, BEHAVIOUR, AND MOOD (max points 16) 
1. Intellectual Impairment (max 4) 
o 0 none 
o 1 mild (consistent forgetfulness with partial recollection of events with no other 
difficulties) 
o 2 moderate memory loss with disorientation and moderate difficulty handling 
complex problems 
o 3 severe memory loss with disorientation to time and often place, severe impairment 
with problems 
o 4 severe memory loss with orientation only to person, unable to make judgments or 
solve problems 
2. Thought Disorder (max 4) 
o 0 none 
o 1 vivid dreaming 
o 2 "benign" hallucination with insight retained 
o 3 occasional to frequent hallucination or delusions without insight, could interfere 
with daily activities 
o 4 persistent hallucination, delusions, or florid psychosis. 
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3. Depression (max 4) 
o 0 not present 
o 1 periods of sadness or guilt greater than normal, never more than a week 
o 2 sustained depression for more than one week 
o 3 vegetative symptoms (insomnia, anorexia, abulia, weight loss) 
o 4 vegetative symptoms with suicidality 
4. Motivation (Initiative) (max 4) 
o 0 normal 
o 1 less of assertive, more passive 
o 2 loss of initiative or disinterest in elective activities 
o 3 loss of initiative or disinterest in day to day (routine) activities 
o 4 withdrawn, complete loss of motivation 
---------------
II - ACTIVITIES OF DAILY LIVING (max points 52) 
---- --------------------- -------------
5. Speech (max 4) 
o 0 normal 
o 1 mildly affected, no difficulty being understood 
o 2 moderately affected, may be asked to repeat 
o 3 severely affected, frequently asked to repeat 
o 4 unintelligible most of time 
6. Salivation (max 4) 
o 0 normal 
o 1 slight but noticeable increase, may have nighttime drooling 
o 2 moderately excessive saliva, may have minimal drooling 
o 3 marked drooling 
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7. Swallowing (max 4) 
0 o normal 
0 1 rare choking 
0 2 occasional choking 
0 3 requires soft food 
0 4 requires NG tube or G-tube 
8. Handwriting (max 4) 
0 o normal 
0 1 slightly small or slow 
0 2 all words small but legible 
0 3 severely affected, not all words legible 
0 4 majority illegible 
9. Cutting Food (Handling Utensils) (max 4) 
o 0 normal 
o 1 somewhat slow and clumsy but no help needed 
o 2 can cut most foods, some help needed 
o 3 food must be cut, but can feed self 
o 4 needs to be fed 
10. Dressing (max 4) 
o 0 normal 
o 1 somewhat slow, no help needed 
o 2 occasional help with buttons or arms in sleeves 
o 3 considerable help required but can do some things alone 
o 4 helpless 
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11. Hygiene (max 4) 
o 0 normal 
o 1 somewhat slow but no help needed 
o 2 needs help with shower or bath or very slow in hygienic care 
o 3 requires assistance for washing, brushing teeth, going to bathroom 
o 4 helpless 
12. Turning in Bed (Adjusting Bed Clothes) (max 4) 
o 0 normal 
o 1 somewhat slow no help needed 
o 2 can turn alone or adjust sheets but with great difficulty 
o 3 can initiate but not turn or adjust alone 
o 4 helpless 
13. Falling (Unrelated to Freezing) (max 4) 
o 0 none 
o 1 rare falls 
o 2 less than one per day 
o 3 average of once per day 
o 4 more than one per day 
14. Freezing (When Walking) (max 4) 
o 0 normal 
o 1 rare, may have start hesitation 
o 2 occasional falls from freezing 
o 3 frequent freezing, occasional falls 
o 4 frequent falls from freezing 
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15. Walking (max 4) 
o 0 normal 
o 1 mild difficulty, may drag legs or decrease arm swing 
o 2 moderate difficulty requires no assistance 
o 3 severe disturbance requires assistance 
o 4 cannot walk at all even with assistance 
16. Tremor (max 4) 
o 0 absent 
o 1 slight and infrequent, not bothersome to patient 
o 2 moderate, bothersome to patient 
o 3 severe, interferes with many activities 
o 4 marked, interferes with all activities 
17. Sensory Complaints (Related to Parkinsonism) (max 4) 
o 0 none 
o 1 occasionally has numbness, tingling, and mild aching 
o 2 frequent, but not distressing 
o 3 frequent painful sensation 
o 4 excruciating pain 
... ---~ .. --.-.------------------
III - MOTOR EXAMINATION (max points 108) 
18. Speech (4 max) 
o 0 normal 
o 1 slight loss of expression, diction, volume 
o 2 moderate impairment, monotone, slurred but understandable 
o 3 marked impairment, difficult to understand 
o 4 unintelligible 
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19. Facial Expression (4 max) 
o 0 normal 
o 1 slight hypomymia, could be normal "poker face" 
o 2 slight but definite abnormal diminution in expression 
o 3 moderate hypomymia, lips parted some of time 
o 4 masked or fixed face, lips parted 114" or more with complete loss of expression 
20. Tremor at Rest (5 part question - 20 points max) 
0 Face, lips, chin (4 max) 
0 o absent 
0 1 slight and infrequent 
0 2 mild and present most of time 
0 3 moderate and present most of time 
0 4 marked and present most of time 
0 Left hand (4 max) 
0 o absent 
0 1 slight and infrequent 
0 2 mild and present most of time 
0 3 moderate and present most of time 
0 4 marked and present most of time 
0 Right hand (4 max) 
0 o absent 
0 1 slight and infrequent 
0 2 mild and present most of time 
0 3 moderate and present most of time 
0 4 marked and present most of time 
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0 Left foot (4 max) 
0 o absent 
0 1 slight and infrequent 
0 2 mild and present most of time 
0 3 moderate and present most of time 
0 4 marked and present most of time 
0 Right foot (4 max) 
0 o absent 
0 1 slight and infrequent 
0 2 mild and present most of time 
0 3 moderate and present most of time 
0 4 marked and present most of time 
21. Action or Postural Tremor of Hands (2 part question - max points 8) 
o Left hand (4 max) 
o 0 absent 
o 1 slight, present with action 
o 2 moderate, present with action 
o 3 moderate present with action and posture holding 
o 4 marked, interferes with feeding 
o Right hand (4 max) 
o 0 absent 
o 1 slight, present with action 
o 2 moderate, present with action 
o 3 moderate present with action and posture holding 
o 4 marked, interferes with feeding 
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22. Rigidity (5 part question - max points 20) Gudged on passive movement of major joints 
with patient relaxed in sitting position. Cogwheeling to be ignored.) 
0 Neck (4 max) 
0 o absent 
0 1 slight or only with activation 
0 2 moderate 
0 3 marked, full range of motion 
0 4 severe 
0 Left upper extremity (4 max) 
0 o absent 
0 1 slight or only with activation 
0 2 moderate 
0 3 marked, full range of motion 
0 4 severe 
0 Right upper extremity (4 max) 
0 o absent 
0 1 slight or only with activation 
0 2 moderate 
0 3 marked, full range of motion 
0 4 severe 
0 Left lower extremity (4 max) 
0 o absent 
0 1 slight or only with activation 
0 2 moderate 
0 3 marked, full range of motion 
0 4 severe 
0 Right lower extremity (4 max) 
0 o absent 
0 1 slight or only with activation 
0 2 moderate 
0 3 marked, full range of motion 
0 4 severe 
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23. Finger Taps (2 part question - max points 8) 
(Patient taps thumb with index finger in rapid succession) 
o Left hand (4 max) 
o 0 normal 
o 1 mild slowing and/or reduction in amplitude 
o 2 moderately impaired, definite and early fatiguing, may have occasional 
arrests 
o 3 severely impaired, frequent hesitations and arrests 
o 4 can barely perform 
o Right hand (4 max) 
o 0 normal 
o 1 mild slowing and/or reduction in amplitude 
o 2 moderately impaired, definite and early fatiguing, may have occasional 
arrests 
o 3 severely impaired, frequent hesitations and arrests 
o 4 can barely perform 
24. Hand Movements (2 part question - max points 8) 
(Patient opens and close hands in rapid succession) 
o Left hand (4 max) 
o 0 normal 
o 1 mild slowing and/or reduction in amplitude 
o 2 moderately impaired, definite and early fatiguing, may have occasional 
arrests 
o 3 severely impaired, frequent hesitations and arrests 
o 4 can barely perform 
o Right hand (4 max) 
o 0 normal 
o 1 mild slowing and/or reduction in amplitude 
o 2 moderately impaired, definite and early fatiguing, may have occasional 
arrests 
o 3 severely impaired, frequent hesitations and arrests 
o 4 can barely perform 
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25. Rapid Alternating Movements of Hands (2 part question - max points 8) 
(Pronation and supination of hands, vertically and horizontally, with as large an amplitude 
as possible, both hands simultaneously) 
o Left hand (4 max) 
o 0 normal 
o 1 mild slowing and/or reduction in amplitude 
o 2 moderately impaired, definite and early fatiguing, may have occasional 
arrests 
o 3 severely impaired, frequent hesitations and arrests 
o 4 can barely perform 
o Right hand (4 max) 
o 0 normal 
o 1 mild slowing and/or reduction in amplitude 
o 2 moderately impaired, definite and early fatiguing, may have occasional 
arrests 
o 3 severely impaired, frequent hesitations and arrests 
o 4 can barely perform 
26. Leg Agility (2 part question - max points 8) 
(Patient taps heel on the ground in rapid succession picking up entire leg. Amplitude should 
be at least 3 inches) 
o Left leg (4 max) 
o 0 normal 
o 1 mild slowing and/or reduction in amplitude 
o 2 moderately impaired, definite and early fatiguing, may have occasional 
arrests 
o 3 severely impaired, frequent hesitations and arrests 
o 4 can barely perform 
o Right leg (4 max) 
o 0 normal 
o 1 mild slowing and/or reduction in amplitude 
o 2 moderately impaired, definite and early fatiguing, may have occasional 
arrests 
o 3 severely impaired, frequent hesitations and arrests 
o 4 can barely perform 
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27. Arising From Chair (4 max) 
(Patient attempts to arise from a straight-backed chair, with arms folded across chest) 
o 0 normal 
o 1 slow, may need more than one attempt 
o 2 pushes self up from arms or seat 
o 3 tends to fall back, may need to try more than once but can get up without help 
o 4 unable to arise without help 
28. Posture (4 max) 
o 0 normal erect 
o 1 slightly stooped, could be normal for older person 
o 2 definitely abnormal, moderately stooped, may lean to one side 
o 3 severely stooped with kyphosis 
o 4 marked flexion with extreme abnormality of posture 
29. Gait (4 max) 
o 0 normal 
o 1 walks slowly, may shuffle with short steps, no festination (hastening steps) or 
propulsion 
o 2 walks with difficulty, little or no assistance, some festination, short steps or 
propulsion 
o 3 severe disturbance, frequent assistance 
o 4 cannot walk at all, even with assistance 
30. Postural Stability (4 max) . 
(Response to sudden, strong, posterior displacement produced by pull on shoulders whIle 
patient erect with eyes open and feet slightly apart. Patient is prepared.) 
o 0 normal 
o 1 recovers unaided 
o 2 would fall if not caught 
o 3 falls spontaneously 
o 4 unable to stand 
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31. Body Bradykinesia and Hypokinesia (4 max) 
(Combining slowness, hesitancy, decreased armswing, small amplitude and poverty of 
movement in general.) -
D 0 none 
D 1 minimal slowness, could be normal, deliberate character 
D 2 mild slowness and poverty of movement, definitely abnormal, or decreased 
amplitude 
D 3 moderate slowness, poverty, or small amplitude 
D 4 marked slowness, poverty, or amplitude 
IV - COMPLICATIONS OF THERAPY (In the Past Week) (max points 23) 
-------- ------------- - ---~--------
32. Dyskinesias: Duration (max 4) 
(What proportion of the waking day are dyskinesias present?) (Historical information) 
D o none 
D 1 1-25% of day. 
D 2 26-500/0 of day. 
D 3 51-75% of day. 
D 4 76-100% of day. 
33. Dyskinesias: Disability (max 4) 
(How disabling are the dyskinesias?) (Historical information; may be modified by office 
examination) 
D 0 Not disabling 
D 1 Mildly disabling. 
D 2 Moderately disabling. 
D 3 Severely disablling. 
D 4 Completely disabled. 
34. Dyskinesias: Pain (max 4) 
(How painful are the dyskinesias?) 
DONo painful dyskinesias 
D 1 Slight. 
D 2 Moderate. 
D 3 Severe. 
D 4 Marked. 
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35. Dystonia (max 4) 
(Presence of Early Morning Dystonia?) 
DONo. 
o 1 Yes. 
36. "OtIs" predictable (max 1) 
(Are "off' periods predictable?) 
DONo. 
o 1 Yes. 
37. "OtIs" unpredictable (max 1) 
(Are "off' periods unpredictable?) 
DONo. 
o 1 Yes. 
38. "OtIs" sudden (max 1) 
(Do "off' periods come on suddenly, within a few seconds?) 
DONo. 
o 1 Yes. 
39. "OtIs" duration (max 4) 
(What proportion of the waking day is the patient "off' on average?) 
0 o none 
0 1 1-25% of day. 
0 2 26-50% of day. 
0 351-75%ofday. 
0 476-100% of day. 
40. Does the patient have anorexia, nausea, or vomiting? (max 1) 
DONo. 
o 1 Yes. 
41. Any sleep disturbances, such as insomnia or hypersomnolence? (max 1) 
(Record the patient's blood pressure, height and weight on the scoring form) 
DONo. 
o 1 Yes. 
42. Does the patient have symptomatic orthostasis?(max 1) 
DONo. 
o 1 Yes. 
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v -MODIFIED HOEHN AND YAHR STAGING SCALE 
STAGE 0 = No signs of disease. 
STAGE 1 = Unilateral disease. 
ST AGE 1.5 = Unilateral plus axial involvement. 
STAGE 2 = Bilateral disease, without impairment of balance. 
STAGE 2.5 = Mild bilateral disease, with recovery on pull test. 
STAGE 3 = Mild to moderate bilateral disease; some postural instability; physically 
independent. 
STAGE 4 = Severe disability; still able to walk or stand unassisted. 
STAGE 5 = Wheelchair bound or bedridden unless aided. 
VI - SCHWAB AND ENGLAND ACTIVITIES OF DAILY LIVING SCALE 
100% = Completely independent. Able to do all chores without slowness, difficulty or 
impairment. Essentially normal. Unaware of any difficulty. 
90% = Completely independent. Able to do all chores with some degree of slowness, 
difficulty and impairment. Might take twice as long. Beginning to be aware of difficulty. 
80% = Completely independent in most chores. Takes twice as long. Conscious of difficulty 
and slowness. 
70% = Not completely independent. More difficulty with some chores. Three to four times 
as long in some. Must spend a large part of the day with chores. 
60% = Some dependency. Can do most chores, but exceedingly slowly and with much 
effort. Errors; some impossible. 
50% = More dependent. Help with half, slower, etc. Difficulty with everything. 
40% = Very dependent. Can assist with all chores, but few alone. 
30% = With effort, now and then does a few chores alone or begins alone. Much help 
needed. 
20% = Nothing alone. Can be a slight help with some chores. Severe invalid. 
10% = Totally dependent, helpless. Complete invalid. 
0% = Vegetative functions such as swallowing, bladder and bowel functions are not 
functioning. Bedridden. 
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Mini Mental State Examination (MMSE) 
ORIENTATION 
Date 1 
Day 1 
Month 1 
Year 1 
Season 1 
Clinic 1 
Floor 1 
City 1 
County 1_ 
Country 1_ 
REGISTRATION Plant, Key, Ball 
ATTENTION & CALCULATION 
93, 86, 79,72,65 
or 
WORLD = DLROW out of5 
RECALL The 3 items above out of 3 
(3) 
out of 10 
Score 
Score 
Score 
LANGUAGE: NAMING: Point to and ask the name of: Pen, Watch: 2 Score 
REPETITION: repeat 'No ifs ands or buts' 1 Score 
COrvtM:AND: take paper in R hand 1, fold it in half 1, place on lap/floor 1 =3 Score 
READING: read and obey the command: 'Close your eyes' 1 Score 
WRITING: write a sentence (which makes sense) 1 Score 
DRAWING: pentagons 1 Score 
out of30 
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Due to having Parkinson's Disease, how often during the last month have you ... 
(please tick one box for each question) 
l.Had difficulty doing the leisure activities you would like to do? 
0 [ ] Never 
1 [ ] Occasionally 
2 Sometimes 
3 [ ] Often 
4 [ ] Always 
Total Score 
2. Had difficulty looking after your home, for example, housework, cooking or gardening? 
0 ] Never 
1 [ ] Occasionally 
2 [ ] Sometimes 
3 ] Often 
4 Always 
Total Score 
3. Had difficulty carrying shopping bags? 
o 
1 
2 
3 
4 
] 
] 
] 
Never 
Occasionally 
Sometimes 
Often 
Always 
Total Score 
4. Had problems walking half a mile? 
0 Never 
1 Occasionally 
2 Sometimes 
3 [ ] Often 
-l [ ] Always 
Total Score 
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5. Had problems walking 100 yards (approximately one block)? 
0 Never 
1 Occasionally 
2 Sometimes 
3 ] Often 
4 ] Always 
Total Score 
6. Had problems getting around the house as easily as you would like 
0 Never 
1 Occasionally 
2 Sometimes 
3 [ ] Often 
4 Always 
Total Score 
7. Had difficulty getting around in public places? 
0 Never 
1 Occasionally 
2 Sometimes 
3 Often 
-l Always 
Total Score 
8. Needed someone else to accompany you when you went out? 
0 Never 
Occasionally 
2 Sometimes 
3 Often 
-l ] Always 
Total Score 
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9. Felt frightened or worried about falling in public? 
0 Never 
1 ] Occasionally 
2 Sometimes 
3 [ ] Often 
4 [ ] Always 
Total Score 
10. Been confined to the house more than you would like? 
0 ] Never 
1 ] Occasionally 
2 Sometimes 
3 Often 
4 Always 
Total Score 
11. Had difficulty washing yourself? 
0 Never 
1 Occasionally 
2 ] Sometimes 
3 ] Often 
4 Always 
Total Score 
12. Had difficulty dressing yourself? 
0 Never 
1 ] Occasionally 
2 ] Sometimes 
3 Often 
4 Always 
Total Score 
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13. Had problems doing up buttons or shoe laces? 
0 Never 
1 ] Occasionally 
2 ] Sometimes 
3 ] Often 
4 ] Always 
Total Score 
14. Had problems writing clearly? 
0 Never 
1 Occasionally 
2 Sometimes 
3 Often 
4 Always 
Total Score 
15. Had difficulty cutting up your food? 
o 
1 
2 
3 
4 
] 
] 
Never 
Occasionally 
Sometimes 
Often 
Always 
Total Score 
16. Had difficulty holding a drink without spilling it? 
0 Never 
] Occasionally 
2 Sometimes 
3 Often 
-l Always 
Total Score 
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17. Felt depressed? 
0 [ ] Never 
1 [ ] Occasionally 
2 ] Sometimes 
3 ] Often 
4 [ ] Always 
Total Score 
18. Felt isolated and lonely? 
0 ] Never 
1 [ ] Occasionally 
2 [ ] Sometimes 
3 ] Often 
4 Always 
Total Score 
19. Felt weepy or tearful? 
0 ] Never 
1 ] Occasionally 
2 ] Sometimes 
3 ] Often 
4 ] Always 
Total Score 
20. Felt angry or bitter? 
0 Never 
1 ] Occasionally 
2 ] Sometimes 
3 Often 
-l Always 
Total Score 
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21. Felt anxious? 
o 
I 
2 
3 
4 
] 
] 
Never 
Occasionally 
Sometimes 
Often 
Always 
Total Score 
22. Felt worried about the future? 
0 ] Never 
1 ] Occasionally 
2 ] Sometimes 
3 ] Often 
4 Always 
Total Score 
23. Felt you had to hide your Parkinson's from people? 
0 Never 
1 Occasionally 
2 Sometimes 
3 ] Often 
4 Always 
Total Score 
24. Avoided situations that involved eating or drinking in public? 
0 [ ] Never 
1 [ ] Occasionally 
2 Sometimes 
3 ] Often 
4 ] Always 
Total Score 
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25. Felt embarrassed in public? 
0 Never 
1 ] Occasionally 
2 ] Sometimes 
3 Often 
4 Always 
Total Score 
26. Felt worried about other people's reaction to you? 
o 
1 
2 
3 
4 
] 
] 
] 
] 
Never 
Occasionally 
Sometimes 
Often 
Always 
Total Score 
27. Had problems with close personal relationships? 
o 
2 
3 
4 
] 
] 
Never 
Occasionally 
Sometimes 
Often 
Always 
Total Score 
28. Have you lacked the support you needed form your spouse or partner? 
0 [ ] Never 
[ Occasionally 
2 [ Sometimes 
3 Often 
~ Always 
Total Score 
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29. Have you lacked the support you needed from your family or close friends? 
0 Never 
I Occasionally 
2 ] Sometimes 
3 Often 
4 Always 
Total Score 
30. Unexpectedly fallen asleep during the day? 
0 Never 
I [ ] Occasionally 
2 [ ] Sometimes 
3 ] Often 
4 ] Always 
Total Score 
31. Had problems with your concentration, for example, when reading or watching TV? 
0 Never 
I ] Occasionally 
2 ] Sometimes 
3 ] Often 
4 Always 
Total Score 
32. Felt your memory was failing? 
0 Never 
1 Occasionally 
2 Sometimes 
3 ] Often 
-l Always 
Total Score 
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33. Had distressing dreams or hallucinations? 
0 ] Never 
1 Occasionally 
2 Sometimes 
3 Often 
4 ] Always 
Total Score 
34. Had difficulty speaking? 
0 Never 
1 Occasionally 
2 Sometimes 
3 Often 
4 ] Always 
Total Score 
35. Felt unable to communicate effectively? 
0 ] Never 
1 ] Occasionally 
2 Sometimes 
3 Often 
4 Always 
Total Score 
36. Felt ignored by people? 
0 [ Never 
[ Occasionally 
2 [ Sometimes 
3 Often 
~ ] Always 
Total Score 
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37. Had painful muscles cramps or spasms? 
0 Never 
1 ] Occasionally 
2 Sometimes 
3 Often 
4 Always 
Total Score 
38. Had aches and pains in your joints or body? 
0 Never 
1 Occasionally 
2 ] Sometimes 
3 ] Often 
4 Always 
Total Score 
39. Felt uncomfortably hot or cold? 
0 ] Never 
Occasionally 
2 ] Sometimes 
3 ] Often 
-l ] Always 
Total Score 
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PO ASSESSMENTS Sleep/dyskinesia Date : 
Name: DaB: ________ Unit No: 
Time of assessments: 
Time last dose of PO medication taken: 
Dose the patient experience ON / OFF periods? 
Epworth Sleepiness Scale. 
••••••• •• •• • ••• '" ••• ' 0 • • •••• 
Yes / NO 
Q - HO~ lik~ly a~e you to doze off or fall asleep in the following situations , in contrast to 
feeling Just tired? 
Scale: o = would never doze 
1 = slight chance of dozing 
2 = moderate chance of dozing 
3 = chance of dozi 
Situation Chance of dozi 
1. Sitting and reading 
2. Watching TV 
3. Sitting, inactive in a public place (e.g., a theatre / meeting 
4. As a passenger in a car for an hour without a break 
5. Lying down to rest in the afternoon when circumstances permit 
6. Sitting and talking to someone 
7. Sitting quietly after a lunch without alcohol 
8. In a car, while for a few minutes in traffic 
total 
score>16 equals severe daytime sleepiness 
Parkinson Dyskinesia Scale 
Scale: o = Normal 
1 = Intermittent 
2 = Generalized , mild but continuous, may not be obvious to untrained observer 
3 = Moderate, generalized, definitely noticeable to untrained observer 
4 = Incapacitating 
0 
Head 
RUE 
LUE 
RLE 
LLE 
Trunk total 
Goetz Dyskinesia Rating Scale 
Score: 0 = 
1 = 
2 = 
3 = 
Absent 
Minimal severity: no interference with involuntary motor acts Involved in ~as 
Dyskinesias impair involuntary movements but patient IS capable of e IClently 
completing the motor acts involved in the rated task 
Intense interferencewith movement control so that completing the rated motor 
4 = 
task is greatly limited 
Violent dyskinesias , incompatible with completion of the rated motor tas 
Type of dyskinesia present 
Most disabling - tick only one Seventy Score 
Chorea Chorea 
Dystonia Dystonia 
-
Other, specify .. . ....... ····· 
--
Other, specify ............... 
Concordance/Compliance Adverse Events Record 
Any adverse events Yes/No Occupation 
----How much alcohol do you drink in a week? units 
Does a carer supervise your medication? YIN 
Do you use a dosette box? YIN 
Global Impression: Score the approximate overall treatment 'estimate' as follows 
(this refers to symptoms - a patient with a lot of tremor or stiffness may score themselves undertreated: a 
patient with a lot of dyskinesia may be scored by the doctor/nurse as overtreated): 
Patient's estimate: Undertreatment overtreatment about right 
DoctorlNurse estimate: Undertreatment overtreatmen t about right 
Adverse Event Tick if present 
Nausea 
Dizziness 
Confusion 
Nightmares 
Hallucinations 
Ankle swelling 
Sleepiness 
Insomnia 
Dyskinesia 
Other Please detail 
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Medical Interview Satisfaction Scale 
We are interested in your views about the consultation you have just had with your doctor. 
If you could spend a few minutes completing this questionnaire it would be a great help. 
Please think about the consultation you have just had and indicate whether you agree or disagree \\ith eacl 
of the following statements. 
Circle one number for each statement. 
very \,:r\ 
strongly strongly strongly strongly 
disagree disagree disagree uncertain agree agree agree 
1. The doctor told me just what my 
trouble is. 1 2 3 4 5 6 7 
2. After talking with the doctor, I know 
just how serious my illness is. 1 2 3 4 5 6 7 
3. The doctor told me all I wanted to know 
about my illness. 1 2 3 4 5 6 7 
4. I am not really certain about how to 
follow the doctor's advice. 1 2 3 4 5 6 7 
5. After talking with the doctor, I have a 
good idea of how long it will be before 
I am well again. 1 2 3 4 5 6 7 
6. The doctor seemed interested in me as 
a person. 1 2 3 4 5 6 7 
7. The doctor seemed warm and friendly 
tome. 1 2 3 4 5 6 7 
8. The doctor seemed to take my problems 
3 4 5 6 7 seriously. 1 2 
9. I felt embarrassed while talking with the 
2 3 4 5 6 7 doctor. 1 
10. I felt free to talk to this doctor about 
private matters. 1 2 3 4 5 6 7 
11. The doctor gave me a chance to say 
what was really on my mind. 1 2 3 -l "'I 6 7 
PLEASE GO TO THE NEXT PAGE 
very 
strongly strongly ven 
disagree disagree disagree 
strongly strongl~ 
uncertain agree agree agree 
12. I really felt understood by my doctor. I 2 3 4 5 6 7 
13. The doctor did not allow me to say 
everything I had wanted about my 
problems. 1 2 3 4 5 6 7 
14. The doctor did not really understand 
my main reason for coming. 1 2 3 4 5 6 7 
15. This is a doctor I would trust with 
my life. 1 2 3 5 6 7 
16. The doctor seemed to know what 
(s)he was doing. 1 2 3 4 5 6 7 
17. The doctor has relieved my worries 
about my illness. I 2 3 4 5 6 7 
18. The doctor seemed to know just 
what to do for my problem. I 2 3 4 5 6 7 
19. I expect that it will be easy for 
me to follow the doctor's advice. I 2 3 4 5 6 7 
20. It may be difficult for me to do exactly 
what the doctor told me to do. I 2 3 4 5 6 7 
21. I'm not sure the doctor's treatment 
will be worth the trouble it will take. I 2 3 4 5 6 7 
PLEASE CHECK THAT YOU HAVE GIVEN YOUR OPINION ON EACH STA TEME;'\T 
THANK YOU FOR YOUR HELP TODAY. 
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Parkinson's Disease Therapy Monitoring Study 
Please tell us about the discussion with your doctor/nurse about your treat t. 
. men 
Read each statement and tick one box on each line. 
Strongly Agree Neutral Disagree Strongly 
Agree Disagr~e 
1. The doctor/nurse gave me 
responsibility for deciding how 
to deal with my health problem 
2. The doctor/nurse asked me to 
choose a treatment for my health 
problem 
3. The doctor/nurse gave me 
enough information to make my 
own decision about treatment 
4. The doctor/nurse did not ask my I 
opinion about my medicines i 
Please estimate how accurately you take your medication: 
I miss a dose of medication:- (circle one answer) 
Frequently Sometimes Never 
I take an extra dose of medication:- (circle one answer) 
Frequently Sometimes Never 
THANK YOU FOR TAKING THE TIME TO COMPLETE THIS 
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Name: Date: 
How do you take your medication for Parkinson's Disease? 
Put an X on the line below to show roughly how much of your 
Parkinson's medication you took in the last month. 
We would be surprised if this was 1000/0 for most people: 
0% means you have taken none of your Parkinson's medication 
500/0 means you have taken half your Parkinson's medication 
100% means you have taken every single dose of your Parkinson's medication 
120% means you have taken a few extra doses of your Parkinson's medication 
o 10 20 30 40 50 60 70 80 90 100 110 120 
take take take don't 
all some take about 
of extra 
any half tablets 
of of my my tablets 
my tablets 
tablets 
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Satisfaction with Information About Medicines Scale 
We would like to ask you about the information you have received ab t d" PI 
ou your me Icmes ease rate tho 
infonnation you have received about each of the following aspects of your med" 'If h lClOe~ YOU use more t an 
one medicine, please give your overall feeling about information you have received abou~all ~'our medicine 
What your medicine is called About right Too little N one received \one needed 
What your medicine is for About right Too little None received \on~ needed 
What it does About right Too little None r~c~i\~d \OI1~ needed 
How it works About right Too little None recei\~d None needed 
How long it will take to act About right Too little None received None needed 
How you can tell if 
it is working About right Too little None received None needed 
How long you will 
need to be on your medicine About right Too little None received None needed 
How to use your medicine About right Too little None received None needed 
How to get a further supply About right Too little None received None needed 
Whether the medicine has 
any unwanted (side )effects About right Too little None received None needed 
What are the risks of you 
getting side effects About right Too little None received None needed 
What you should do if you About right Too little None received None needed 
experience unwanted side effects 
Whether you can drink alcohol About right Too little None received None needed I 
I 
whilst taking this medicine i 
Whether the medicine About right Too little None reCel\ ed r\OI1( needed ! 
interferes with other medicines 
Whether the medicine About right Too little None received 
\one n~:cded i; 
will make you feel drowsy 
Whether the medicine About right Too little None r((Cl\ cd 
\l1l1e needed 
will affect your sex life 
~ \l)l1l' needed Too little None r((ci\co What you should do About right 
if you forget to take a dose 
'-
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M1 
M2 
M3 
M4 
M5 
M6 
QUESTIONS ABOUT USING YOUR 
MEDICINES 
• Many people find a way of using their medicines which 
suits them. 
• This may differ from the instructions on the label or from 
what their doctor has said . 
• We would like to ask you a few questions about how you 
use your medicines 
Here are some ways in which people have said that they 
use their medicines 
For each of the statements, please tick the box which 
best applies to you 
Your own way of using your Always Often Sometimes 
medicines 
I forget to take them 
I alter the dose 
I stop taking them for a while 
I decide to miss out a dose 
I take less than instructed 
I take them at regular time 
intervals 
Rarely Never 
-r---
Depression Scale 
Directions: Please choose the best answer for how you have felt over the past week. 
YES \0 
1. Are you basically satisfied with your life? .............................. . 
2. Have you dropped many of your activities and interests? ........ . 
0 0 
0 0 
3. Do you feel that your life is empty? ........................................ . 0 0 
4. Do you often get bored? ........................................................ . 0 0 
5. Are you hopeful about the future? ......................................... . 0 0 
6. Are you bothered by thoughts you can't get out of your head? .. . 0 0 
7. Are you in good spirits most of the time? ............................... . 0 0 
8. Are you afraid that something bad is going to happen to you? .. . 0 0 
9. Do you feel happy most of the time? ...................................... . 0 0 
10. Do you often feel helpless? ................................................... . 0 0 
11. Do you often get restless and fidgety? .................................... . 0 0 
12. Do you prefer to stay at home rather than go out and do things? 0 0 
13. Do you frequently worry about the future? ............................. . 0 0 
14. Do you feel you have more problems with memory than most? .. 0 0 
15. Do you think it is wonderful to be alive now? ........................... . 0 0 
16. Do you feel downhearted and blue? ....................................... . 0 0 
17. Do you feel pretty worthless the way you are now? ................. . 0 0 
18. Do you worry a lot about the past? ........................................ . 0 0 
19. Do you find life very exciting? ............................................... . 0 0 
. t? 20. Is it hard for you to get started on new proJec s ....................... . 0 0 
21. Do you feel full of energy? ................................... ·················· 0 0 
22. Do you feel that your situation is hopeless? ........................ · .. ·· 0 0 
23. Do you think that most people are better off than you are? ........ . 0 0 
24. Do you frequently get upset over little things? ................... ······· 0 0 
25. Do you frequently feel like crying? ..........•........... ·················· .,. 0 0 
26. Do you have trouble concentrating? ................. ···················· .. . 
27. Do you enjoy getting up in the morning? ................................. . 
28. Do you prefer to avoid social occasions? ................................ .. 
29. Is it easy for you to make decisions? ..................................... .. 
30. Is your mind as clear as it used to be? ................... · ............... .. 
0 0 
0 0 
0 0 
0 0 
0 0 
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1. 
. BRIEF MEDICATION QUESTIONNAIRE I : 
Please hst below all medications you took in !he PAST WEE{ (BMQ 2003) 
each of the questions in the boxes below [U add'r I . ~oreachmedlca.tlOnyou II~. please answer 
. se 11000 page ifnecessary] 
a. Medication b. How many c. How many d.How mucb e. How many f 
name days did you times per day :: :'f ·yr. It --did you take ti oes did vou S .. 
'..1' '.1"-
.. 
take it? did you take it? each time? miss takin-g i t7 
reason were d'·. Ih:,' 
you tak:ng It, :1'r':I(:n~ won; 
:"vr ,'ouO) 
I; .,::v 
~=so~what 
}; nc: 4:~.t: 
.; d,: ~'t O:)W 
2, Do any of your medications bother you in any way? (Check one) 
a. IF YES, please name the medication and explain how it bothers you. 
YESl 1 NOll 
Medication Name In what way does it bother you? 
3. How much problem or concern are you having in the follOWing areas [circle one] 
None A little Alol 
a. My medication causes side effects. . . . . . . . . . . . . . . . . . . . . . . . . . 0 1 2 
b.1t is hard to remember all the doses. .... .... .. ..... . .... .... 0 , I 
c. It is hard to pay for the medication. . . . .. ................... 0 2 
d.1t is hard to open the container. . . . . . . . . . . . . .. . . . . . . .. . . .. .. 0 2 
e. It is hard to get my refill on time. . . . . . . . . . . . . . . . . . . . . . . . . . . 0 2 
f It is hard to read the print on the container. . . . . . . . . . . . . . . . . . . 0 2 
g. The dosage times are in:onvenient . . . . . . . . . . . . . . . . . . . . . . . . . 0 ) L 
h. My medication Cllllses other problem or concern... ...... . . .... 0 ) 
If other problem or concern, please explain: _________________________ _ 
4. Did you stop taking any medications in the PAST SIX MONTIiS? (Cbeck one) YES [ 1 
If yes, please list the medications you stopped. For each, answer the q ueshons in the boxes below 
NO[ J 
a. Medication name b. For what reason c. How well did tbe d How rr.uc~ 1ld ., 
e Fc- wlllt ~uc~ c:j,j 
w::re you taking it? medicine work for you? bother you? 
YO'j stop tatCClg i~~' 
1= very 0= none 
2= somewhat I=alittle 
3= not at all 2= a lot 
4 don't know 
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Beliefs about Medicines Questionnaire 
Your views about medicines prescribed for your 
Parkinson's Disease 
We would like to ask you about your personal views about medicines prescribed for 0 
h Y u. These are statements ot er people have made about their medicines. 
Please show how much you agree or disagree with them by ticking the appropriate box 
strongly 
disagree disagree uncertain 
My health, at present, depends on my medicines 1 2 
Having to take medicines worries me 1 2 
My life would be impossible without my medicines 1 2 
Without my medicines I would be very ill 1 2 
I sometimes worry about long-term effects of my medicines 1 2 
My medicines are a mystery to me 1 2 
My health in the future will depend on my medicines 1 2 
My medicines disrupt my life 1 2 
I sometimes worry about becoming too dependent on my medicines 1 2 
My medicines protect me from becoming worse 1 2 
Your views about medicines in general 
We would like to ask you about your personal views about medicines in general. 
These are statements other people have made about medicines in general. 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
agree 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
strongly 
agree 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
Please indicate the extent to which you agree or disagree with them by ticking the appropriate box 
strongly strongly 
disagree disagree uncertain agree agree 
Doctors use too many medicines 1 2 3 4 5 
People Who take medicines should stop their treatment 
for a While every now and again 1 2 3 4 5 
Most medicines are addictive 1 2 3 4 5 
Natural remedies are safer than medicines 1 2 3 4 5 
MediCines do more harm than good 1 2 3 4 5 
All medicines are poisons 1 2 3 4 5 
Doctors place too much trust on medicines 1 2 3 4 
5 
If doctors had more time with patients 
1 2 3 4 5 they would prescribe fewer medicines 
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Beliefs about Medicines for Parkinson's Disease Questionnaire 
Your views about medicines prescribed for your Parkinson's disease 
We would like to ask you about your personal views about medicines prescribed 
for your Parkinson's Disease. These are statements other people with Parkinson's 
Disease have made about their medicines. Please show how much you agree or 
disagree with them by circling the appropriate number. 
Strongly Disagree Neutral Agree Strongly I 
Disagree Agree 
.-~- -I have no concerns about my 1 2 3 4 5 
Parkinson's medication 
--- -
I worry that my Parkinson's 1 2 3 4 5 
medicines will stop working 
The side effects of my medicines 1 2 3 4 5 
are unpredictable 
I worry about having to take so 1 2 3 4 5 
many tablets 
I am concerned that the 1 2 3 4 5 
medication causes drowsiness 
I would like to delay any increase 1 2 3 4 5 
in my medication for 
as long as possible 
I worry about getting 1 2 3 4 5 
side effects in the futu re 
-
These medicines will not 1 2 3 4 5 
help all of my symptoms ~~-
I worry that I will need more and 1 2 3 4 5 
more medication as time goes on 
4 5 I am concerned about the 1 2 3 
medicines causing involuntary I 
I movements 
4 15 I I would like to delay adding new 1 2 3 
~ medication for as long as possible -+-
4 5 II worry that the benefits of the 1 2 3 
! medication will suddenly I I I 
! disappear I -- ---+ 
3 14 5 : Using this medicine regularly now 1 2 
I I will make it less effective in the " 
future 1 ._- --
3 14 5 
,~. 
2 
I I worry that the medication 1 
~_~orsens some of my sympJoms I --- -~- - -
